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Abstract
Malaria is a threat to approximately 40% of the world’s population. Artemisinin and its 
derivatives in combination therapy are the world’s number one treatment against 
malaria. Agricultural production remains the primary source of artemisinin, however 
alternative methods are constantly being seeked to combat the unreliable and 
fluctuating processes present today. In addition, reported cases of parasitic resistance 
to the combination therapies emphasise the urgent need to produce novel and active 
analogues to replace the existing first line treatments. 
Artemisinin is a terpenoid extracted from Artemisia annua. Terpenes constitute 
one of the largest families of natural products that boast a substantial degree of 
chemical diversity and functionality. The broad diversity of biological applications of 
terpenes has found several uses, particularly in medicine.
Terpene synthases convert linear isoprenyl diphosphates into complex 
hydrocarbon structures that exhibit exquisite stereochemistry. Amorphadiene 
synthase converts farnesyl diphosphate to amorpha-4,11-diene. This bicyclic frame,
with four stereocenters is the first precursor found in the biosynthesis of artemisinin. 
Terpene synthases are studied extensively by scientists, because of their ability to 
generate complex structures that require several synthetic steps to reproduce the 
same complexity. 
This project focuses on studying the promiscuity of amorphadiene synthase. 
By using the recombinant protein in vitro gives the advantage of feeding the enzyme 
with novel FDP analogues, in attempt to introduce new functionalities in the resulting 
amorphadiene structure. These added functional groups then serve as platforms to 
carry out further chemical steps or can be carried forward to the respective artemisinin 
derivative, and consequently tested for antimalarial activity. A library of FDP analogues 
were designed, synthesized and incubated with ADS to test for enzymatic activity. In 
addition to the search for new amorphadiene derivatives, one of the synthesized FDP 
analogues, 12-hydroxy FDP, was converted to dihydroartemisinic aldehyde. 
Dihydroartemisinic aldehyde is a precursor found further down the schematic pathway 
to artemisinin. A three-step chemo-enzymatic approach to producing 
dihydroartemisinic aldehyde was established, providing an alternative method to 
sourcing artemisinin. 
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1Chapter 1. Introduction
21. 1 Malaria
1.1.1 Overview of the disease
Malaria is a parasitic disease that is a threat to over 40% of the world’s population. It is 
passed to a human through the bite of an infected female Anopheles mosquito.[1,2] In 
1907, Charles Louis Alphonse Laveran was awarded the Nobel Prize in Physiology or 
Medicine for his research carried out in 1880 determining that it was protozoa that 
caused diseases such as malaria. Following his work, Ronald Ross identified female 
mosquitos as the host vectors for the parasites in 1897. He was awarded a Nobel Prize
in Physiology or Medicine in 1902.[3]
The parasites responsible for this deadly disease are collectively termed as 
Plasmodium with Plasmodium falciparum causing the most severe and deadly 
infections. There are three other Plasomodium species known to cause malaria in 
humans, P. vivax, P. malariae and P. ovale. The symptoms seen in a patient can vary; 
uncomplicated malaria will cause fevers and chills that can be treated with no major 
complications. Severe malaria will result in anaemia, kidney failure, seizures, and even
lead to death if left untreated. Children and pregnant women are the most vulnerable to 
catching this parasitic disease.[4]
The fight to control malaria has been an on-going struggle for over a century. 
Currently, the disease remains a major and growing threat to the public health and 
economic development of many countries. The regions that are affected by malaria are 
the sub tropical countries that lie on the equator, they possess the hottest and driest 
climates with low terrains. These optimal conditions enable mosquitos to successfully
multiply and allow the Plasmodium mosquito to complete their growth cycle in their 
hosts. It is estimated that 90% of all malaria deaths occur on the African continent.[5,6]
In 2015 the Centers for Disease Control and Prevention (CDC) stated that 214 million 
cases of malaria occurred worldwide, spread across 106 countries.[7]
When a mosquito feeds off a human for blood, she injects sporozoites into the 
human’s blood stream. These sporozoites rapidly invade the liver cells where they 
develop during asexual reproduction to form merozoites. Depending on the class of 
Plasmodium, some of these liver stage parasites can remain dormant in the liver for 
years, allowing initiation of a cycle of asexual reproduction in the absence of a new 
mosquito bite. When the liver cells rupture due to the intensive replication of 
merozoites, which typically takes 5-10 days, the parasites are released back into the 
blood stream where they invade the red blood cells. Similarly, they begin to asexually 
reproduce in the red blood cells, eventually causing the destruction of each cell they 
infect. This is what causes the clinical symptoms of malaria, such as high fevers and 
chills.[8,9]
3A small proportion of these merozoites will further develop into male and female 
gametocytes, and it is in this form that the parasites are taken back by a mosquito that 
feeds off that human. Whilst in the mosquito, the fusion of the male and female 
gametocytes forms diploid zygotes, which in turn become ookinetes. These migrate to 
the midgut of the mosquito; pass through the gut wall and form oocysts. Meiotic 
division of the oocysts lead to the formation of sporozoites which migrate to the salivary 
glands, ready to start another cycle of transmission (Figure 1.1).[10,11]
Figure 1.1 Cartoon representation of the life cycle of Plasmodium in an infected human 
(Black) and in a mosquito (Red). 
 
1.1.2 Traditional chemotherapy for malaria 
Quinine (1, Figure 1.2) was the first successful chemical compound that was found to 
treat malaria, and its use is reported as far back as the early 1600s. Quinine is a 
component of the bark of the cinchona tree originally found in Peru, South America. It 
is an alkaloid compound and due to its basic nature, is always presented as a salt, 
most commonly the dihydrochloride salt.[12] In 1820 French scientists, Pierre Pelletier 
4and Joseph Caventou, extracted the compound from the bark and isolated the pure 
alkaloid to be administered to patients. Before then it was simply dried, ground and 
mixed into some liquid such as wine or a spirit for administration, possibly the source of 
origin for the gin and tonic partnership that is still popular today. It remained the 
mainstream antimalarial drug for another century before more efficient, synthetic 
antimalarials became available.[13] While there are many other antimalarials that have 
been discovered to date, quinine continues to play a role in the management of 
malaria, and today is still recommended as the second line of treatment for the 
disease.[1]
Chloroquine (2, Figure 1.2) was the next major antimalarial drug that replaced 
quinine. Bayer AG synthesized the compound in 1934 as a result of the German 
government commissioning a search for a quinine alternative.[14] At first its properties 
were identified as too toxic to start clinical trials, and so it wasn’t until 1942 that it was 
found to be active against malaria and there were no serious problems found with the 
toxicity.[15] More importantly it was found to be far superior compared to its derivatives
that were being used at the time.[12] Chloroquine rapidly became available for all blood 
stage human malaria infections.[16] In addition, it was also used as a prophylactic drug 
after Mario Pinotti introduced the medicated salt program ‘Pinotti’s method’. 
Chloroquine was mixed into common cooking salt as a way of distributing it to 
everyone.[17] Chloroquine resistance in Plasmodium falciparum was first observed in 
the early 1960s and eventually the resistance grew until chloroquine could not be used 
as the first line treatment for malaria any longer.[18]
Pyrimethamine (3) and sulfadoxine (4, Figure 1.2) were the next major 
antimalarials to replace chloroquine.[19,20] After antifolates were found to be a
successful treatment of leukemia and tumours, scientists started to focus on treating 
other rapidly dividing cells such as parasites with these antifolates.[21] The combination 
of the two drugs was introduced in the 1970s. Pyrimethamine and sulfadoxine are 
antifolate agents used synergistically, acting together to inhibit enzymes important in 
the parasites folate biosynthesis pathway. Dihydrofolate reductase (DHFR) is inhibited 
by pyrimethamine and dihydropteroate synthase (DHPS) is inhibited by sulfadoxine.[22]
Neither of these antifolates is efficient enough to act alone as monotherapy treatment
so the combination of the two is crucial.[23] Studies show that resistance to this duo is 
associated with point mutations in DHFR and DHPS.[24]
Mefloquine (5, Figure 1.2) was discovered by researchers at the Walter Reed 
Army Institute of Research in attempts to find a replacement for the first antimalarial, 
quinine. Initially the synthesis of this compound was very expensive, and so with the 
partnership of the ‘UNICEF-UNDP-World Bank-WHO’ special program for research and 
training in tropical diseases, and the pharmaceutical company Hoffmann-La Roche, a 
5cheaper synthetic pathway led to the product registration of mefloquine in 1984.[25] In 
1986, mefloquine was combined with the sulphadoxine-pyrimethamine combination to 
treat malaria stricken patients. This trio of drugs was found to be effective until 
resistance developed for this combination, which led to their abandonment in 
1989.[12,14]
Figure 1.2 Quinine (1), chloroquine (2), pyrimethamine (3), sulfadoxine (4) and mefloquine 
(5). 
 
1.1.3 Artemisinin and its derivatives
In the 1990s resistance to available antimalarial drugs worsened across the globe, and 
as a consequence, morbidity and mortality rates increased. The majority of deaths 
reported were those of African children.[26] In an attempt to reduce the death rate and 
control the parasitic disease, artemisinin based combination therapies (ACTs) were 
introduced. The success of the ACTs at a time where resistance had caused a fear of 
untreatable malaria was seen as a positive development. In 2005, the World Health 
Organisation (WHO) recommended that ACTs should be used as first line treatment for 
all severe malaria in countries where malaria was endemic.[27]
Artemisinin (6) (Figure 1.3) is derived from the herb Artemisia annua, also 
known as sweet wormwood, originally found in China. Although artemisinin was only 
introduced in the 1990s, the herb itself has been used for centuries in traditional 
Chinese medicine.[28] The earliest report of its use appears in Chinese books dating 
back to 168 BC, where the use of A. annua was reported to treat haemorrhoids, chills 
6and fevers.[14] The re-discovery of sweet wormwood came after the Chinese 
government set up a program named ‘Project 523’ in 1967 to screen traditional 
remedies in search for a new antimalarial drug. Professor Tu Youyou extracted the 
active ingredient artemisinin from the sweet wormwood herb into cold ether and this, 
when tested, exhibited antimalarial activity.[29,30] Professor Tu Youyou received the 
2011 Lasker Award in clinical medicine[31] and was awarded a Nobel Prize in 
Physiology or Medicine in 2015.[32]
In 1972 the active ingredient, artemisinin, was extracted and purified.[33] This 
isolation of the compound led to the identification of its sesquiterpene trioxane lactone 
structure.[34] Artemisinin was proven to be an antimalarial of rapid action, high efficiency 
and low toxicity that gave quicker parasite clearance than all formerly used
antimalarials.[33] The disadvantages of artemisinin are poor solubility in water and oil
and the high recrudescence rate of Plasmodium when artemisinin is used to treat 
malaria. This led to the synthesis of artemisinin derivatives. Water-soluble derivatives 
of artemisinin included artesunate (7) and artelinate (8), and the oil-soluble derivatives 
saw the creations of artemether (9) and arteether (10) (Figure 1.3).[35,36]
Figure 1.3 Artemisinin (6), artesunate (7), artelinate (8), artemether (9) and arteether (10).  
 
The concept of ACTs presents the idea that by giving two drugs, the chances of a 
parasite developing resistance to both drugs at the same rate are reduced.[37,38] In 
addition to this, since artemisinin and its derivatives have a very short elimination half-
life after being administered into a patient, this precludes the possibility of using it on its 
7own as monotherapy treatment. Combining the artemisinins with other antimalarial 
drugs that have a longer half-life, grants a more effective method for treating the 
parasitic disease with a reduced possibility of recrudescence.[39,40]
The discovery of artemisinin introduced an entirely new class of drugs for 
treatment of malaria. Unlike the former antimalarials, artemisinin and its derivatives all 
contain a unique 1,2,4-trioxane ring structure which is believed to be responsible for 
the antimalarial activity.[41,42] Another difference from the other antimalarial drugs is that 
artemisinin lacks nitrogen containing heterocyclic ring systems. Despite the 
artemisinins being a unique class of molecules and to date, the only group of 
antimalarials that have not received an excessive amount of parasitic resistance, there 
is still a lot to learn about them. Although there are several theories on their mode of 
action, the precise nature of how the drug inhibits malarial growth is still to be 
established.[43–47]
Antimalarials are among the most commonly used medications in tropical 
regions of the world. Unfortunately their extensive misuse has caused human-hosted
malaria parasites to evolve mechanisms of resistance and so there is a continuous 
race to provide alternative antimalarials that are efficient and cost effective.[37,48] To 
continue using the existing artemisinins without appreciating that resistance 
unfortunately will alter the success of these drugs would be irresponsible. Therefore 
there is always a constant duty for scientists to find an alternative; to create a new drug
that will be ready to take over as the next first line of treatment to contribute to global 
malaria control.
1. 2 Terpenes
Terpenes and terpenoids constitute one of the largest families of natural products that 
boast an amazing degree of chemical diversity and functionality. To date, there are 
more than 60,000 known terpenes, mainly found in plants, but they are also found in 
fungi, bacteria and humans.[49] This thesis however will solely focus on terpenes 
derived from plants. 
In plants, not only do terpenes exist as primary metabolites, serving purposes 
such as membrane structure and function (e.g. campesterol, 11)[50] and photosynthetic
pigments (e.g. b-carotene, 12)[51], they also exist as a product of secondary 
metabolism.[52,53] Secondary metabolites in plants have properties that include repelling 
herbivorous insects (e.g. 7-epizingiberene, 13)[54] and attracting pollinators (e.g. b-
phellandrene, 14)[55].
The broad diversity of biological applications of terpenes is of great interest to 
scientists, particularly in medicine and agriculture. The use of oils isolated from plants 
in traditional medicine dates back over 4500 years ago, many of which are still in use 
8today.[56] At present times, terpenes are used as anti-cancer drugs (e.g. taxol, 15) and 
antimalarials (e.g. artemisinin, 6) as well as for non-medicinal use, such as fragrance 
ingredients (e.g. (-)-menthol, 16) and flavourings (e.g. (R)-limonene, 17), to name but a 
few (Figure 1.4).[57]
Figure 1.4 Campesterol (11), b-carotene (12), 7-epizingiberene (13), b-phellandrene (14), 
taxol (15), artemisinin (6), (-)-menthol (16), and (R)-limonene (17). 
 
All terpenes are constructed by the repetitive coupling of the branched five-carbon 
building blocks, isopentenyl diphosphate (IDP, 18) and dimethylallyl diphosphate 
(DMADP, 19).[58] The resulting terpenes are classified into groups depending on how 
many isoprene units (20, Figure 1.5) the terpene skeleton is comprised of (Table 1.1). 
Otto Wallach presented the concept of an empirical isoprene rule in 1887. Initially, the 
‘empirical isoprene rule’ was used to define terpenes as compounds that were 
composed of one or more isoprene units, with an empirical formula of C5H8 (20, Figure 
1.5).[59] Research by Leopold Ruzicka in 1953 led to the rule being modified. Renaming 
it the ‘biogenetic isoprene rule’ added the possibility of the fused, acyclic terpene
skeleton cyclizing and undergoing rearrangements to form the final product.[60,61]
9Figure 1.5 IDP (18), DMADP (19) and isoprene (20). A: Regular ‘head to tail’ coupling of 
IDP and DMADP. B: Irregular ‘head to head’ coupling of IDP and DMADP. 
 
Table 1.1 Classification of terpenes
Class Cx Precursor Example
Hemiterpenes 5 dimethylallyl diphosphate (DMADP) isoprene
Monoterpenes 10 geranyl diphosphate (GDP) limonene
Sesquiterpenes 15 farnesyl diphosphate (FDP) amorpha-4,11-diene
Diterpenes 20 geranylgeranyl diphosphate (GGDP) taxol
Sesterterpenes 25 geranylfarnesyl diphosphate (GFDP) cheilanthatriol
Triterpenes 30 (2) x farnesyl diphosphate gossypol
Tetraterpenes 40 (2) x geranylgeranyl diphosphate b-carotenoid
1.2.1 Biosynthesis of terpenes
In plants the precursors to all terpenes, IDP and DMADP, are biosynthesized via two 
different pathways, depending on the subcellular compartment of the plant they are 
generated in.[62] The mevalonate (MEV) pathway is found in the cytosol whereas the 
deoxyxylulose phosphate (DXP) pathway (also known as the non-mevalonate 
pathway) is found in the plastids.[63] In addition to this, different groups of terpenes are 
also produced in different compartments of a plant. Monoterpenes and diterpenes tend 
to be made in the plastid compartments of plants, whereas sesquiterpenes and 
triterpenes tend to be synthesised in the cytosol compartments.[64]
Mevalonate pathway
The mevalonate pathway (Scheme 1.1) starts with a Claisen condensation of two 
molecules of acetyl-coenzyme A (acetyl-CoA, 21) to form acetoacetyl-CoA (22). An 
addition of a third acetyl-CoA molecule affords 3-hydroxy-3-methylglutaryl-CoA (HMG-
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CoA, 23). This aldol reaction is catalysed by HMG-CoA synthase.[65] HMG-CoA 
reductase, with two equivalents of NADPH, converts HMG-CoA to mevalonic acid (24).
Two sequential ATP-dependent phosphorylations follow to form 5-diphosphomevalonic 
acid (mevalonic acid diphosphate, 25) with the use of mevalonate kinase and 5-
phosphomevalonate kinase.[66] Mevalonic acid diphosphate undergoes an ATP-
dependent decarboxylation and an elimination of water, catalysed by 
diphosphomevalonate decarboxylase, to afford IDP (18). Lastly, IDP isomerase 
catalyses an isomerisation to DMADP (19).[67]
Scheme 1.1 Biosynthesis of IDP (18) and DMADP (19) via the mevalonate pathway.
Deoxyxylulose phosphate pathway
The alternative deoxyxylulose pathway (Scheme 1.2) begins with the addition of an 
‘activated acetaldehyde’, generated from pyruvate (26) and thiamine diphosphate 
(TDP), to glyceraldehyde 3-phosphate (27) to form 1-deoxy-D-xylulose 5-phosphate 
(28).[68] 1-Deoxy-D-xylulose 5-phosphate (28) is converted to 2C-methyl-D-erythritol 4-
phosphate (29) catalysed by 1-deoxy-D-xylulose 5-phosphate reductoisomerase (IspC) 
in a NADPH-dependent reaction. The next step involves the addition of cytidine 
monophosphate (CMP) on to the terminal phosphate group of 29 to form 4-
diphosphocytidyl-2C-methyl-D-erythritol (30), which then follows with an ATP-
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dependent phosphorylation to produce 4-diphosphocytidyl-2C-methyl-D-erythritol 2-
phosphate (31). This intermediate cyclises to 2C-methyl-D-erythritol 2,3-
cyclodiphosphate (32) with the loss of CMP.[69] A reductive ring opening of the cyclic 
diphosphate forms 1-hydroxy-2-methyl-2-(E)-butenyl diphosphate (33). The final step 
of the deoxyxylulose phosphate pathway consists of two stepwise single-electron 
transfers from an iron-sulfur cluster and a cleavage of the hydroxyl moiety to yield an 
allylic carbanion. Deprotonation of the carbanion affords either IDP or DMADP.[70]
Scheme 1.2 Biosynthesis of IDP (18) and DMADP (19) via the deoxyxylulose phosphate 
pathway.
Isoprenyl diphosphate elongation
A family of enzymes called isoprenyl diphosphate synthases catalyse the chain 
elongation reactions that involve sequential condensations of IDP and DMADP 
(Scheme 1.3). Geranyl diphosphate synthase carries out the most simple chain 
elongation reaction involving a condensation of IDP and DMADP to produce GDP
(34).[71] The isoprenyl diphosphate synthase directs the condensation by initiating a 
Mg2+ dependent cleavage of the diphosphate moiety from DMADP. The resulting cation 
is attacked by the electron rich double bond on a molecule of IDP resulting in a tertiary 
carbocation (35) (Scheme 1.3). A deprotonation of 35 at C2 results in the formation of 
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GDP.[72] The formation of FDP (36), catalysed by FDP synthase, adds a second 
molecule of IDP onto GDP to create a C15 hydrocarbon chain. Subsequent elongations 
occur with additional units of IDP to create GGDP (37, C20) and increasingly longer 
isoprenyl chains.[73]
Scheme 1.3 Biosynthesis of isoprenyl diphosphates catalysed by prenyltransferases.
Isoprenyl diphosphates are converted to mature terpenes by terpene synthases 
(Section 1.3). They often then undergo further redox modifications mediated by a 
series of cytochrome P450s and other oxidoreductases to produce the many 
thousands of different terpenoid metabolites of plants (Figure 1.6).[74] Examples are 
found across all classes of terpenes. Monoterpene precursor GDP (34) is cyclised to a-
pinene (38) by a-pinene synthase and further converted to (+)-verbenone (39) for 
example. Verbenone is used by bark beetles as a dispersal pheromone to modulate 
the attack density on conifers.[75–77] FDP (36) is converted to the sesquiterpene 
germacrene A (40), catalysed by germacrene A synthase and then further converted to 
costunolide (41), an insect deterrent produced in lettuce and chicory.[78,79] An example 
for the C20 precursor, GGDP (37), is seen in the conversion to the diterpene 
abietadiene (42), which is further oxidised to ferruginol (43), the major constituent of 
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resin which is secreted from the miro tree (Podocarpus ferrugineus) as a chemical 
defense against any cuts or incisions made to the tree bark (Figure 1.6).[80–82]
Figure 1.6 Examples of conversions of isoprenyl diphosphates to the terpenoids (+)-
verbenone (39), costunolide (41) and ferruginol (43). 
 
1. 3 Terpene synthases 
Terpene synthases are crucial for catalysing the stereoselective conversion of acyclic 
isoprenyl diphosphates into a vast number of chiral terpenes. Tens of thousands of 
natural terpene products have been identified to date, all stemming from a small 
number of precursors.[83] This draws attention to the complex nature of the chemical
reactions taking place in the active site of these synthases, and their ability to create 
unique compounds with structural and stereochemical precision. Terpene synthases 
guide substrates through changes in bonding, hybridization, and configuration in series 
of precise cascades.[84] Terpene synthases exhibit a high degree of functionality for the 
active site to control all these rearrangements. They are also specifically composed to 
handle the highly reactive intermediates formed in the cascade of reactions. The 
hydrophobic active site effectively mimics an inert organic solvent in a normal 
cyclisation reaction and the presence of fixed and protected dipoles and aromatic 
residues with ring p-electrons stabilise the carbocation intermediates formed.[85–87]
14
One example of a terpene synthase that boasts remarkable precision is lanosterol 
synthase. This is used in the biosynthesis of cholesterol and produces only 1 out of a 
possible 128 stereoisomers of lanosterol.[88] There are, however, terpene synthases 
that show more promiscuity in their product profile, generating multiple terpenes. An 
example of a more promiscuous synthase is g-humulene synthase, which generates an 
astonishing 52 products from FDP as its sole substrate.[89]
There are two different mechanisms for initiating the polycyclisation cascade
that leads to the formation of terpenes; therefore terpene synthases can be divided into 
two classes. Class I terpene synthases require three magnesium ion co-factors to co-
ordinate to the diphosphate group, resulting in a cleavage of the group and ionisation 
of the isoprenyl chain.[86,90] Class II terpene synthases differ in their initial catalytic step.
Instead of dephosphorylating the isoprenyl diphosphate they generate the initial 
carbocation via a protonation of the distal C=C bond or an epoxide derivative 
thereof.[91,92]
The terms ‘terpene’ and ‘terpenoid’ are used interchangeably in the literature 
with no consensus on their definitions. For clarity in this work however, a terpene is 
defined as the hydrocarbon or alcohol product specifically arising as a product from 
terpene synthase catalysis, whereas terpenoids are defined as the downstream 
biosynthetic derivatives of the initial terpene.
1.3.1 Sesquiterpene synthases
Sesquiterpene synthases catalyse the metal dependent conversion of FDP to generate 
a rich diversity of sesquiterpene scaffolds. Most plant sesquiterpene synthases consist 
of two a-helical domains and belong to the family of class I synthases. The C-terminal 
a-domain is known as the catalytically active domain as it holds the active site where 
FDP enters and is converted to a sesquiterpene.[93] The function of the N-terminal 
domain is still unclear, as it appears to lack catalytic activity, however it is proposed 
that, in some cases at least, it is crucial for desolvating the substrate and ensuring the 
correct folding of the C-terminal domain.[94–96]
Common to all sesquiterpene synthases, the active site contains two metal 
binding regions that bind three Mg2+ ions, necessary for the initiation of the catalytic 
cycle. The first motif is an aspartate rich ‘DDXXD/E’ motif, which binds MgA2+ and MgC2+
and the second, a ‘DTE’ motif that binds MgB2+.[97] There are a few exceptions, for 
example (+)-d-cadinene synthase from Gossypium arboreum does not possess a DTE 
motif and instead has a second DDXXD motif, and (+)-germacrene D synthase from 
Solidago canadensis has a NDTYD motif to replace the first DDXXD motif.[98,99] These 
highly conserved motifs were first observed when the X-ray crystal structure of farnesyl 
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diphosphate synthase (FPS) was solved.[100] Even with the slight differences, the metal 
binding motifs are all used for the same purpose. They bind to three Mg2+ ions, which 
in turn co-ordinate with the diphosphate moiety of FDP. The carbon-phosphoester 
bond breaks through ionisation and generates a highly reactive carbocation. The 
binding of the trinuclear magnesium cluster to the diphosphate triggers closure of the 
active site, shielding the carbocation from water.[101,102] Following the cleavage of the 
diphosphate group, sesquiterpene synthases chaperone the reaction through a series 
of reactions that culminate in the quenching of a final carbocationic species.[103] 5-Epi-
aristolochene synthase (TEAS) from Nicotiana tabacum was one of the first 
sesquiterpene synthases to have its crystal structure solved.[104] In later work by 
creation of a complex with TEAS and an FDP analogue that acts as an inhibitor, 2-
fluoro-farnesyl diphosphate (2F-FDP, 44), a clear view of how the FDP substrate is 
positioned in the active site of a sesquiterpene synthase was revealed (Figure 1.7).[101]
Figure 1.7 Left: Cartoon representation of the crystal structure of 5-epi-aristolochene 
synthase from Nicotiana tabacum (PDB 3MO1), showing the N-terminal domain in blue 
and the catalytic C-terminal domain in red. Middle: Schematic view of the TEAS:2F-FDP 
complex. Right: simplified representation of the coordination of [Mg2+]3-2F-FDP. D444, 
T448 and E452 coordinate to one Mg2+ ion and D301 and D305 coordinate the other two 
Mg2+ ions. Mg2+ ions are shown as green balls and 2F-FDP (44, inset picture) is 
represented where the black denotes phosphorus and the yellow denotes oxygen.
1.3.2 Amorpha-4,11-diene synthase and artemisinin
Amorpha-4,11-diene synthase (ADS) (Figure 1.8) from A. annua is a 571 residue 
sesquiterpene synthase that catalyses the conversion of FDP (36) into amorpha-4,11-
diene (hereafter referred to as amorphadiene, 45). ADS catalyses the first committed 
step of artemisinin biosynthesis in A. annua (Scheme 1.4).[105,106]
OPP
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Figure 1.8 Cartoon representation of ADS. The homology model is based on the crystal 
structure of a-bisabolol synthase from A. annua (4GAX.pdb) with 82% sequence identity
to ADS.[107] Blue denotes the N-terminal domain and red denotes the catalytic C-terminal 
domain. The homology model was constructed using SWISS-MODEL 
(http://swissmodel.expasy.org/).[108–110]
Scheme 1.4 Biosynthesis of artemisinin (6).
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After the initial ADS dependent cyclisation of FDP to amorphadiene, a cytochrome 
P450 dependent hydroxylase (CYP71AV1) oxidises amorphadiene to artemisinic 
alcohol (46) and then further to artemisinic aldehyde (47).[111] The same hydroxylase 
can further oxidise 47 to artemisinic acid (48), however this compound has been shown
not to be a precursor to artemisinin, despite earlier reports claiming otherwise.[112]
Artemisinic aldehyde is reduced by a reductase (DBR2) to form dihydroartemisinic 
aldehyde (49), which is then oxidised to dihydroartemisinic acid (50) by aldehyde 
dehydrogenase 1 (ADH1).[113,114] The conversion of dihydroartemisinic acid to 
artemisinin is believed to be non-enzymatic.[115–118]
Interestingly, the intermediates and enzymes involved in the biosynthesis of 
artemisinin were not discovered in sequential order. By extracting from A. annua, the 
structural elucidation of artemisinic acid was determined by IR and 1H NMR 
spectroscopy, in addition to biogenetic considerations, prior to the discovery of 
amorphadiene.[119,120] Initially named cadina-4,11-diene, the structure of amorphadiene 
was first determined in 1984 by NMR spectroscopy and gas chromatography-mass 
spectrometry (GC-MS). The structure was elucidated when it was discovered as an 
unknown terpene in the plant Viguiera oblongifolia gardner.[121,122]
Franssen and co-workers[123] were the first group to identify amorphadiene in A. 
annua and proposed its presence as an early intermediate in the biosynthesis of 
artemisinin. Leaf extracts of A. annua were analysed by GC-MS and 14 sesquiterpene 
compounds were found. The identity of amorphadiene was demonstrated by 
comparison of its peak in the GC with that of an authentic sample that had been 
prepared from artemisinic acid. The structure and configuration of amorphadiene made 
it a suitable candidate to be the terpene precursor to artemisinin. Furthermore, the 
formation of amorphadiene from FDP was the major sesquiterpene synthase activity in 
A. annua. Although there was a high amorphadiene synthase activity found in the 
plant, the small quantities of amorphadiene detected suggested that there were further 
modifications to the sesquiterpene, such as oxidations to produce oxygenated 
artemisinin precursors, and that the initial synthase activity of ADS was the rate-
determining step in the biosynthesis of artemisinin.[124]
The catalytic mechanism of amorphadiene synthase has been studied and 
reported by numerous groups and is fully established. The first question to address 
was the order of cyclisations that occur in the catalytic mechanism of ADS. After an 
isomerisation of FDP to nerolidyl diphosphate (NDP, 51), a 1,6 cyclisation occurs 
affording bisabolyl cation 52, followed by a hydride shift to form (53) and then a 1,10-
cyclisation to yield amorphyl cation (54). Alternatively the 1,10 cyclisation is achieved 
first, resulting in a germacradienyl cation (55), subsequently undergoing a hydride shift 
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to 56 and then a 1,6-ring closure to form cation 57 (Scheme 1.5).[125] After identification 
of minor enzymatic products arising from an incubation of ADS with FDP, Brodelius 
and co-workers proposed that the framework of amorphadiene was built via a 1,6-
cyclisation followed by a 1,10-cyclisation.[126] In the array of sesquiterpenoids 
generated by ADS, all the monocyclic compounds, assumed to be a result of 
premature quenching, were various isomers of bisabolene. Further to this, none of the 
minor products contained a germacrene based structure (55), implying that no initial 
1,10-cyclisation occurs (Scheme 1.6).[127] The presence of g-humulene (58) did 
however indicate that a 1,11-cyclisation was achievable through ADS catalysis. (E)-b-
farnesene (59) also demonstrated that acyclic sesquiterpene production occurs. The 
remaining minor products were either a result of quenching of intermediates by water, 
yielding (E)-a-bisabolol (60), amorpha-4-en-11-ol (61) and amorpha-4-en-7-ol (62), or 
through deprotonation, producing b-sesquiphellandrene (63), amorphadiene (45) and 
amorpha-4,7(11)-diene (64).
Scheme 1.5 Formation of amorphadiene (45) from FDP (36) via an initial 1,6 cyclisation 
(red) or a 1,10 cyclisation (blue).
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Scheme 1.6 Enzymatic products arising from incubation of ADS and FDP (36) reported by 
Brodelius and co-workers.[126]
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Furthermore, Brodelius and co-workers[128] report that ADS is capable of converting
GDP (34), the precursor of monoterpenes, into cyclic products; limonene (17), a-
terpineol (66) and terpinen-4-ol (67) (Scheme 1.7). These products support the 
proposition of ADS carrying out an initial 1,6-cyclisation, when compared to TEAS, a 
sesquiterpene synthase that carries out an initial 1,10 cyclisation. An incubation of 
TEAS with GDP only forms acyclic products, linalool (68) and myrcene (69).
Scheme 1.7 Enzymatic products arising from incubation of ADS (blue) and TEAS (red) 
with GDP (34). 
Determining the exact catalytic mechanism of ADS was accomplished through the use 
of deuterium labelled substrate analogues. This not only identified the stereochemistry 
of the enzymatic product but also enabled identification of the intermediate 
carbocations.
Brodelius and co-workers reported the use of single deuterated FDP; (1R)-[1-
2H]-FDP (70) and (1S)-[1-2H]-FDP (71), and double deuterated FDP; [1,1-2H2]-FDP 
(72), to solve the catalytic mechanism of ADS (Figure 1.9).[128] It was observed by GC-
MS that the molecular ion [M]+ (73) of amorphadiene shifts by 1 and 2 atomic mass 
units (AMUs) when both single and double deuterated FDP is incubated with ADS, 
respectively. In addition to this, the [M-CH3]+ ion (74) also was shown to shift 1 and 2 
AMUs, showing that none of the three methyl groups (C13, C14 and C15) contained
any deuterium. Cation 75 observed at m/z = 121, the product when amorphadiene is 
cleaved at C1/C10 and C7/C8, retains the deuterium ions of both single and double 
deuterated FDP. However cation 76 observed at m/z = 93, formed by the cleavage of 
C1/C10 and C6/C7, only shows a shift in 1 AMU when ADS is incubated with (1R)-[1-
2H]-FDP but does not retain any deuterium label from an incubation of ADS with (1S)-
[1-2H]-FDP (Figure 1.9 and Table 1.2). 
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Figure 1.9 Single deuterated (70 and 71) and double deuterated (72) FDP. Ions 73-76 are 
observed in a mass spectrum of amorphadiene (45). 
 
Table 1.2 Mass spectrometric parent and fragment ions from unlabelled and labelled 
amorphadiene.
Substrate Ions (m/z) of amorphadiene product
73 74 75 76 
36 205 189 121 93
70 205 190 122 94
71 205 190 122 93
72 206 191 123 94
The information observed from fragment ions 75 and 76 show that the 1-pro-S 
hydrogen of FDP (36) shifts from C1 to C7, during the catalytic mechanism. In addition,
this observation also implies that the mechanism goes through a 1,3-hydride shift 
instead of two consecutive 1,2-hydride shifts. If two consecutive hydride shifts took 
place, the 1-pro-S hydrogen of FDP would shift to C6 and in the deuterium labelled 
tests, this deuterium would still be observed in fragment ion 76 (Scheme 1.8).
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Scheme 1.8 Proposed mechanistic steps to illustrate the fragmentation patterns 
observed in the mass spectra resulting from single (70 and 71) and double (72) 
deuterated FDP.
The mechanism of ADS has also been studied by 1H and 2H NMR spectroscopy. Kim 
and co-workers also synthesised compounds 70, 71 and 72 to incubate with ADS. On 
observation of the 2H NMR spectra, when double deuterated 72 was incubated with 
ADS, there were two signals at dH = 1.38 and 2.60 corresponding to the deuterium 
signals of D-7 and D-1 respectively. When using only (1R)-[1-2H]-FDP (70) the 
incubation yielded a single labelled product with a signal at dH = 2.60, whereas when 
(1S)-[1-2H]-FDP (71) was used, a single signal appeared at dH = 1.38. To support this 
data additional spectra were measured using 1H NMR spectroscopy. Firstly the 1H 
NMR spectrum for a double labelled amorphadiene lacked the characteristic signals at 
dH = 1.40 and 2.55 showing the presence of deuterium at H-7 and H-1 respectively. 
When using only (1R)-[1-2H]-FDP with ADS, the 1H NMR spectrum lost the signal at dH
= 2.55, characteristic of H-1. Similarly the incubation with (1S)-[1-2H]-FDP generated a 
compound that lacked the signal at dH = 1.40. Both of these NMR spectroscopic
techniques confirmed the same findings; the proton in the 1S position migrates to C7 
showing that the mechanism must undergo a 1,6 ring closure, while the 1R proton 
remains at C1.[125]
With the deuterium labelling studies, the catalytic mechanism of ADS has been 
fully elucidated; a Mg2+-dependent expulsion of the diphosphate moiety of FDP (36), 
followed by isomerisation yields NDP (51). This allows rotation to give the cisoid 
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conformer necessary for a 1,6-cyclisation to form the bisabolyl cation (52). A highly 
stereoselective [1,3]-hydride shift to cation 53, followed by a 1,10-cyclisation, leads to 
the bicyclic amorphyl cation (54). Finally a deprotonation to quench the amorphyl 
cation from C12 or C13 generates amorphadiene (45) (Scheme 1.9).
Scheme 1.9 ADS catalysed conversion of FDP (36) to amorphadiene (45). 
 
1.3.3 Commercial production of artemisinin
There are various methods for probing artemisinin, with the majority of world production 
arising from extraction of the compound from dry plant material.[129] Screening for plant 
lines that can be bred with the existing Artemisia plant to enhance the yield of 
artemisinin is an active area of research.[130–132] A. annua is mostly cultivated in China, 
Vietnam, India and Africa. The plant takes around 8 months to fully grow, after which 
the dried leaves are sent to artemisinin-extraction facilities. The extracted artemisinin is 
commonly sent to a third contractor which oversees the conversion of artemisinin into 
its derivatives. The long cultivation periods, in addition to few manufacturers at some 
stages of the production cycle, and too many at others leads to an unstable supply of 
the artemisinins as well as a constant fluctuation in the price of the antimalarials.[133,134]
Elegant total syntheses of artemisinin have also been carried out as an alternative 
approach to this drug.[135,136] Srihari and co-workers reported a total synthetic route, 
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starting with commercially available (R)-citronellal (79). The synthesis of artemisinin 
(6), was achieved in 11 steps with an overall yield of 5% (Scheme 1.10).[135]
Scheme 1.10 Total synthesis of artemisinin (6) starting with (R)-citronellal (79) reported 
by Srihari and co-workers.[135]
An effective, and arguably a more reliable and efficient, route for sourcing artemisinin 
has been achieved using a biosynthetic approach. Strains of Saccharomyces 
cerevisiae have been developed to produce artemisinic acid (48, Scheme 1.11), a 
precursor to artemisinin.[137,138] This is then extracted from the yeast and converted to 
artemisinin through a series of chemical procedures.[139–141] There are four steps 
required for the chemical conversion. First, artemisinic acid is reduced to 
dihydroartemisinic acid (50). An esterification of the carboxylic acid moiety of 50 yields 
the methyl ester derivative, 88 and subsequent generation of a singlet oxygen
produces the hydroperoxide moiety on 89. This is followed by an acid catalysed Hock 
cleavage and rearrangement to form artemisinin (6) in the presence of molecular 
oxygen (Scheme 1.11). 
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The esterification of dihydroartemisinic acid was required, as explained by 
Newman and co-workers,[139] to prevent the formation of a five-membered lactone 
containing compound, dihydroepideoxyarteannuin B (90) which is a side reaction 
blocked by the formation of the ester 88 (Scheme 1.12). However, Levesque and 
Seeberger[141] report the synthesis of artemisinin via flow chemistry where they form 
hydroperoxide 91 directly from dihydroartemisinic acid (50). They state that with the 
formation of ester 88, the formation of another side product, the six-membered lactone 
ring 92 is increased (Scheme 1.12). To our knowledge, there has not been a reported 
synthesis where the synthesis of both side products, 90 and 92, have both been 
prevented. 
Scheme 1.11 Biosynthetic approach to the synthesis of artemisinin (6) reported by 
Newman and co-workers.[139] The intermediates in red are synthesised chemically once 
artemisinic acid (48) has been extracted from the yeast.
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Scheme 1.12 Formation of side products 90 and 92 during the Hock cleavage.[142]
1. 4 Exploiting the promiscuity of sesquiterpene synthases
The promiscuity of sesquiterpene synthases has been studied and recorded by several 
research groups. Novel analogues of the natural substrate, FDP (36), have been 
synthesised and incubated with various sesquiterpene synthases to test their ability of 
catalysing an unnatural substrate into corresponding novel terpenoids. This area of 
research is of great interest as it provides the opportunity to introduce a heteroatom 
molecule into the terpene scaffold without the need of additional chemical steps. Novel 
analogues have also been used as mechanistic probes for elucidating the mechanistic 
steps of sesquiterpene synthases.
Allemann and co-workers[143] explored the biosynthetic utility of two plant 
sesquiterpene synthases, germacrene A (GAS) and germacrene D synthase (GDS). 
These enzymes catalyse the Mg2+-dependent conversion of FDP (36) to germacrene A 
(40) and germacrene D (93), respectively (Scheme 1.13). Germacrene D is an
important semiochemical that is responsible for affecting the olfactory response of 
insects.[144–147]
Based on the biological significance of germacrene A and germacrene D, a 
selection of methylated and fluorinated FDP analogues were synthesised to study the 
efficiency of the GAS and GDS catalysed conversions to produce non-natural 
germacrenes, with the potential of creating more potent semiochemicals. GAS and 
GDS were both capable of producing fluorinated germacrenes (6-fluoro germacrene A 
94, 6-fluoro germacrene D 95, 14-fluoro germacrene A 96 and 14-fluoro germacrene D 
97) from 6-fluoro FDP (98) and 14-fluoro FDP (99). In addition, methylated 
germacrenes, 14-methyl germacrene A (100) and 14-methyl germacrene D (101) were 
yielded when both enzymes were incubated with 14-methyl FDP (102) (Figure 1.10). 
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GC-MS and NMR spectroscopy was used to identify the production of the novel 
germacrene products.
Scheme 1.13 GAS (red) and GDS (blue) catalysed conversion of FDP (36) to germacrene 
A (40) and germacrene D (93).
Figure 1.10 GAS and GDS catalysed conversions of fluorinated (98 and 99) and 
methylated (102) FDP analogues to produce novel germacrene A (red) and germacrene D 
(blue) derivatives.
Chappell and co-workers[148] showed that the plant sesquiterpene synthase, tobacco 5-
epi-aristolochene (TEAS), also exhibited certain substrate promiscuity. TEAS catalyses 
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the conversion of FDP (36) into the bicyclic sesquiterpene, aristolochene (103) 
(Scheme 1.14). 
Scheme 1.14 TEAS catalysed conversion of FDP (36) to aristolochene (103).
An aza-analogue of GDP, 8-anilino GDP (107), was synthesised and incubated with 
TEAS because it was predicted that if the analogue bound to the active site and 
inhibited the catalytic mechanism of TEAS, then this substrate could be used to help 
refine the structural features of the enzyme in crystallographic studies. Although 8-
anilino GDP is an analogue of the 10-carbon monoterpene precursor, GDP, the length 
of the isoprenyl chain is more consistent with that of FDP (Scheme 1.15). 8-Anilino 
GDP can be considered a structural analogue of FDP, where an aniline group replaces 
the terminal isoprene unit. 8-Anilino GDP was characterised as a non-competitive 
inhibitor of TEAS by measuring the conversion rate of [1-3H]-FDP to [1-3H]-5-epi-
aristolochene in the presence of varying concentrations of 8-anilino GDP. Upon 
studying the crystal structure of the TEAS-8-anilino GDP complex, the Fo-Fc electron 
density map of the model exhibited a region of electron density in the active site. This 
observation suggested that ionization and macrocyclization of the novel substrate 
within the TEAS active site had occurred. NMR spectroscopy was used to identify the 
hexane extractable product generated by an incubation of 8-anilino GDP with TEAS as 
a novel 13-membered alkaloid (108) (Scheme 1.5).[148]
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Scheme 1.15 Top: 8-anilino GDP (107) and FDP (36). Bottom: Proposed mechanism for 
the formation of alkaloid 108.
1. 5 Aims of project
Malaria is the most common and damaging parasitic disease worldwide, killing millions 
of people every year. Unfortunately the countries that suffer from this dreadful disease 
are those that have typically less than $10 per capita annually to spend on healthcare. 
Therefore the treatment of malaria in these countries must come at a price that is not 
prohibitive.[149] The wrong usage of antimalarials, for example in the dosage that a 
patient receives, or incompletion of a treatment cycle, contributes to the rise of parasitic 
resistance. Today, the artemisinins are used in ACTs as the first line treatment for 
malaria, but if parasitic resistance to these antimalarials worsens before a new 
alternative is available, it would be a great global disaster. Therefore there is a 
constant race to not only find the most cost effective and reliable way to supply 
artemisinins to the world, but also to find an alternative that will be ready to serve as 
the next first line treatment. 
This project was divided into two parts. The first aim was to explore the 
promiscuity of the recombinant enzyme ADS. With previous knowledge of 
sesquiterpene synthases catalysing the conversion of FDP analogues into novel 
sesquiterpenoids,[143,148] the objective was to synthesise FDP analogues and test the 
enzymatic activity of ADS with them. Any amorphadiene derivatives produced can then 
be further converted to new corresponding derivatives of artemisinin and tested for 
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antimalarial activity. ADS is a very important enzyme for this approach in creating new 
artemisinins because it is responsible for generating the scaffold of artemisinin, which
exhibits 4 stereocenters. If amorphadiene was synthesised chemically, many chemical 
steps would be required to replace the one enzymatic step catalysed by ADS.
Furthermore, the synthesis would be complicated by the necessary construction of the 
correct stereochemistry.[135,136] For this reason, using ADS to produce analogues of 
artemisinin is advantageous.
The second aim of this project focuses on finding a route to produce artemisinin 
in a reliable and cost effective manner. ADS has been used previously in vivo to 
provide an improved production of artemisinin.[139] Carrying out incubations with the 
enzyme in vitro gives the advantage of employing substrate analogues that may be 
converted by the enzyme to, ultimately, artemisinin analogues. Both the biosynthetic 
pathway observed in plants,[111] and the chemical synthesis used by several groups,[137]
show the necessity of oxidising amorphadiene to form artemisinin, and more 
importantly, in which position the initial oxidation occurs. A hydroxylated analogue of 
FDP was designed, and incubated with ADS to potentially form a precursor further 
down the schematic pathway to artemisinin (Section 5), thus reducing the overall steps
required to produce the antimalarial.
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Chapter 2. Characterisation of amorphadiene synthase
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2. 1 Preface
The aim of the work described in this chapter was to fully characterise ADS. 
Experimental procedures were optimised to provide an efficient method for efficient 
heterologous expression of the amorpha-4,11-diene synthase gene in E. coli and to 
purify the recombinant ADS protein. In addition, it was planned to study the stability 
and structure of the enzyme by the means of pH studies and size exclusion 
chromatography. Steady-state kinetics were performed with the use of tritiated FDP to 
characterise the catalytic efficiency of ADS and compare the activity with kinetic 
parameters reported in the literature. The enzymatic product of ADS was confirmed, 
not only by comparing the GC-MS data to reported literature but also by characterising 
the product by NMR spectroscopy. Lastly, this chapter describes the production of ADS 
mutants to aid in the investigation of the contribution of the N-terminal domain to the 
catalytic mechanism. 
2. 2 Subcloning the ADS gene into pET21d vector
The ADS gene was obtained from GenBank (Acc. No. JF951730.1). The gene was 
supplied in a pTrc99a expression vector (pTrc99a-ADS). After transforming the plasmid 
into competent E. coli BL21-(DE3)-Codon Plus RP (BL21 RP) cells, the gene was 
expressed. This was carried out by culturing the transformed cells at 30 °C until the 
optical density at 600 nm (OD600) reached 0.7, at which time the expression was
induced with IPTG (0.5 mM) and the cells were grown for 4 h at 37 °C prior to 
harvesting the cells. After extracting the recombinant protein from the cells by 
sonication, purification of the enzyme was attempted. A pre-packed Q-Sepharose Fast 
Flow anion exchange column was used in an attempt to purify ADS. Cell lysis buffers 
(buffer 1: 20 mM Tris base, 5 mM EDTA, 2 mM b-ME, pH 8; buffer 2: buffer 1 with 1 M 
NaCl) were set up to create a gradient with increasing sodium chloride concentrations
to elute bound protein from the anion exchange column. SDS polyacrylamide gel 
electrophoresis (SDS PAGE) was used to analyse the fractions collected from the Q-
Sepharose column. Analysis of the resulting gel demonstrated that ADS did not bind to 
the column and had eluted from the column with the initial low salt wash. In attempts to 
overcome this problem, purification was repeated at pH 9, 10 and 11 and also using
anionic resin (DEAE Sepharose fast flow) at pH 6, 7, and 8. SDS PAGE verified that 
the protein did not bind to any of these resins at any given pH, and therefore that the 
purifications attempted using these methods had been unsuccessful.[98,150]
In an attempt to find another way to purify ADS, a hexahistidine-tag (His-tag) 
motif was introduced to the C-terminus of the protein. The addition of a His-tag motif 
should enable purification of ADS via nickel affinity chromatography. Before introducing 
a His-tag motif, the ADS gene was subcloned into a different expression vector, 
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pET21d. The pET21d vector contains an out of frame sequence for encoding a His-tag
motif, which the pTrc99a vector does not possess. 
The plasmid pET21d-GDS, present in the Allemann group library and 
containing the gene for germacrene D synthase, was used as the source of the 
required pET21d vector. pTrc99a-ADS and pET21d-GDS were digested with NcoI and 
BamHI restriction endonucleases to give the desired, isolated ADS gene and empty 
pET21d vector (Figure 2.1). The digestions were monitored using agarose gel 
electrophoresis and the desired fragments were cut out of the gel and purified using a 
QIAquick gel extraction kit protocol (Figure 2.2). These two complimentary, open 
fragments were ligated using T4 DNA ligase to give the new plasmid, pET21d-ADS. 
Figure 2.1 Cartoon representation of the insertion of the ADS gene into a pET21d vector.
Competent E. coli XL1 Blue cells were transformed with the resulting plasmid and 
colonies were grown on an agar plate containing ampicillin (100 µg/mL) in order to then 
inoculate LB medium with a single colony. The newly ligated plasmid was extracted 
using a QIAprep Spin Miniprep Kit Protocol and tested for successful ligation through 
the means of re-digestion. pET21d-ADS was digested with BglII because there are two 
BglII sites in the newly ligated plasmid, absent in the two parent plasmids, yielding a 
1041 base pair fragment when digested. In addition to this, NcoI and BamHI were also 
used to re-digest pET21d-ADS. This digestion yielded a 1649 base pair fragment, the 
isolated ADS gene (Figure 2.2). Digested samples were analysed by agarose gel 
34
electrophoresis. Samples that showed evidence of digestion were sequenced to 
demonstrate that the formation of pET21d-ADS was successful.
Figure 2.2 Agarose gels showing the results from digestion of DNA during the 
preparation of pET21d-ADS. Left: Results from digestions with BamHI and NcoI. Lanes 1-
4) Ptrc99a-ADS, Lanes 5-7) pET21d-GDS, Lane 8) DNA ladder measured in kilobase pairs. 
Right: Results from re-digestions of pET21d-ADS. Lane 1) DNA ladder measured in 
kilobase pairs, Lane 2) BglII, Lane 3) NcoI and BamHI, Lane 4) uncut pET21d-ADS.
2. 3 Introducing a C-terminal hexa-histidine motif into the pET21d-ADS 
plasmid
Once the formation of the plasmid, pET21d-ADS, was confirmed by DNA sequencing, 
site directed mutagenesis was performed to introduce a single nucleotide deletion into 
the nucleotide sequence at the 3’-end. This deletion was required to bring the C-
terminal hexa-histidine coding sequence of pET21d in frame with the ADS coding 
sequence. The ADS gene was followed by a stop codon that preceded the out of frame 
His-tag sequence, therefore a pair of primers were designed to eliminate the original 
stop codon, shift the His-tag in frame with the ADS coding sequence and create a new 
stop codon that followed after the His-tag (Figure 2.3). 
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Figure 2.3 Nucleotide coding sequence and deduced amino acids involved in introducing 
an ‘in-frame’ his tag motif.
During the SDM reaction, the mutagenic primers were integrated into the newly 
synthesised plasmid and the His-tag was shifted in frame with the ADS coding 
sequence. Once the SDM reaction was complete the resulting plasmids were digested 
with a DpnI restriction enzyme.[151] This was required to remove the original plasmid, 
which served as a template.[152] DpnI only digests the template plasmid because only 
this plasmid is methylated on the adenine residues in the sequence GATC, as a result 
of being purified from a dam+ strain in E. coli. The newly synthesised plasmids do not 
have this methylation and therefore are left intact.[153]
After site directed mutagenesis was performed, the resulting PCR product was 
transformed into E. coli XL1 Blue cells to clone the plasmid, after which sequencing 
confirmed successful addition of the c-terminal His-tag motif (pET21d-ADS His).
2. 4 Heterologous expression of the ADS gene
In order to determine the optimal conditions for the heterologous expression of the 
ADS gene, E. coli BL21 RP cells were transformed with the gene and test expressions 
were carried out using different culture conditions to assess the optimum isopropyl b-D-
1-thiogalactopyranoside (IPTG) concentration, temperature and duration of subsequent 
cell culture time (expression) (Figure 2.4). Test expressions were designed based on
two different literature procedures. Brodelius and co-workers[127] cultured cells at 30 °C 
until the optical density at 600 nm (OD600) reached 0.5 and induced with IPTG (0.2 
mM). The cells were then cultured at 30 °C for another 4 h prior to harvesting the cells. 
Kim and co-workers[125] also cultured cells at 30 °C until optical density reached 0.5, but 
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instead cells were induced with double the amount of IPTG (0.4 mM). The cells were 
then cultured at 20 °C for 6 h.
In addition to following these two protocols, a third test was implemented which 
consisted of inducing the cells when the optical density reached 0.5 using IPTG (0.4 
mM) and culturing them at 16 °C for 21 h. SDS PAGE was carried out to determine 
which protocol produced the most soluble protein. ADS has a relative molecular mass
of 66400 and therefore was detected around the 66.2 k band visible in the protein 
marker ladder (Figure 2.4). Whereas the first two sets of expression conditions showed 
varying amounts of ADS, the third set did not show any evidence of ADS expression.
Under the optimal conditions found, cells were cultured at 30 °C until the optical density 
reached 0.5, at which they were induced with IPTG (0.4 mM) and grown for 6 h at 20 
°C prior to harvesting the cells. Resulting pellets were stored at -20 °C. 
Figure 2.4 SDS-polyacrylamide gel showing the results from test expressions of ADS in 
BL21 RP cells. Lane 1) protein molecular weight ladder (x103 Mr), 2) empty, 3-7) samples 
taken at 0, 1, 2, 3 and 4 h after induction at 30 °C, 8) empty, 9-15) samples taken at 0, 1, 2, 
3, 4, 5 and 6 h after induction at 20 °C.
2. 5 Extraction and purification of ADS
In order to purify ADS, pellets of harvested cells were defrosted and re-suspended in a 
Tris cell lysis buffer and sonicated. Sonication causes fragmentation of the cells, which 
are then centrifuged to separate the cell debris from the supernatant mixture. If the 
protein is successfully extracted into the supernatant solution it is further purified. If the 
protein is still encapsulated in the pellet, a basic extraction method is carried out to 
extract the protein from inclusion bodies by unfolding and refolding the protein’s tertiary 
structure. The procedure involves increasing the pH of the re-suspended pellet to ~11 
in attempt to unfold the protein’s tertiary structure. The solution is left to stir for 30 min 
before the pH is returned back to pH 8, allowing for the tertiary structure to re-fold. The 
use of several cell lysis buffers have been reported in literature and three of those 
different buffers (cell lysis buffer 1[127], cell lysis buffer 2[125] and cell lysis buffer 3[154], 
ADS
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see Section 7.1.8) were tested for the extraction of ADS. When cell lysis buffer 1 (20 
mM NaxPO4, 0.5 M NaCl, 5 mM MgCl2, 10% v/v glycerol) was used, ADS did not 
extract into the supernatant solution after sonication or basic extraction. It is proposed 
that this could be due to protein aggregation and precipitation because the cell lysis 
buffer does not contain any reducing agents such as b-mercaptoethanol (b-ME) or 
dithiothreitol (DTT). No detergents such as TRITON, Tween 20 or CHAPS were used in 
the buffer either. Reducing agents are frequently used in cell lysate, purification and 
incubation buffers because it stops the formation of disulfide bonds between cysteine 
residues of neighbouring proteins, which can cause aggregation. Detergents can also 
be used to help solubilize membrane proteins and reduce the chance of the protein 
staying encapsulated in the pellet. When cell lysis buffer 2 (100 mM Tris-HCl, 1 mM
PMSF, 5 mM MgCl2, 10% v/v glycerol) was used, a slight improvement was observed 
with ADS protein present in the supernatant solution, but only after a basic extraction 
was carried out. The best results were found with the use of cell lysis buffer 3 (50 mM 
Tris-Base, 0.5 M NaCl, 5 mM imidazole, 20 mM b-ME 10% v/v glycerol). ADS protein 
was present in the supernatant solution after sonication, without the need for a basic 
extraction (Figure 2.5). This buffer was used subsequently for the extraction of ADS 
from the cell lysate. It is suggested that cell lysis buffer 3 resulted in the most efficient 
extraction of protein from the cell lysate because the buffer included a reducing agent, 
DTT, in addition to the detergent Tween 20. 
The extracted ADS protein was then purified using a Ni2+-NTA affinity column
(Figure 2.6). Affinity resin with bound divalent nickel ions were used to coordinate with 
the His-tag motif. This resulted in the ADS protein solely binding to the column, as the 
other proteins that do not have a His-tag flowed through the column with the cell lysate.
The column was washed with cell lysis buffer 3 consisting of increasing amounts of
imidazole. This enabled fractionation from the column with an excess of imidazole 
displacing the histidine residues, allowing the free protein to elute from the column. 
ADS started to elute in buffer containing 40 mM imidazole but impurities were also 
observed. Pure protein eluted during a wash with cell lysis buffer 3 containing 60 mM 
imidazole. Fractions containing the desired protein were pooled and dialysed against a 
dialysis buffer (Section 7.1.4) to remove the imidazole. The resulting protein was 
concentrated with an Amicon ultrafiltration system (MWCO - 30,000). The protein 
concentration was determined by the Bradford method.[155,156]
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Figure 2.5 SDS-polyacrylamide gels of attempts to extract ADS from cell lysate. Left: 
Lane 1) protein molecular weight ladder (x103 Mr), 2) empty, 3-4) re-suspended pellet and 
supernatant solution after sonication using cell lysis buffer 1, 5-6) re-suspended pellet 
and supernatant solution after basic extraction using cell lysis buffer 1, 7-8) re-
suspended pellet and supernatant solution after sonication using cell lysis buffer 2. 
Right: 1-2) supernatant solution after the first and second basic extraction using cell 
lysis buffer 2, 3-4) supernatant solution after basic extraction and sonication using cell 
lysis buffer 3, 5) re-suspended pellet after sonication using buffer 3, 6) re-suspended 
pellet after basic extraction using cell lysis buffer 2, 7) protein molecular weight ladder 
(x103 Mr).
Figure 2.6 SDS polyacrylamide gel showing selected fractions from the Ni-NTA 
purification of ADS. 1) protein molecular weight ladder (x10-3 Mr), 2) empty, 3-4) flow 
through, 5) empty, 6-7) cell lysis buffer with 5 mM imidazole, 8) cell lysis buffer with 10 
mM imidazole, 9-10) cell lysis buffer with 20 mM imidazole, 11) cell lysis buffer with 40mM 
imidazole, 12) cell lysis buffer with 60 mM imidazole, 13) cell lysis buffer with 80 mM 
imidazole, 14) cell lysis buffer with 100 mM imidazole, 15) cell lysis buffer with 300 mM 
imidazole.
ADS
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2. 6 Characterisation of amorphadiene synthase and amorphadiene
2.6.1 Product analysis using GC-MS 
Analytical incubations of ADS and FDP were carried out, not only to test activity of the 
purified ADS enzyme, but also to compare the product profile to those in reported 
literature. Incubations were left for 24 h and pentane extractable products were 
analysed using GC-MS (Figure 2.7). GC-MS analysis showed one major compound 
present, with a molecular ion at m/z = 204. The mass spectrum of the enzymatic 
product, amorphadiene (45) corresponds well with what is reported in literature.[124] As 
with previous reports, the most abundant peak is at m/z = 119. Depending upon the 
report used as the reference, the two second most abundant peaks, m/z = 189 (~ 90%) 
and m/z = 93 (~ 70%) either correlate[124] or are reversed.[123]
Figure 2.7 GC-MS analysis of pentane extractable products arising from incubation of 
ADS with FDP (36), Left: Gas chromatogram highlighting the formation of one major 
product, Right: The corresponding mass spectrum of the compound eluting at 13.26 min.
2.6.2 Size exclusion chromatography
Size exclusion chromatography (Superdex 75 10/300 GL) was used to determine 
whether ADS existed as a monomer, dimer or a bigger multi-subunit complex in 
solution.[157] The retention volumes of various proteins with known molecular mass 
were measured, in addition to the retention volume of ADS (Figure 2.8). Comparing the 
retention volumes of various proteins with the retention volume of ADS revealed that 
the protein existed as a monomer. In addition to comparing the retention volumes, the 
equation extrapolated from the calibration curve of molecular mass against retention 
volume also gave an estimate of the molecular weight of ADS. Using the equation 
(Figure 2.8), the molecular weight of ADS was calculated as 61000 compared to the 
actual molecular weight of 66400. 
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Figure 2.8 Left: Normalised and overlaid size-exclusion chromatograms of bovine serum 
albumin (BSA), d-cadinene synthase (DCS), pepsin, human dihydrofolate reductase 
(HuDHFR), E. coli dihydrofolate reductase (EcDHFR) and amorphadiene synthase (ADS), 
Right: Calibration curve of protein molecular mass against retention time.
2.6.3 pH Stability profile
Circular dichroism (CD) spectroscopy was used in preliminary analysis to examine the 
effect of varying solution pH on the secondary structure of ADS. CD spectroscopy is a 
useful technique for this study because each secondary structure element, such as a-
helices or b-sheets, has a specific CD signature spectrum measured in the UV region. 
This knowledge can be used when following changes in the structure of a molecule.[158]
Greenfield provided an example of this by measuring the CD of polypeptides and 
proteins with representative secondary structures. All sesquiterpene synthases are 
composed of several antiparallel a-helices.[86,100,159] Proteins with an a-helical 
secondary structure, such as ADS, display distinctive minima at 208 nm and 222 nm, in 
addition to a maximum at 193 nm.[160]
CD spectra of ADS (10 µM) were recorded between 190 nm and 300 nm at 
room temperature (recorded as 22.7 °C). Between the values of pH 6 and pH 9, in a 20 
mM NaxPO4 buffer, the folding of the enzyme was not affected as shown by an 
unchanging CD spectrum (Figure 2.9). Furthermore, the folding of the protein did not 
change over a period of 20 min. 
Once this was established the steady state kinetics were determined using the 
same range of pH values in the assay buffers.
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Figure 2.9 CD spectra of ADS at different pH values (pH 6-9). Spectra were recorded at 0, 
10 and 20 min intervals.
2.6.4 Steady-state kinetics
The catalytic efficiency of a sesquiterpene synthase is commonly measured by the use 
of steady state kinetics. This technique involves incubating various concentrations of 
radiolabelled substrate (in this case [1-3H]-FDP) with a set concentration of enzyme 
(ADS), for a specific length of time. An organic solvent, such as hexane, extracts the 
enzymatic-radiolabelled product and the radioactivity is measured through scintillation 
counting. The substrate is not soluble in the organic solvent and therefore only the 
radiolabelled product is present in the organic extracts. The results from the scintillation 
counting are used to obtain initial rates vs. substrate concentration, which is then re-
plotted to give a Michaelis-Menten curve, V = (Vmax.[S]) / (KM + [S]), to determine the 
kinetic parameters KM and kcat. The Michaelis constant, KM, is equal to the substrate 
concentration at which the rate of the reaction is half of the maximum. KM is 
approximately the inverse of the substrates affinity to the enzyme. The catalytic 
constant, kcat, measures the number of substrate molecules that are converted into 
products per unit of time. The ratio kcat/KM is a measure of the catalytic efficiency of the 
enzyme.
pH 6 pH 7
pH 8 pH 9
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To perform steady state kinetics, all parameters that influence the catalytic 
incubation were first optimised. The factors that were considered to have an effect 
were: incubation time, enzyme concentration, magnesium ion concentration, and the 
pH of the incubation. Each of the factors, in turn, was varied in analytical incubations 
with tritiated FDP and ADS (Figure 2.10). The resulting radioactivity was measured and 
the conditions that gave a rate; proportional to enzyme concentration, linear with time, 
constant with saturated magnesium concentration, and lastly a pH value that gave the 
maximum rate, were carried further for all future steady state kinetics. 
Figure 2.10 Graphs showing radioactivity counts per minute (CPM) against (top left) 
incubation time, (top right) enzyme concentration, (bottom left) magnesium 
concentration and (bottom right) pH for turnover of [1-3H]-FDP (10 mM) with ADS in an 
incubation buffer (20 mM HEPES, 1 mM DTT, 10 mM MgCl2).
Analytical incubations with tritiated FDP (10 µM) and ADS (100 nM) in incubation buffer 
(20 mM HEPES, 1 mM DTT, 10 mM MgCl2, pH 7.5) were set up for the incubation time
to be investigated. Incubations were performed between 0-30 min at 30 °C. Results 
showed that after 15 min, there was no increasing radioactivity observed in the hexane 
extracts. The incubation time of 10 min was chosen, as it was close to the maximum 
counts per minute (which is proportional to the product concentration), but still in the 
linear range. It is important to pick a value where time and counts follow a linear 
relationship because this assures that the initial rate is being measured. Enzyme 
43
concentration was then varied between 50-500 nM. The rate of product formation was 
directly proportional to enzyme concentration up to 200 nM. 100 nM was chosen as the 
optimal enzyme concentration because the rate must be proportional to the enzyme 
concentration in order for the enzyme concentration to be the only limiting factor. 
Variation of Mg2+ concentrations showed that the rate was directly proportional to Mg2+
concentrations up to 10 mM whereupon increasing metal ion concentration had no 
increasing effect upon rate, indicating that they were at saturating conditions at this 
concentration and above; therefore 10 mM Mg2+ was used in all incubation buffers 
subsequently. The pH value for the incubations was varied between 6 and 9. The rate 
increased as the pH of the incubations increased to 7.5, whereupon increasing pH had 
no effect on the rate. Therefore the pH value of 7.5 was chosen for all further 
incubations. 
The optimised conditions: 100 nM enzyme, 10 mM MgCl2, pH 7.5 and an 
incubation time of 10 min were used to measure the steady state kinetics of ADS 
catalysed turnover of [1-3H]-FDP. kcat and KM values, calculated as an average 
weighted mean from three separate experiments, were determined to be 0.016 ± 0.006
s-1 and 2.25 µM ± 0.30 µM respectively (Figure 2.11). The catalytic efficiency was 
calculated at 7.1 x 10-3 µM-1 s-1. The measured KM is consistent with that published by
Brodelius and co-workers, (KM was reported as 2.0 µM)[127] however the kcat was found 
to be 3-fold higher. Furthermore the values measured for ADS are similar to those 
measured for other sesquiterpene synthases.[98,161]
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Figure 2.11 Representative Michaelis-Menten graph of steady-state kinetic parameters of 
ADS.
2.6.5 Product analysis using NMR spectroscopy
To confirm the production of amorphadiene (45, Figure 2.12), an incubation of ADS 
with FDP was carried out on a scale that produced enough material to be analysed by 
NMR spectroscopy (>2 mg of product). Preparative scale incubations were carried out 
using typically around 50-100 mg of FDP. Incubations were left for 24 h and pentane 
extractable products (~80% yield) were analysed using NMR spectroscopy (Figure 
2.13). Both 1H and 13C NMR spectroscopy were used to carry out a series of 1D and 
2D experiments and the enzymatic product was identified as amorphadiene (45), with 
the spectra corresponding to data previously published (Table 2.1).[124,162] The 
characteristic peaks of amorphadiene are found at dH = 5.05, 4.87 and 4.64 ppm, 
highlighting the presence of the alkene protons at C2 and C13, respectively. A doublet 
at dH = 0.88 ppm corresponds to the C14 methyl group, and further downfield there are 
two singlets observed at dH = 1.74 and 1.60 ppm corresponding to the allylic methyl 
groups, C12 and C15, respectively. The proton at C1 appears as a broad multiplet at 
dH = 2.55 ppm.
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Figure 2.12 Structure of amorphadiene with the numbering system used in the 
assignment.
Figure 2.13 1H NMR spectrum (500 MHz, CDCl3) (Top) and 13C NMR spectrum (125 MHz, 
CDCl3) (Bottom) of pentane extractable products from an incubation of ADS with FDP 
(36).
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Table 2.1 Complete assignment of amorphadiene (45). Chemical shifts are reported 
relative to TMS in ppm.
2. 7 Mutagenesis of ADS
Without a crystal structure of amorphadiene synthase, the identities of the specific 
residues that are involved in the catalytic mechanism remain elusive. Zhang and co-
workers[107] tackled this by identifying a sesquiterpene synthase from A. annua, a-
bisabolol synthase (BOS), which exhibits a high sequence identity with ADS (82%). 
BOS converts FDP into 5 monocyclic sesquiterpenoids: a-bisabolol (60), trans-a-
bisabolene (111), b-bisabolene (112), cis-a-bisabolene (113) and cis-g-bisabolene 
(114) (Scheme 2.1). The crystal structure of BOS was solved and due to the similarities 
in sequence and mechanism (Scheme 2.1), the crystal structure was a good candidate 
as a template for ADS. A homology model was created for ADS (Section 1.3.2) and 
several presumed plasticity residues (residues which are crucial for the catalysis of the 
enzymes natural product) were identified and studied. Among these residues, T399, 
located in the substrate-binding pocket was found to be crucial for the activity of ADS. 
When threonine was replaced with a hydrophobic amino acid, such as leucine (ADS-
T399L), the product distribution changed considerably. Instead of amorphadiene (45) 
being the major compound of 92%, equal amounts of amorphadiene and amorpha-
4,7(11)-diene (64) were observed, in addition to low amounts of b-sesquiphellandrene 
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(63) and zingiberene (115) (Scheme 2.1). The formation of these additional products 
suggested that the change from threonine caused the enzyme to lose regioselectivity 
at the deprotonation step, as well as allowing for premature quenching of the C1 on 
cation 53 (Scheme 2.1). Similar product profiles were observed when threonine was 
replaced with alternative neutral amino acids, alanine and asparagine. Replacing 
threonine with charged residues, aspartic acid and arginine, resulted in a loss of 
catalytic activity. 
Mutant ADS-T399S showed a substantial increase in enzyme activity (kcat/KM
increased by approximately 72%), and possessed a higher turnover rate of FDP (kcat
increased by approximately 83%). Zhang and co-workers[107] proposed that the 
increase in activity was likely a result of accelerated product release since by replacing 
a threonine with a serine, the hydroxyl side chain remained in position 399 but 
increased in polarity. This in turn creates a more hydrophilic environment that would 
result in a faster release of the hydrophobic product. 
With all these findings combined, it was concluded that not only did the hydroxyl 
group on the side chain of threonine have an effect on the regioselective deprotonation 
step, but also on the rate of product release. 
Scheme 2.1 Proposed mechanisms for the conversion of FDP into sesquiterpene 
products catalyzed by BOS (red), ADS, ADS-T399L and ADS-T399S (black), with the 
additional products generated by ADS-T399L (blue).
A different approach was taken in this project when performing site directed 
mutagenesis on ADS. Instead of focusing on the C-terminal domain, which is 
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responsible for the enzymatic catalysis, SDM was performed in the N-terminal domain. 
The function of the N-terminal domain is still unclear, however it was observed first with 
TEAS, and later with (+)-bornyl diphosphate synthase (BPPS) from Salvia officinalis
that upon ligand binding to the C-terminal located active site, the N-terminus caps the 
active site of the enzyme to adopt a closed conformation, implying that it might be 
important for product release and desolvation of the active site.[104,163] By using SDM, 
purposely-engineered mutants can aid the mapping of the structure and function of the 
N-terminal domain. 
Previous work carried out in the Allemann group[96] (and unpublished work) 
involved constructing truncated and single point mutation variants inside the N-terminal 
domain of E-b-farnesene synthase (EBFS)[161,164] and d-cadinene synthase (DCS)[98,165].
EBFS and DCS catalyse the conversion of FDP to E-b-farnesene (59) and d-cadinene 
(116), respectively (Scheme 2.2). To examine the contribution of the N-terminal domain 
to the active site closure and desolvation, truncated variants were designed in attempts 
to gradually impair the structure of the N-terminal domain. Deletions, starting at the N-
terminus, of 14 (M14) and 24 (M24) residues in EBFS and 8 (M8), 20 (M20) and 30 
(M30) residues in DCS were constructed. 
It was found that with DCS, mutants M8 and M20 were reasonably functional 
synthases compared to the wild type, and the gradual deletion of residues led to a 
higher accumulation of germacradiene-4-ol (117), reaching 75% of total products by 
the M30 mutant (Scheme 2.2). This hydroxylated compound was proposed to be a 
result of premature quenching, by water, of the more stable allylic germacren-6-yl 
carbocation (55) due to an increase of solvation (Scheme 2.2). Steady state kinetics 
could not be recorded for M30 due to its very poor enzymatic activity. 
Similarly, mutants M14 and M24 of EBFS showed efficient catalytic activity with 
M14, however no activity with M24 (Scheme 2.2). The inactivation of M30 (DCS) and 
M24 (EBFS) clearly indicates that the N-terminal domain has an effect on the catalysis 
by these synthases. The accumulation of increasing amounts of germacradiene-4-ol 
(117), as the truncation of DCS increases, is most likely due to premature quenching of 
water, which implies that the N-terminal domain is involved in the desolvation and 
active site closure of the enzyme. This further implies that the structural contribution of 
the N-terminal domain to catalysis resides mainly in a highly conserved inner 
polypeptide strand (M21RPKADF27QPS30 in DCS) and (R15PPMTKH21APS24 in EBFS), 
despite the slightly different sequence of residues.
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Scheme 2.2 Proposed catalytic mechanisms of EBFS (Black & Green) and DCS (Black & 
Red). Increasing truncations of DNA in DCS causes premature quenching of germacrene-
6-yl cation (118) to form germacradiene-4-ol (117) (Blue).
To further investigate the role of the N-terminal domain, particularly after the conserved 
[XRP/PPXXXF/HXPS] motif, the X-ray crystal structure of DCS was compared to a 
homology model of EBFS (generated using the unrestricted algorithm of I-TASSER). 
The comparisons of both showed that aromatic residues, F30 in EBFS and F36 in 
DCS, were both positioned facing inwards towards the catalytic C-terminal domain. To 
explore whether they had any function towards catalysis, the phenylalanine residues 
were replaced with alanine residues. These single point mutations showed a 
substantial 4-fold increase in kcat and a small reduction in KM that combined, gave a 7-
fold enhancement of the catalytic efficiency for both enzymes. This observation could 
imply that although this phenylalanine residue is too far (>12 Å) from the active site of 
both enzymes, it is likely to be part of the structural determinant responsible for the 
product release, which is suggested to be the rate limiting step during the catalysis of 
sesquiterpene synthases.[166]
With these interesting results for EBFS and DCS in mind, the same approach 
was taken with ADS to see if the results would be complementary. The amino acid 
sequence of ADS was aligned with EBFS and DCS and it was found that EBFS M14 
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and DCS M20 were equivalents to ADS M8 (Figure 2.14). ADS M8 was created to see 
if enzymatic activity was retained like the latter mutants. Additionally if ADS M8 
produced any hydroxylated products, it would add further corroborating evidence for 
the postulate that the truncated segment causes an increase of solvation in the active 
site. 
Figure 2.14 Amino acid sequence alignment of the N-terminal residues of DCS, ADS and 
EBFS. Blue residues highlight the [XRP/PPXXXF/HXPS] motif. Orange residues highlight 
the phenylalanine in all three enzymes that was replaced with an alanine. Black M8, M20 
and M30 are truncated variants of DCS. Green M14 and M24 are truncated variants of 
EBFS. Red M8 is a truncated variant of ADS.
In order to truncate the first 8 residues of ADS, a primer was designed to introduce an 
NcoI restriction site in the corresponding point in the gene coding for the ninth residue. 
This resulted in mutant ADS-I9M/R10G (Figure 2.15). The unwanted mutation of R10G, 
required for the formation of the new NcoI site, was restored back to the original 
residue (G10R) with the use of another designed primer (Section 7.1.7) to form mutant 
ADS-I9M. 
The gene coding mutant ADS-I9M/R10G possesses two NcoI restriction sites 
located on the first and ninth residue, and therefore was digested with NcoI restriction 
enzyme to enable the truncation of 24 base pairs that code for the first 8 amino acids. 
Agarose gel electrophoresis was carried out to separate the two resulting fragments of 
DNA. The open stranded plasmid was ligated back together using T4 DNA ligase,
following the manufacturer’s protocol, to form ADS-M8/R10G. The fourth mutant 
created was ADS-M8, achieved by changing the glycine (G10) back to the original 
arginine (Figure 2.15).
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Figure 2.15 Design of mutants ADS-I9M/R10G, ADS-M8/R10G, ADS-M8 and ADS-I9M. Red 
residues denote NcoI sites; Green M’s denote start codons. i) Introduction of a second 
NcoI site, ii) digestion with NcoI restriction enzyme to truncate 24 base pairs that code 
for the first 8 amino acid sequence, iii) mutation G2R, iv) mutation G10R.
The four new mutants produced by heterologous expression in E. coli proved to be 
active variants, as shown by observation of pentane extractable products by GC-MS 
(Figure 2.16). Each gas chromatogram of the products deriving from incubation of each 
mutant with FDP was compared with that generated from incubation of the wild-type 
ADS (ADS-WT) with FDP. GC chromatograms of all the ADS variants did not show any 
formation of hydroxylated products.
In addition to studying the target mutant ADS-M8, steady state kinetics were 
measured for all four variants, summarized below (Table 2.2). Mutant ADS-M8 retained 
good enzymatic activity, with kcat and KM values of 0.0051 ± 0.0001 s-1 and 1.25 ± 0.10 
µM respectively (Figure 2.16). The catalytic efficiency was calculated at 4 x 10-3 µM-1 s-
1. Compared to ADS-WT, the Michaelis constant, KM, was almost half the value and the 
catalytic constant, kcat, was 3.2 fold less. This resulted in the catalytic efficiency of the 
enzyme, kcat/KM being almost half of that of ADS-WT. These results correlate with what 
was observed for DCS.[96] Although DCS-M20 had a larger KM than DCS, the kcat also 
decreased by 2.5 fold and the kcat/KM reduced by over 4 fold. The reduced catalytic 
constant and catalytic efficiency of ADS-M8 help conclude that although the specific 
function of the N-terminal domain remains unclear, it can be presumed that it plays a 
part in the structural contribution to the enzymes catalysis.
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Figure 2.16 Top left: Overlaid gas chromatograms of ADS-WT and ADS-I9M/R10G. Top 
right: Overlaid gas chromatograms of ADS-WT and ADS-M8/R10G. Bottom left: Overlaid 
gas chromatograms of ADS-WT, ADS-I9M and ADS-M8. Bottom right: Representative 
graph for the calculation of steady-state kinetic parameters of ADS-M8.
Table 2.2 Steady state kinetics carried out on ADS, ADS-I9M/R10G, ADS-M8/R10G, ADS-
I9M, ADS-M8 and ADS-F24A. 
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Carrying out additional Michaelis-Menten kinetics on mutants I9M/R10G, M8-R10G 
and I9M, showed that the replacement of arginine 10 with glycine (R10G) had a larger 
effect on the catalytic efficiency than truncating the first 8 residues from ADS. In both 
I9M/R10G and M8-R10G, the kcat was reduced to less than half of that measured for 
the WT and the binding constant, KM, was increased by more than 5-fold. This set of 
results strongly correlate with the idea that the structural contribution of the N-terminal 
domain to enzymatic catalysis resides mainly in a highly conserved inner polypeptide 
strand (I9RPIANF15PPS18), as was proposed previously.[96]
Amino acid sequence alignment highlighted that ADS had a phenylalanine in 
the same position as EBFS and DCS, however due to the shorter DNA coding 
sequence for ADS, this phenylalanine was in position 24 in the amino acid sequence, 
compared to F30 in EBFS and F36 in DCS (Figure 2.14). SDM was performed on ADS 
to replace the phenylalanine with an alanine (ADS-F24A) and the new mutant 
produced by heterologous expression in E. coli led to be an active variant, as shown by 
observation of pentane extractable products by GC-MS (Figure 2.17). Measurement of 
the steady state kinetics of ADS-F24A surprisingly did not follow the trend shown by 
EBFS and DCS but instead a kcat that had decreased by more than 10-fold (1.29 x 10-3 
s-1), and a slightly larger KM (2.67 µM) was found. This combination resulted in a 14-fold 
decrease in catalytic efficiency (5 x 10-4 µM-1s-1), relative to wild type ADS (Figure 
2.17). 
Figure 2.17 Left: Overlaid GC spectra of ADS-WT and ADS-F24A. Right: Representative 
graph for the calculation of steady-state kinetic parameters of ADS-F24A.
2. 8 Summary
To conclude, E. coli was successfully transformed with the ADS gene and 
heterologous expression of the gene in E. coli under optimal conditions produced the
corresponding ADS enzyme. The gene was originally transferred from a pTrc99a 
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vector to a pET21d vector to allow for a hexa-histidine motif to be introduced into the 
C-terminus of the pET21d-ADS plasmid. The addition of a His-tag allowed for an 
efficient purification of the ADS protein via nickel affinity chromatography. The 
enzymatic product, amorphadiene, was characterised by the means of NMR 
spectroscopy and GCMS and was in agreement with reported literature. 
Steady state kinetics were performed to determine the catalytic efficiency of 
ADS, and compare it to the catalytic efficiency of ADS reported in the literature. 
Parameters that influence the catalytic incubation were first optimised. Once the 
optimal conditions were determined; 100 nm ADS, 10 mM MgCl2, pH 7.5 and an 
incubation time of 10 min, steady state kinetics were carried out. kcat and KM values 
were determined to be 0.016 ± 0.006 s-1 and 2.25 µM ± 0.30 µM respectively. The 
catalytic efficiency was calculated at 7.1 x 10-3 µM-1 s-1. The measured KM is consistent 
with that published by Brodelius and co-workers,[127] however the kcat was found to be 
3-fold faster.
Lastly ADS mutants were designed and created to assess the contribution of 
the N-terminal domain on the enzymes catalysis. Mutant ADS-M8 possessed a 
truncation of 8 amino acids from the N-terminus of the enzyme and the catalytic 
efficiency of the mutant was almost half of that reported for the wild type, indicating that 
the N-terminal domain can be presumed to play a part in the structural contribution to 
the enzymes catalysis.
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Chapter 3. Synthesis of farnesyl diphosphate 
analogues
56
3.1 Preface
This chapter will cover the design and synthesis of each FDP analogue that was 
chosen to be tested as a substrate of ADS. A range of FDP analogues were designed 
and synthesised, including methylated, oxygenated and aza-derivatives with these 
alterations situated in various positions of the FDP backbone (Figure 3.1). This series 
of analogues enabled exploration of the scope of promiscuity displayed by ADS.
Figure 3.1 FDP analogues that were synthesised in this project. The numbering system 
shown on FDP (36) will be used throughout this report.
57
3.2 Diphosphorylation of farnesol analogues
To synthesise FDP analogues, the corresponding farnesol derivatives were first made, 
and then diphosphorylated. The diphosphorylation began with a halogenation of the 
alcohol on the farnesol derivative (119).[167,168] This was followed by a direct 
displacement of the halide (120) with tris(tetrabutylammonium) hydrogendiphosphate 
(121), to produce the corresponding diphosphate analogue 122 (Scheme 3.1) as 
described by Poulter and co-workers.[169]
Conversion of farnesol analogues to the corresponding allylic halide was carried 
out following two different procedures. The first yielded a farnesyl chloride analogue 
achieved by a nucleophilic substitution, via a mesylate intermediate, with lithium 
chloride.[167]
Alternatively, to prepare farnesyl bromide analogues, a direct nucleophilic 
substitution was carried out with phosphorous tribromide.[168]
The tris(tetrabutylammonium) hydrogendiphosphate salt was prepared by 
passing disodium dihydrogen diphosphate (123) through a Dowex AG 50W-X8 cation 
exchange resin (100-200 mesh, H+ form). Deionized water was used to elute the free 
acid and the resulting solution was titrated to pH 7.3 with tris(tetrabutylammonium) 
hydroxide. The resulting solution was lyophilised to yield 121 in the form of a white 
powder that was freshly recrystallized from ethyl acetate immediately prior to use.
Once the farnesol derivatives were diphosphorylated, purification of the 
corresponding FDP analogues was carried out in two different manners, resulting in the 
FDP salt with two alternative counter ions. The first method required purifying the crude 
FDP tris(tetrabutylammonium) salt by flash chromatography on silica gel (eluting with 
6:2.5:0.5, isopropanol: water: 30% ammonium hydroxide). TLC fractions that contained 
the diphosphate (6:3:1, isopropanol: water: 30% ammonium hydroxide, Rf: 0.3, 
visualisation with 4.2% ammonium molybdate and 0.2% ceric sulfate in 5% H2SO4) 
were pooled. The isopropanol was removed under reduced pressure and the remaining 
solution was lyophilized to give the FDP analogue possessing 
tris(tetrabutylammonium) counter ions (124).[170] The second purification method was 
performed by passing the crude FDP tris(tetrabutylammonium) salt through a column of 
DOWEX 50W-X8 cation exchange resin (ammonium form) to generate the FDP 
trisammonium salt, which was then further purified by reverse phase high performance 
liquid chromatography (HPLC – method used is stated in Section 7.2.1). Pure fractions 
were lyophilised to yield purified FDP analogues possessing ammonium counter ions 
(125).[169]
The advantage of exchanging the counter ions to ammonium ions was that, 
when exchanged, the form of the FDP analogue changes from an oil to a powder, 
making it easier to weigh as well as it possessing better chromatographic properties. 
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ADS was challenged with both forms of FDP (36). The enzyme was able to convert 
both into amorphadiene. In addition to this observation, by keeping the 
tris(tetrabutylammonium) ions, the purification time was halved, from two days to one. 
Scheme 3.1 Method of preparation of the FDP analogues synthesised in this work and 
purified to yield either tris(tetrabutylammonium) (124) or ammonium (125) salts.
3.3 Synthesis of FDP (36)
The synthesis of FDP (36, Scheme 3.2) was required to test the catalytic activity of 
ADS by GC-MS analysis, in addition to carrying out full kinetic analyses. The synthesis 
was performed following protocols reported by Meyers,[167] Poulter,[169] and Keller[170]
Beginning with commercially available farnesol (126), farnesyl chloride (127) was 
synthesised via a mesylate intermediate.[167] Farnesyl chloride was diphosphorylated 
with the use of tris(tetrabutylammonium) hydrogen diphosphate (121). The 24 h 
reaction of 127 and 121 afforded FDP (36) with tris(tetrabutylammonium) counter ions 
(124), achieving an overall yield of 51%.
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Scheme 3.2 Synthesis of FDP (36).
3.3.1 Methylated FDP analogues
Methylated analogues (12-methyl FDP, 128, 13-methyl FDP, 129, and 14-methyl FDP, 
130) were the first group of analogues chosen to test as substrates of ADS. The size of 
the functional group added to the FDP backbone was one of the concerns when 
designing this project. The dimensions of the enzymes active site and the extent to 
how big a substrate it can accommodate are unknown, and starting with a minimal 
change in size was seen as a good to start. Choosing a hydrocarbon group, instead of 
a heteroatom such as a hydroxyl group, also reduces the possibility of the novel 
analogue intercepting with the enzymatic mechanism, by either reacting with amino 
acid residues in the active site or with an intermediate carbocation during the catalytic 
cycle. 
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3.3.2 12-Methyl FDP (128)
Scheme 3.3 Synthesis of 12-Methyl FDP (128).
12-Methyl FDP (128) was prepared via a seven step synthesis (Scheme 3.3). This 
analogue has been previously synthesised in the Allemann group following a different 
synthetic route.[171] The first step was an acid-catalysed protection of farnesol (126) to 
form the tetrahydropyran ether 131 (94% yield).[172] This was followed by an allylic 
oxidation using a combination of selenium dioxide, salicylic acid and tert-butyl 
hydroperoxide to produce aldehyde 132 (23% yield).[173,174] The limitations that 
selenium dioxide brings, such as forming the reduced form of selenium and 
organoselenium by-products, were prevented by using it in a catalytic quantity and 
using tert-butyl hydroperoxide as a co-oxidant to regenerate SeO2 in situ. A Wittig 
olefination was carried out to convert 132 to 133 using methyl triphenyl phosphonium 
bromide and n-butyl lithium (56% yield).[175] The terminal unsaturated alkene in 133
was then hydrogenated with the use of a homogeneous catalyst 
chlorotris(triphenylphosphine)rhodium(I), also known as Wilkinson’s catalyst, used 
because of its ability to selectively hydrogenate the terminal alkene without affecting 
the other carbon-carbon double bonds in the compound (71% yield).[176] Once 134 was 
prepared, a deprotection of the tetrahydropyran ether with p-toluene sulfonic acid and 
methanol afforded the resulting alcohol 135 (94% yield), which in turn was brominated 
with phosphorous tribromide to 136 (89% yield) and immediately diphosphorylated to 
the final product, 128, with the use of salt 121.[168,169,177] After a 24 h reaction, the crude 
product was directly purified using flash chromatography on silica gel (6:2.5:0.5, 
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isopropanol: water: 30% ammonium hydroxide)[170] and was used as the 
tris(tetrabutylammonium) salt (124) (51% yield).
3.3.3 13-Methyl FDP (129)
Scheme 3.4 Synthesis of 13-methyl FDP (129).
13-Methyl FDP (129), a novel analogue to our knowledge, was synthesised in ten
steps (Scheme 3.4). With the use of N-bromosuccinimide in THF/H2O, a bromohydrin 
was successfully created from the distal alkene group of 131 to give 137 (67%
yield).[178] An intramolecular SN2 reaction with potassium carbonate and methanol 
formed the epoxide 138 (81% yield),[178] which was cleaved with sodium periodate and 
periodic acid to form aldehyde 139 (87% yield).[179] Once aldehyde 139 had been 
prepared, the next step was to carry out an olefination reaction that favoured the 
formation of the Z-alkene 140. 
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A Horner-Wadsworth-Emmons modification of the classic Wittig olefination was 
carried out to form an a, b-unsaturated ester (140). A typical phosphonoester, such as 
triethyl phosphonoacetate, could not be used in this synthesis, as it is commonly 
known that Horner-Wadsworth-Emmons reactions preferentially favours the formation 
of E-olefins.[145,180] To overcome this problem, triethyl phosphonoacetate had to be 
modified in a way that would yield Z-olefins stereoselectively. It has been reported by 
Still and Gennari,[181] by using a phosphonoester such as ethyl trifluoroethyl 
phosphonopropionate (141), electron-withdrawing groups are introduced to stabilize 
the formation of the erythro intermediate adduct. This in turn facilitates the elimination 
step to produce a Z-olefin (Scheme 3.5). 
Scheme 3.5 Possible products that result from a Horner-Wadsworth-Emmons olefination. 
A threo adduct gives rise to E-isomers, whereas an erythro adduct will result in the 
production of Z-isomers.
Three different procedures were carried out for the production of 141 (Scheme 3.6). 
The first procedure consisted of a Michaelis-Arbuzov reaction.[182,183] This is a SN2 
reaction where a nucleophilic phosphite, in this case triethyl phosphite 142, attacked an 
electrophilic alkyl halide, ethyl 2-bromopropionate 143. The resulting anionic halide 
then underwent a second SN2 reaction by attacking one of the alkyl groups attached to 
the phosphorous, forming a new alkyl halide and phosphonate 144 with a yield of 65%. 
Once 144 was synthesised, phosphorous pentachloride was used to yield 145 (61%
yield).[184] The replacement of the alkyloxy groups with chlorides generated a highly 
reactive phosphoryldichloride ready for the following reaction. Trifluoroethanol, with the
aid of diisopropylethylamine, was reacted with 145 to give 141 (22% yield).[181] After 
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each step the product was purified by fractional distillation under reduced pressure. 
The overall yield for this synthesis was poor, and was recorded as 9%.
The second approach to synthesising 141 was aimed at avoiding the use of the 
harsh reagent phosphorous pentachloride, which is corrosive, toxic and carcinogenic, 
in addition to finding better conditions for the last step with trifluoroethanol. Oberthur 
and co-workers[185] prepared the dichloride 145 via two steps, starting with triethyl 
phosphonopropionate (144). With the use of neat trimethylsilyl chloride, the reaction 
was carried out in screw-cap pressure tubes to afford 146. The only side product 
formed in this reaction was chloromethane, and therefore no further purification was 
required as chloromethane was removed with evaporation under reduced pressure. 
145 was prepared from 146 with the use of oxalyl chloride without the formation of any 
major side products, so again no purification was required. The final step was modified
from the first approach as trifluoroethanol was added with the addition of triethylamine 
instead of diisopropylethylamine and with the addition of 4-dimethylaminopyridine 
(DMAP).[186] In contrast to the first approach, this synthesis only required one 
purification step, after all three reactions. The overall yield was 84%.
The final approach to the synthesis of 141 only consisted of one step. Ethyl-2-
bromopropionate (143) was refluxed with trifluoroethyl phosphite (147) in the presence 
of potassium fluoride/alumina to yield 141 at 12%.[187]
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Scheme 3.6 Three alternative approaches for the synthesis of 141.
With both 139 and 141 synthesised, they were combined using the Still-Gennari 
olefination method to produce 140 (41%, 95:5, 11-Z:11-E). The olefination was carried 
out at -78 °C with the use of KHMDS/18-crown-6 as the base. Ando[188] states that in 
general, the vinyl protons of a Z-isomer exhibit signals in 1H NMR spectra that are seen 
further up-field compared to those of a corresponding E-isomer. This can be observed 
clearly when comparing a 1H NMR spectrum of 140 and its corresponding E-isomer
148 (Figure 3.2).
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Figure 3.2 Top: 1H NMR spectrum (300MHz, CDCl3) of 10Z-140. Bottom: 1H NMR spectrum 
(300MHz, CDCl3) of 10E-148.
Once the Still-Gennari reaction had produced the desired a,b-unsaturated ester 140, 
reduction with DIBAL gave alcohol 149 in a 62% yield.[189] The next functional group 
interconversion was challenging, as it required several steps. First, the alcohol moiety
of 149 was converted to a mesylate using methanesulfonyl chloride (MsCl) and 
triethylamine (NEt3), followed by a nucleophilic displacement of the mesylate group 
using lithium bromide. The resulting bromide 150 was displaced with a methyl group 
using lithium dimethyl cuprate to form 151 in a 60% yield. It was essential to carry out 
all three steps on the same day due to the instability of the bromide intermediate. 
The final two steps required deprotection of the alcohol functionality and 
diphosphorylation. Deprotection was carried out by pyridinium p-toluenesulfonate in 
methanol to form alcohol 152 (49% yield).[177] Diphosphorylation of the resulting 
farnesol analogue was generated from the corresponding chloride as described earlier. 
The crude diphosphate was passed through a cation exchange column replacing the 
tris(tetrabutylammonium) ions with ammonium ions.[167,169,190] 13-Methyl FDP (129) was 
obtained in a 36% yield after purification by HPLC.
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3.3.4 14-Methyl FDP (130)
Scheme 3.7 Synthesis of 14-methyl FDP (130).
14-Methyl FDP was synthesised over a total of 11 steps (Scheme 3.7) following a
synthetic route previously reported by Rawat and Gibbs.[191] The synthesis began with 
the formation of a dianion, prepared by treating ethyl acetoacetate (153) sequentially 
with sodium hydride and n-butyl lithium, and alkylating that dianion to dimethylallyl 
bromide (154) with a 64% yield.[192] The resulting product 155, was transformed in a 
highly stereoselective manner to the vinyl triflate 156 (80% yield), the intermediate 
required for the formation of 157 (80% yield).[193,194] With the addition of an ethyl group 
on the a-isoprene unit of 157, an additional chain elongation reaction was necessary to 
complete the synthesis of 130. Compound 157 was reduced to the geranyl derivative 
67
158 (80% yield), brominated to 159 (99% yield) and treated with a second dianion 
derived from ethyl acetoacetate, as described previously, to yield 160 (56% yield).[191]
160 was converted to an enol phosphate intermediate 161 (62% yield), to allow 
for substitution of the phosphate group with a methyl group by stereoselective coupling 
with lithium dimethylcuprate to form 162 (47% yield).[195] Ester 162 was reduced with 
DIBAL to give farnesol derivative 163 (86% yield), brominated to 164 (94% yield), and 
diphosphorylated to the final compound 130.[168,169] 130 was purified by flash 
chromatography on silica gel (6:2.5:0.5, isopropanol: water: 30% ammonium 
hydroxide) and was used as the tris(tetrabutylammonium) salt with a 44% yield.[170]
3.4 Oxygenated FDP analogues
Oxygenated FDP analogues were designed to introduce a variety of oxygenated 
functional groups in different positions of the FDP framework. These derivatives 
included the addition of acetoxy groups (13-acetoxy FDP, 165, 12-acetoxy FDP, 166, 
and 8-acetoxy FDP, 167), alcohol groups (12-hydroxy FDP, 168, and 8-hydroxy FDP, 
169) and methoxy groups (8-methoxy FDP, 170, and 12-methoxy FDP, 171).
Oxygenated FDP analogues were synthesised to investigate whether ADS 
could convert them into corresponding oxygenated amorphadiene analogues, with the 
oxygenated moiety providing a platform for further reactivity. It was also postulated that 
the use of heteroatom containing analogues might also enable premature quenching of 
carbocations hence competing with other nucleophiles present and giving insight into 
the catalytic mechanism.
Furthermore, looking at the biosynthesis of artemisinin (Section 1.3.2, Scheme 
1.4), it is clear that amorphadiene is converted to artemisinin through a series of 
oxygenated intermediates as a result of cytochrome P450 oxidations. By introducing an 
oxygen into FDP before the cyclisation to amorphadiene, it was postulated that ADS 
might be capable of generating an oxygenated intermediate of artemisinin, bypassing 
the need for one or more of the P450 enzymes.
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3.4.1 13-Acetoxy FDP (165)
Scheme 3.8 Synthesis of 13-acetoxy FDP (165).
The synthesis of 13-acetoxy FDP (165, Scheme 3.8), a novel analogue to our 
knowledge, began in the same manner as 13-methyl FDP (129, Section 3.4.2). Once 
intermediate 149 was synthesised, the alcohol was reacted with acetic anhydride and 
pyridine to introduce the acetoxy functional group on C13, and produce 172 (96% 
yield).[196] The following steps to the final FDP analogue required a deprotection of the 
tetrahydropyran ether, to form 13-acetoxy farnesol 173 (99% yield), followed by a 
diphosphorylation via a bromide intermediate, 174 (36% yield), to form the final 
product, 165.[168,169,177] 165 was purified by flash chromatography on silica gel 
(6:2.5:0.5, isopropanol: water: 30% ammonium hydroxide) and was used as the 
tris(tetrabutylammonium) salt with a yield of 20%.[170]
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3.4.2 12-Acetoxy FDP (166) and 12-hydroxy FDP (168)
Scheme 3.9 Synthesis of 12-acetoxy FDP (166) and 12-hydroxy FDP (168).
The allylic oxidation of 131, using a combination of selenium dioxide, salicylic acid and 
tert-butyl hydroperoxide (Section 3.4.1) not only produced aldehyde 132, but in 
addition, alcohol 175, which was actually the major product formed in this reaction, 
(175 - 48% yield).[173,174] To add the acetoxy functional group at C12, alcohol 156 was 
treated with acetic anhydride in the presence of pyridine to form 176 (95% yield).[196]
Acid catalysed deprotection of the THP ether resulted in 177 (97% yield) and 
diphosphorylation of 177 via a chloride intermediate produced 12-acetoxy FDP 
(166).[169,177] The crude product was passed through a cation exchange column,
replacing the tris(tetrabutylammonium) ions with ammonium ions, and purified by HPLC 
to give a yield of 35% over the two last steps (Scheme 3.9).[190]
12-Hydroxy FDP (168, Scheme 3.9), a known analogue synthesised by 
Koyoma and co-workers[197], was synthesised by hydrolysis of the acetoxy group with 
the use of 30% ammonium hydroxide. The reaction was carried out in deuterated water 
(D2O) to allow for easy monitoring of the reaction by 1H NMR spectroscopy. The 
reaction was complete once the acetyl methyl group corresponding to a singlet at dH = 
2.2 ppm, could no longer be observed. The protons on C12, corresponding to a singlet, 
shifted upfield from dH = 4.50 to 3.88 ppm (Figure 3.4). Once the reaction was 
complete, the solution was lyophilised to give 168 quantitatively as a white solid.
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Figure 3.3 1H NMR spectrum (500 MHz, D2O) of 12-acetoxy FDP 166 (top) and of 12-
hydroxy FDP 168 (below). Expansion of the region from dH = 2.0 to 5.6 ppm.
3.4.3 8-Hydroxy FDP (169) and 8-acetoxy FDP (167)
Scheme 3.10 Synthesis of 8-hydroxy FDP (169) and 8-acetoxy FDP (167).
The addition of a hydroxyl and acetoxy moiety on C8 of FDP was improved and 
shortened from the previous synthesis of analogues 166 and 168 (Section 3.5.2). The 
synthesis was optimised (Section 5) to reduce the overall steps to the desired 
analogues, and this was accomplished by starting with commercially available farnesyl 
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chloride (127). The allylic oxidation reaction, used previously for the synthesis of 
intermediates 132 and 175, also, as an additional product generates an alcohol group 
on C8 of FDP to create 178 (20%).[173,174] Using farnesyl chloride instead of the THP 
ether 131, conditions for the allylic oxidation were changed to accommodate the less 
stable intermediate. Instead of carrying out the reaction at room temperature, the 
reaction was left for 24 h at 0°C, and the workup that followed was maintained as cold 
as possible. This was achieved by using ice-cold diethyl ether for the extractions and 
storing each extract over ice. The resulting 8-hydroxy farnesyl chloride (178) was used 
immediately in the next step to avoid any decomposition of the chloride intermediate. 
The diphosphorylation was carried out in the same way as discussed for the previous 
analogues and the resulting product, 8-hydroxy FDP (169) was purified by flash 
chromatography on silica gel (6:2.5:0.5, isopropanol: water: 30% ammonium 
hydroxide) to result in a pure tris(tetrabutylammonium) salt with a yield of 57% 
(Scheme 3.10).[170]
8-Acetoxy FDP (167) was synthesised by treating FDP analogue 169 with 
acetic anhydride and pyridine (67% yield).[196] This reaction was carried out in 
deuterated chloroform (CDCl3) to enable the easy monitoring of the product formation 
by 1H NMR spectroscopy (Figure 3.5). The reaction was complete once the methyl 
group in the acetyl moiety, C17 of 167, could be observed as a singlet at dH = 2.2 ppm 
in addition to the downfield shift of the proton on C8, seen as a triplet, from dH = 3.93 to 
4.95 ppm (Figure 3.5).
72
Figure 3.4 1H NMR (500 MHz, CDCl3) spectrum of 8-hydroxy FDP 169 (top) and of 8-
acetoxy FDP 167 (bottom). Expansion of the region from dH = 2.0 to 5.5 ppm.
3.4.4 8-Methoxy FDP (170) and 12-methoxy FDP (171)
Scheme 3.11 Proposed synthesis of 8-methoxy FDP (170) and 12-methoxy FDP (171).
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The addition of a methoxy functional group on FDP at C8 (8-methoxy FDP, 170) and 
C12 (12-methoxy FDP, 171) were carried out in the same manner (Scheme 3.11). 
Once both intermediates, 179 and 175, were synthesised by allylic oxidation of 131, 
they were treated with sodium hydride and methyl iodide to afford 180 and 181, with a 
yield of 38% and 76%, respectively.[173,174,198] Both intermediates were deprotected to 
the corresponding farnesol derivatives, 182 and 183, with 10% hydrochloric acid (87% 
and 80% yield, respectively), before being diphosphorylated to final compounds, 8-
methoxy FDP (170) and 12-methoxy FDP (171).[169] Both FDP analogues were purified 
by flash chromatography on silica gel (6:2.5:0.5, isopropanol: water: 30% ammonium 
hydroxide) and used as the tris(tetrabutylammonium) salts (52% and 32% yield, 
respectively).[170]
3.5 Aza-FDP analogues
12-Acetamido FDP (184) and 12-amino FDP (185), both novel FDP analogues to our 
knowledge, were designed in attempts to create the corresponding aza derivatives of 
amorphadiene. There have been reports of novel artemisinin analogues containing 
nitrogen that possess antimalarial activities.[199,200] If ADS is capable of converting aza-
FDP analogues to the bicyclic amorphadiene framework, there is a possibility of 
carrying that aza group through to the desired artemisinin structure, and this gives the 
possibility of creating new antimalarials. In addition to this, the additional functional 
group also provides a new platform to perform further reactions, once an 
amorphadiene analogue has been created.
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3.5.112-Acetamido FDP (184)
Scheme 3.12 Synthesis of 12-acetamido FDP (184).
12-Acetmido FDP (184) was synthesised in 8 steps (Scheme 3.12). Once the hydroxyl 
intermediate, 175 was formed, a Gabriel synthesis was carried out to convert the 
hydroxyl moiety to an amine. A Gabriel synthesis consisted of using potassium 
pthalimide, triphenylphosphine and diisopropyl azodicarboxylate (DIAD) to replace the 
alcohol with a pthalimide, forming 186 (75% yield), which was subsequently treated 
with hydrazine to give amine 187 (71% yield).[201–204] Acetylation of amine 187 was 
carried out with excess isopropenyl acetate (188) in the absence of a solvent and 
catalyst.[205] Isopropenyl acetate is an efficient source for adding an acetyl group to an 
amine moiety because the alcohol 189 produced as a side product tautomerises to 
acetone (190) and serves purpose as a solvent in addition to shifting the equilibrium to 
the product (Figure 3.6). The corresponding acetamide 191 was obtained in a 
quantitative yield that required no further purification.
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Figure 3.5 Acetylation of amine 187 with isopropenyl acetate (188).
The THP ether of 191 was deprotected with p-toluene sulfonic acid to yield 12-
acetamido farnesol (192) in 87% yield.[168] The alcohol was brominated to 193 (90% 
yield) and diphosphorylation of the bromide led to the formation of 12-acetamido FDP 
(184).[169,177] The product was purified by flash chromatography on silica gel (6:2.5:0.5, 
isopropanol: water: 30% ammonium hydroxide) to provide a pure 
tris(tetrabutylammonium) salt, in 9% yield. 
3.5.2 12-Amino FDP (185)
Scheme 3.13 Synthesis of 12-amino FDP (185).
The synthesis of 12-amino FDP (185, Scheme 3.13) also required the formation of 
intermediate 187. It was not possible from this intermediate to deprotect the THP ether 
and diphosphorylate to 12-amino FDP (185), because of the nucleophilic property of 
the amine. The lone pair on the nitrogen will attack at C1 of a neighbouring molecule 
once the deprotected alcohol 194 is brominated (195) (Figure 3.7). 
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Figure 3.6 Intermolecular nucleophilic attack from the lone pair on the nitrogen 
preventing the diphosphorylation of 12-amino farnesyl bromide (195).
The amine group therefore had to be protected with fluorenylmethyloxycarbonyl 
chloride (Fmoc-Cl). Once 196 was formed with a 74% yield, the THP ether was 
deprotected to 197 (86% yield), brominated to 198 (89% yield) and finally 
diphosphorylated to 199.[168,169,177] The crude product was purified by flash 
chromatography on silica gel (6:2.5:0.5, isopropanol: water: 30% ammonium 
hydroxide) to provide a pure tris(tetrabutylammonium) salt with a yield of 22%. In 
addition to purifying the FDP analogue, the purification also cleaved the FMOC group 
due to the basic solution used to elute the compound off the column to yield 12-amino 
FDP (185).
3.6 Summary
This chapter has covered the synthesis of a library of analogues that will be incubated 
with ADS to test for substrate activity. The library was designed to add various 
functional moieties in a range of locations on the FDP skeleton. Each FDP analogue, in 
turn, was tested with ADS and their enzymatic products, if any, are reported in Chapter 
4. 
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Chapter 4. Characterisation of ADS generated products
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4.1 Preface
FDP analogues were incubated with ADS in attempts to create novel amophadiene 
analogues. In addition to this goal, the incubations also gave insight into the extent of 
the enzymatic promiscuity by using a variety of functional groups, positioned in various 
locations on the FDP backbone. With this array of analogues, it was observed that 
ADS was capable of producing amophadiene analogues, as well as converting FDP 
analogues through different mechanisms to produce other cyclic and acyclic 
compounds. Incubations of ADS with FDP analogues were primarily analysed by GC-
MS. The mass spectra of novel products formed in this report, catalysed by ADS, could 
not be definitively identified by the National Institute of Standards and Technology 
(NIST)[206] library due to the products being unnatural terpenes. However, their 
fragmentation patterns were compared to those of amorphadiene and other 
sesquiterpenes to see if there was any correlation that could help indicate the structure 
of the unknown products. Upon observing a maximum of two products, the incubation 
was repeated on a preparative scale to obtain enough material for NMR analysis.
Preparative scale incubations were not carried out for incubations that produced more 
than two products because the enzymatic products proved difficult to separate. All 
incubations carried out with ADS and an FDP analogue were carried out in parallel to 
an incubation of the analogue with no ADS. This control was implemented so that any 
product observed by GC-MS was assured to be an enzymatic product. 
4.2 Methylated FDP analogues
4.2.1 12-Methyl FDP (128)
Figure 4.1 12-Methyl FDP (128)
Incubation of ADS with 12-methyl FDP (Figure 4.1) produced five pentane extractable 
products, when analysed by GC-MS (for the analysis of all enzymatic products, a 
temperature gradient of 80 °C (1 min hold) to 180 °C (4 °C min-1, 2 min hold) was used, 
with an injector temperature of 100 °C) (Figure 4.2). All five compounds had a 
molecular ion with m/z = 218 corresponding to C16H26 or the expected mass for a 
methyl substituted sesquiterpenoid. Upon studying the mass spectra, it was clear that 
the compounds eluting at 16.82 and 17.66 min showed similar fragmentation patterns
with base peaks at m/z = 189. The remaining three compounds, at 18.52, 19.21 and 
24.68 min also showed similar fragmentation patterns, differing from the first pair, they 
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exhibited base peaks at m/z = 119. The mass spectra of the last three compounds 
were comparable with that of amorphadiene, which also has a base peak at m/z = 119 
(Figure 4.2).
Figure 4.2 A: Total ion chromatogram of pentane extractable products from incubation of 
ADS and 12-methyl FDP (128). B-F: Mass spectra of the eluted compounds. G: Mass 
spectrum of amorphadiene (45).
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The fragmentation patterns seen in mass spectra cannot give a definite identification of 
products, but can support predictions of products formed. Due to the incubation giving 
five products, it was not considered feasible to repeat this incubation on a preparative 
scale to analyse the products by NMR spectroscopy.
The identification of certain fragments in the mass spectra can aid in predicting 
possible products formed from an incubation of ADS with 12-methyl FDP. Brodelius 
and co-workers[128] report the use of single ([1-2H]-FDP) and double ([1,1-2H2]-FDP) 
deuterated FDP at C1 to solve the identification of certain fragments observed in a 
mass spectrum of amorphadiene (Section 1.3.2, Figure 1.9). By combining the use of 
deuterated analogues with the knowledge of the catalytic mechanism of ADS, their 
group identified peaks at m/z = 189, 121, and 93 (Figure 4.3). The differences in m/z
between the major fragment peaks in the mass spectra of amorphadiene arising from
FDP, [1-2H]-FDP and [1,1-2H2]-FDP led to assignment of cation 74 at m/z = 189, cation 
75 at m/z = 121 and cation 76 at m/z = 93. 
Figure 4.3 Proposed cations resulting from the fragmentation of amorphadiene (45) 
reported by Brodelius and co-workers.[128]
It was hypothesised that the additional methyl group on C12 would not interfere with 
the mechanism of ADS until the last cation, the ‘12-methyl amorphyl cation’ (200, 
Scheme 4.1) was formed, because C12 is not directly involved in the catalytic cycle. 
The last step, a deprotonation to quench cation 200, could then occur from three 
feasible locations. Deprotonation at C13 would result in an amorphadiene analogue, 
201. Alternatively, deprotonation at C12 would result in two isomers of another 
amorphadiene analogue, 202 and 203. Lastly, a deprotonation at C10 could occur, and 
this would give rise to 204. The formation of a fifth compound is not possible through 
an alternative deprotonation step to quench cation 200. Instead it is postulated that 
either a 1,2 or 1,3-hydride shift, followed by a deprotonation of the subsequent cation, 
205 or 206 respectively, could be plausible for the formation of the final compound 
yielding products such as 207 or 208 (Scheme 4.1).
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Scheme 4.1 Proposed products formed from incubation of ADS with 12-methyl FDP (128).
Furthermore to attempt identification of the products, plausible fragmentation routes for 
each proposed product were proposed. Hence it was postulated that compounds 201
and 204 would give mass spectra that had a base peak at m/z = 189 (16.82 and 17.66 
min). This would indicate the loss of an ethyl group, giving cation 74 (Figure 4.3). The 
same peak at m/z = 189 is observed for amorphadiene, indicating a loss of a methyl 
group. Compounds 202 and 203 however do not have an ethyl group attached on C11 
so the peak at m/z = 189 for these compounds will not represent the most stable cation 
formed. In fact in the mass spectra for the compounds at 18.52 and 19.21 min, the 
peak at m/z = 189 decreases to around 40%. In these mass spectra, the base peak is 
at m/z = 119, which represents cation 75. This is a feasible base peak for compounds 
202 and 203. A base peak at m/z = 119 for products 207 and 208 is also feasible.
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4.2.2 13-Methyl FDP (129)
Figure 4.4 13-Methyl FDP (129)
Incubation of ADS with 13-methyl FDP (129, Figure 4.4) generated three pentane 
extractable products (Figure 4.5), which all had a molecular ion peak with m/z = 218. 
The fragmentation patterns observed in the mass spectra were found to be similar to 
those analysed for the analogue, 12-methyl FDP (128). Unfortunately these two 
substrates were tested with ADS in different periods of the research project and so they 
were not analysed using the same GC column. This precluded the possibility of 
comparing the enzymatic products by co-elution or by comparing their retention times. 
Nevertheless, it did not affect the fragmentation pattern in the mass spectra, and so 
these could still be used to compare the two sets of products.
Figure 4.5 A: Total ion chromatogram of pentane extractable products from incubation of 
ADS and 13-methyl FDP (129). B-D: Mass spectra of the eluted compounds. 
A B
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Similar to the mass spectra observed for 12-methyl FDP (128), the first two compounds 
observed in the GC, at 27.46 and 28.03 min, give a base peak at m/z = 189. Assuming 
ADS transforms 13-methyl FDP in the same manner to the natural substrate, FDP, until 
it forms the 13-methyl amorphyl cation 209, structures such as 210 and 201 can be 
achieved with a deprotonation on C10 and C12 respectively, and seem fitting for the 
identification of the first two unknown compounds (Scheme 4.2). These assignments 
are based on the theory given behind the formation of compounds 201 and 204
discussed above (Section 4.2.1). The third compound at 28.94 min differs, with the 
base peak found at m/z = 119. The absence of a second compound with a base peak 
at m/z = 119 could imply that only the generation of 202 or 203 is possible (Scheme 4.1 
and 4.2). The reduced number of products generated by 13-methyl FDP (129) and 
ADS, relative to 12-methyl FDP (128) and ADS, could suggest that the analogue is 
bound in an orientation in the active site that prevents the C10-C11 bond freely rotating 
when the corresponding 13-methyl amorphyl cation (209) is formed, and therefore the 
two analogues are not converted to the same products. If the conformations of 12-
methyl FDP and 13-methyl FDP are different when bound in the enzymes active site, 
all of the viable locations to deprotonate and therefore quench the amorphyl cation 209
might not be accessible by basic residues. In addition to this, the C11-C13 bond may 
also not be capable of freely rotating (Scheme 4.2).
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Scheme 4.2 Proposed products formed from incubation of ADS with 13-methyl FDP (129).
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4.2.3 14-Methyl FDP (130)
Figure 4.6 14-Methyl FDP (130)
Incubation of ADS with 14-methyl FDP (130, Figure 4.6) generated one pentane 
extractable product, when analysed by GC-MS. The single enzymatic product had the 
expected molecular ion peak with m/z = 218 (Figure 4.7). 
Figure 4.7 A: Total ion chromatogram of the pentane extractable product from incubation 
of ADS and 14-methyl FDP (130). B: Mass spectrum of the eluted compound.
It was hypothesised that if ADS carried out the same catalytic mechanism with 14-
methyl FDP as it does with the natural substrate, FDP, it would form an amorphadiene 
analogue, 14-methyl amorphadiene (211, Scheme 4.3). 
Since only one product was observed by GC-MS, this incubation was carried 
out on a preparative scale (Section 2.6.5) to generate enough material to analyse and 
characterise the enzymatic product by NMR spectroscopy. The 1H NMR spectrum 
(Figure 4.8) of the enzymatic product supported the structure of an amorphadiene 
analogue. Due to the identical chemical shifts for the olefinic protons on C2 and C13, 
as well as the proton on C1, in both 1H NMR spectra of amorphadiene (45, Section
2.6.5, Figure 2.13) and the proposed 14-methyl amorphadiene (211, Figure 4.8), it was 
confirmed that ADS had converted this compound via same mechanism as for the 
natural substrate, FDP. The region between dH = 2.0 and 0.5 ppm however was 
contaminated with impurities that were not successfully separated. Unfortunately this 
hindered the identification of the new alkyl peak for the additional methyl group on C14, 
as well as the possibility of observing the loss of the doublet around dH = 0.8 ppm for 
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the presence of the methyl group on C7 in the amorphadiene 1H NMR spectrum. It was 
predicted that the position of the new methyl group on C14 would not affect the rest of 
the synthesis to achieve the corresponding artemisinin derivative, 14-methyl 
artemisinin (212, Scheme 4.3).
Figure 4.8 1H NMR spectrum (500 MHz, CDCl3) of the pentane extractable product from a 
preparative scale incubation of ADS with 14-methyl FDP (130). ‘*’ symbol indicates 
impurities.
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Scheme 4.3 Proposed mechanism of ADS catalysed turnover of 14-methyl FDP (130) and 
the corresponding artemisinin analogue (212).
4.2.4 15-Methyl FDP (219)
Figure 4.9 15-Methyl FDP (219)
15-Methyl FDP (219, Figure 4.9) was previously synthesised by Dr. Sabrina Touchet 
and was generously gifted to test with ADS on an analytical scale. Incubation of ADS 
with 15-methyl FDP produced one major pentane extractable product, when analysed 
by GC-MS. The mass spectrum of this product revealed a molecular ion peak with m/z
= 218 (Figure 4.10).
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Figure 4.10 A: Total ion chromatogram of the pentane extractable product from 
incubation of ADS and 15-methyl FDP (219). B: Mass spectrum of the eluted compound.
It was predicted in this case that the additional methyl group on 15-methyl FDP, 
compared to the natural substrate, would not interfere with the usual reaction pathway 
demonstrated for FDP. A proposed mechanism (Scheme 4.4) conveys how it is 
plausible for ADS to convert 15-methyl FDP (219) into 15-methyl amorphadiene (220). 
In addition to not interfering with the mechanism of ADS, it was predicted that the 
position of the methyl group on C15 would not interfere with the formation of the 
corresponding artemisinin derivative, 221 (Scheme 4.4). 
Fragments 228-231 were suggested as plausible cations resulting from the 
fragmentation of 15-methyl amorphadiene (Figure 4.11) and relate well with the 
fragmentation peaks observed in the mass spectrum (Figure 4.10). Cations 228-231
are also in agreement with cations 73, 232, 233 and 234 formed from the 
fragmentation of amophadiene. The base peak at m/z = 133, which represents cation 
230, correlates with the base peak observed for amorphadiene at m/z = 119, with an 
increase of m/z = 14 corresponding to the extra CH2 group (Figure 4.11).
As this was a gift for an analytical scale incubation, there was not enough of the 
enzymatic product to analyse by NMR spectroscopy to confirm the formation of the 
proposed ‘15-methyl amorphadiene’.
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Scheme 4.4 Proposed mechanism of ADS catalysed turnover of 15-methyl FDP (219) and 
the corresponding artemisinin analogue (221).
Figure 4.11 Plausible ions formed from the fragmentation of 15-methyl amorphadiene 
(top) and amorphadiene (bottom).
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4.3 Oxygenated analogues
4.3.1 12-Hydroxy FDP (168)
Figure 4.12 12-hydroxy FDP (168)
It is known that amorphadiene is oxidised at position C12 to create artemisinic alcohol 
(46) during the biosynthesis of artemisinin (Scheme 4.5). A plan was implemented to 
introduce an alcohol group on C12 of the FDP backbone, before the analogue was 
incubated with ADS, rendering the cytochrome P450 (CYP71AV1) reaction, which 
achieves this oxidation on amorphadiene in-vivo, unnecessary.[111,116] 12-Hydroxy FDP 
(168, Figure 4.12) was created on this basis, to incubate with ADS and attempt to 
create the corresponding compound, artemisinic alcohol directly and without the need 
for the subsequent oxidation reaction (46, Scheme 4.5).
Scheme 4.5 Biosynthetic pathway to artemisinin (6) in Artemisia annua.
Incubation of ADS with 12-hydroxy FDP (168) generated three pentane extractable 
products, when analysed by GC-MS. All three compounds showed molecular ion peaks
with m/z = 220 (Figure 4.13). 
In order to identify the chemical structures of these compounds, preparative 
scale incubations were carried out to obtain enough material to characterise them by 
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NMR spectroscopy. Surprisingly, the 1H NMR spectrum (Figure 4.14) of the enzymatic 
products showed that ADS did not convert 12-hydroxy FDP into artemisinic alcohol. 
The prominent pair of doublets found around dH = 9.6 ppm indicated the presence of 
two aldehydes. Furthermore, upon studying the 1H NMR spectrum, it was confirmed 
that although artemisinic alcohol was not produced, as expected, the bicyclic 
hydrocarbon frame of amorphadiene was present in the unknown products. This was 
concluded from the presence of the olefinic protons at dH = 5.1 and 5.3 ppm and the 
protons at C1 observed at dH = 2.4 and 2.5 ppm, which are all representative of those 
protons found in amorphadiene (45, Section 2.6.5, Figure 2.13).
Figure 4.13 A: Total ion chromatogram of the pentane extractable products from 
incubation of ADS and 12-hydroxy FDP (168). B-D: Mass spectra of the eluted 
compounds. 
 
It was evident instead that two aldehydes were present since the two sets of doublets 
around dH = 9.6 ppm are characteristic of CH=O protons. Artemisinic aldehyde (47) and 
dihydroartemisinic aldehyde (49) are both downstream intermediates in the 
biosynthesis of artemisinin. Artemisinic aldehyde, (47, Scheme 4.5) was eliminated as 
a possible product since the mass spectrum of this compound requires a molecular ion 
peak with m/z = 218, not 220 as observed.
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Figure 4.14 1H NMR spectrum (500 MHz, CDCl3) of the enzymatic products generated 
from incubation of ADS with 12-hydroxy FDP (168).
By comparing the mass spectra and 1H NMR spectrum of the enzymatic products, with 
those found in literature for dihydroartemisinic aldehyde, it was confirmed that the two 
epimers of dihydroartemisinic aldehyde (11S-49 and 11R-49, Figure 4.14) were 
isolated from incubation of ADS and 12-hydroxy FDP.[105] The compounds observed in 
the GC at 22.29 and 22.48 min share similarities in the fragmentation patterns 
observed in the mass spectra, displaying peaks with identical m/z values, and only 
differing in their base peaks. The mass spectrum of 11R-49 has a base peak at m/z = 
162, whereas 11S-49 displays a base peak at m/z = 187, and so it was proposed that 
these two peaks represented the two epimers generated in a 2:7 (R:S) ratio. 
Surprisingly, when the same sample was analysed by NMR spectroscopy, this ratio 
changed to 2:3 (R:S). The difference in ratios observed by GC-MS and NMR 
spectroscopy is still open for discussion, as a reasonable rationale has not been found
yet. It has previously been stated that the (R)-epimer (11R-49) is the desired precursor 
to artemisinin with research groups managing to distinguish between the two epimers 
of dihydroartemisinic aldehyde by comparing their elution times with the elution time of 
an authentic sample of (11R)-dihydroartemisinic aldehyde.[114,162] By comparing the gas 
chromatogram with the gas chromatograms found in literature, the predominant 
compound produced from incubation of ADS and 12-hydroxy FDP (168) was found to 
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be (11S)-dihydroartemisinic aldehyde. In addition to this, (11R)-dihydroartemisinic 
aldehyde was synthesised from commercially available (11R)-dihydroartemisinic acid 
(50) via two steps to confirm this assignment, which will be further discussed in Section 
5. The NMR spectroscopy and GCMS characterisation of the synthesised (11R)-
dihydroartemisinic aldehyde was in agreement with the data found in literature.[105,162]
With a hydroxyl group added to C12 of FDP, it can be assumed that the 
enzyme will convert the analogue through the same mechanism as FDP until the ‘12-
hydroxy amorphyl cation’ (235) is formed. With the natural substrate, FDP (36), the 
enzyme completes the mechanism with a deprotonation at C12 or C13 to produce 
amorphadiene (45). Instead, with 12-hydroxy FDP, there are two plausible 
mechanisms to achieve dihydroartemisinic aldehyde. Firstly, a 1,2-hydride shift can 
take place on the a-carbon forming cation 236, followed by a deprotonation of the 
alcohol group to afford the aldehyde. Alternatively, a deprotonation on the a-carbon 
can form an enol intermediate 237. Tautomerism of the enol to the more stable 
aldehyde form, also affords dihydroartemisinic aldehyde (Scheme 4.6). 
Scheme 4.6 Proposed mechanism for the formation of 49 from incubation of ADS and 12-
hydroxy FDP (168).
In addition to the two epimers of dihydroartemisinic aldehyde, a third compound at 
21.23 min was also observed in the gas chromatogram. The identity of this third 
compound is suggested to be the corresponding enol that tautomerizes with the 
aldehydes, but this has yet to be unambiguously demonstrated. To support this
proposition and clarify whether the aldehydes tautomerise with an enol intermediate, 
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an incubation of ADS with 12-hydroxy FDP in a deuterated buffer was carried out. This
experiment was intended to test whether an incorporation of a deuterium could be 
observed in the aldehydes, however this test would not be able to identify which 
mechanism achieves the products. The mass spectrum of the incubation products 
revealed that there was an incorporation of deuterium in (11S)-dihydroartemisinic 
aldehyde, shown by an increases of m/z = 1 in the molecular ion (Figure 4.15). This 
incorporation shows that it is viable for the enzyme to deprotonate the a-hydrogen, 
forming an enol (237), which effectively tautomerizes to the resulting aldehyde. 
Surprisingly, the deuterium incorporation was not observed in the mass spectrum for 
the (11R)-epimer. This suggests that only the (11S)-epimer is in equilibrium with enol 
237, whereas once the (11R)-epimer is formed, it remains as the stable conformer.
Figure 4.15 Mass spectra of (11-S)-[11-1H]-dihydroartemisinic aldehyde (top) and (11-S)-
[11-2H]-dihydroartemisinic aldehyde (bottom). An increase of m/z = 1.01 can be observed 
prior to the fragmentation peak indicating a loss of the CHOCHCH3 tail (m/z = 162.14).
This observation further indicates that the incorporated deuterium is positioned on C11.
H
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4.3.2 12-Acetoxy FDP (166)
Figure 4.16 12-Acetoxy FDP (166)
12-Acetoxy FDP (166, Figure 4.16) was a synthetic precursor to the previously 
discussed analogue 12-hydroxy FDP (168) (Section 3.5.2, Scheme 3.9). The products 
generated when 12-acetoxy FDP was incubated with ADS were, surprisingly, identical 
to those generated from 12-hydroxy FDP (Figure 4.17).
Figure 4.17 Total ion chromatogram of the pentane extractable products from incubation 
of ADS and 12-hydroxy FDP (168) (top) and 12-acetoxy FDP (166) (bottom).
There were three possibilities considered as to how 12-acetoxy FDP was converted to 
the same products as 12-hydroxy FDP. The first plausible solution was that the acetyl 
group is hydrolysed non-enzymatically in the buffer, forming 12-hydroxy FDP (168). 
This proposition however did not seem likely since the conditions required to de-protect 
the acetoxyl moiety to produce 12-hydroxy FDP (Section 3.5.2, Scheme 3.9) required a 
base, in this case 30% ammonium hydroxide, and the reaction was relatively slow, 
therefore it was not feasible for the analogue to de-acetylate in a buffer that has a pH 
value of 7.5. Additionally, a control incubation was set up with 12-acetoxy FDP in the 
incubation buffer without any enzyme. This was to verify whether it was the Mg2+, 
present in the buffer, acting as a Lewis acid and cleaving the acetate group off. This 
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control experiment did not yield any 12-hydroxy FDP and therefore it was concluded 
that this was not the case. 
The second possibility was that ADS de-acetylates 12-acetoxy FDP with the 
use of a nucleophilic residue, such as a cysteine or serine, to form 12-hydroxy FDP 
before the catalytic mechanism takes place. This de-acetylation could take place either 
outside or inside of the enzymes active site pocket. This possibility can also be argued 
against because the observation of a same product profile observed with analogues 
168 and 166 is not observed with any other sesquiterpene synthases that are studied 
in the Allemann group. In fact 12-acetoxy FDP was not a substrate of any of the 
sesquiterpene synthases that are studied within the Allemann group, e.g. GAS, GDS 
and EBFS. On the other hand, 12-hydroxy FDP does generate enzymatic products 
when incubated with enzymes such as GDS (Section 1.4) and EBFS (Section 2.7).
The last possibility is that it is simply converted by the enzyme as a substrate 
(Scheme 4.8). 
Scheme 4.7 Proposed mechanism for the formation of 49 from incubation of ADS and 12-
acetoxy FDP (166).
The observation that no enol acetate 238 is produced from 166 via carbocation 239
(Scheme 4.7) implies that enol 237 (Scheme 4.6) is most likely not a product of ADS 
catalysis but forms exclusively from (11S)-49 after its release from the enzymes active 
site.
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4.3.3 13-Acetoxy FDP (165)
Figure 4.18 13-Acetoxy FDP (165)
13-Acetoxy FDP (165, Figure 4.18) was designed to determine whether the position of 
the hydroxyl/ acetoxyl group on C12 or C13 of FDP had an effect on the ratio of the 
epimers of dihydroartemisinic aldehyde generated. 12-Acetoxy FDP (166) and 12-
hydroxy FDP (168) displayed 60-75% of the enzymatic product distribution to be (11S)-
dihydroartemisinic aldehyde, however it is the (11R)-epimer that is required for the 
synthesis of artemisinin. By changing the position of the alcohol group to C13, there 
was a possibility of the ratio of epimers reversing, producing (11R)-dihydroartemisinic 
aldehyde as the dominant product. The synthesis of 13-acetoxy FDP is one step 
shorter than 13-hydroxy FDP (Section 3.5.1, Scheme 3.8), and for this reason, 13-
acetoxy was tested first with ADS to prove or disprove the hypothesis made.
Incubation of ADS with 13-acetoxy FDP generated one pentane extractable 
product, when analysed by GC-MS, with a molecular ion of m/z = 220 (Figure 4.19). 
Surprisingly the compound was not (11R)-dihydroartemisinic aldehyde as expected, 
but the (11S)-epimer as determined by comparing the gas chromatogram with that of 
the material generated from 12-acetoxy FDP (Figure 4.19). 
Figure 4.19 Left: Total ion chromatogram of the pentane extractable products from 
incubation of ADS and 12-acetoxy FDP (166) (top left) and 13-acetoxy FDP (165) (bottom 
left). Right: Mass spectrum of the eluted compound from incubation of ADS and 13-
acetoxy FDP. 
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These results indicate that the dominant epimer generated is not a result of whether 
the hydroxyl/acetoxyl group is attached to C12 or C13 of FDP. 
The absence of significant amounts of (11R)-dihydroartemisinic aldehyde could
imply that enol 237 does not tautomerise to the (11R)-epimer under the reaction 
conditions used (pH ~7.5) (Scheme 4.6). These results suggest that only one pathway 
operates to yield the observered epimeric mixture of aldehydes 49. The formation of 
both epimers of dihydroartemisinic aldehyde, from 12-hydroxy FDP (168) or 12-acetoxy 
FDP (166), most likely procedes through an oxygen-assisted non-stereopecific 
intramolecular 1,2-hydride shift at carbocation 235 and 239, respectively, followed by a 
deprotonation on the alcohol group of the resulting carbocation 236 (or a deacetylation 
from 240) (Scheme 4.6 and 4.7). 
Since the stable enol acetate 242 is also not observed from incubation of ADS 
with 13-acetoxy FDP (165), a deprotonation at C13 of carbocation 243, followed by 
subsequent tautomerisation of the resulting enol 242 to (11S)-49 appears unlikely. 
Hence a stereospecific [1,2]-hydride shift of Hb on carbocation 243 followed by a 
deacetylation of the resulting carbocation 244 most likely accounts for the exclusive 
formation of (11S)-49 (Scheme 4.8).
Scheme 4.8 Proposed mechanism for the formation of (11S)-49 from incubation of ADS 
and 13-acetoxy FDP (165).
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4.3.4 8-Hydroxy FDP (169)
Figure 4.20 8-Hydroxy FDP (169)
During the biosynthetic conversion of amorphadiene to artemisinin, the groups 
corresponding to C8 and C9 on the FDP backbone are not transformed in any way 
(Scheme 4.9), hence an addition to FDP in either of those positions would potentially 
be a benign change to the substrate that may remain unchanged through subsequent 
steps and, ultimately, form an analogue of artemisinin. In addition to this, it was 
predicted that a functional group added on C8 would also not interfere with the 
formation of the endoperoxide bridge, which is crucial for the antimalarial activity.[41,45]
Scheme 4.9 FDP (36), Amorphadiene (45) and artemisinin (6) with C8 and C9 of the FDP 
skeleton highlighted in red.
Incubation of ADS with 8-hydroxy FDP (169, Figure 4.20) generated six pentane 
extractable products as judged by GC-MS analysis. The mass spectra for all six 
compounds revealed a molecular ion peak with m/z = 220 (Figure 4.21). The molecular 
weight of 220 indicated that the enzymatic product was consistent with a hydroxylated 
terpenoid.
Due to the large number of enzymatic products produced, this incubation was 
not repeated on a preparative scale to analyse the products by NMR spectroscopy, 
and therefore there is no definite conclusion as to what ADS produced when incubated 
with 8-hydroxy FDP.
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Figure 4.21 A: Total ion chromatogram of the pentane extractable product from 
incubation of ADS and 8-hydroxy FDP (169). B: Total ion chromatogram expanded
between the region of 15 and 20 min. C-H: Mass spectra of the eluted compounds.
Examination of the mass spectra of all six compounds, revealed that the first two 
compounds observed in the GC, with retention times of 15.57 and 17.57 min, have 
very similar fragmentation patterns in their mass spectra, both with a base peak at m/z
A B
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= 93. It is proposed that these two products are two isomers of the same compound. 
This is understandable as 8-hydroxy FDP was prepared as a racemate, and therefore 
for each enzymatic product formed, there is a possibility of having the (S)- and (R)- 
isomer. The fragmentation pattern observed for the first two compounds is 
characteristic for the presence of a farnesene (Figure 4.22).[207,208] The base peak at 
m/z = 93 can be identified as fragment 246 (Scheme 4.10), which supports the 
formation of a farnesene. The peak at m/z = 151 indicates that the hydroxyl group has 
not migrated to another carbon to quench a cation. This is supported by the feasible 
fragmentation leading to cation 247 (Scheme 4.10). Cation 248, with m/z = 202 is a 
prominent peak found in mass spectra of alcohols, it displays the loss of a water 
molecule. A plausible mechanism was predicted for the fragmentation leading to 
cations 246, 247 and 248 starting with the molecular ion 249 (Scheme 4.10).
Scheme 4.10 Proposed mechanisms for the formation of the major fragments 246, 247
and 248.
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8-Hydroxy FDP was incubated with E-b-farnesene synthase (EBFS), a sesquiterpene 
synthase also studied within the Allemann group. It was assumed that the enzymatic 
product produced from an incubation of EBFS and 8-hydroxy FDP was 8-hydroxy-E-b-
farnesene (250, Figure 4.22). Based on this assumption, overlaid gas chromatograms 
of products formed from incubations with EBFS and ADS, each with 8-hydroxy FDP, 
suggested that none of the enzymatic products produced by ADS were 8-hydroxy-E-b-
farnesene (250, Figure 4.22). This observation suggests that if the first two compounds 
observed in the GC are farnesenes, then they could either be the two isomers of 8-
hydroxy-(E,E)-a-farnesene (251) or 8-hydroxy-(Z,E)-a-farnesene (252) (Figure 4.22).
Figure 4.22 Left: 8-hydroxy-E-b-farnesene (250), 8-hydroxy-(E,E)-a-farnesene (251) and 8-
hydroxy-(Z,E)-a-farnesene (252), Right: Overlaid gas chromatograms of pentane 
extractable products from incubation of EBFS with 8-hydroxy FDP (blue) and ADS with 8-
hydroxy FDP (red).
It can also be argued that a base peak at m/z = 93 can also be identified as the 6 
membered ring intermediate, 76 (Section 4.2.1, Figure 4.3), which is observed as the 
base peak for some 6-membered ring sesquiterpenes.[206,209] Once ADS has catalysed 
the isomerisation of 8-hydroxy FDP to the corresponding 8-hydroxy NDP (253), which 
is ionised to cation 254, a 1,6-cyclisation follows to form 255. The addition of an alcohol 
group on C8 might hinder the [1,3]-hydride shift that would occur next with the natural 
substrate FDP. Instead a deprotonation at C6 can yield compound 256. Alternatively, a 
[1,3]-hydride shift can still take place, forming cation 257, and then the addition of the 
alcohol group might hinder the following 1,10-cyclisation. In this case, deprotonation at 
C4, C6 or C15 will form compounds 258, 259 and 260, respectively (Scheme 4.11).
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Scheme 4.11 Proposed mechanisms for the formation of 256, 258, 259 and 260 from 
incubation of ADS and 8-hydroxy FDP (169).
The fifth compound observed in the gas chromatogram, with a retention time of 19.26 
min, again was not given a definite assignment but the mass spectrum was 
comparable to what was observed for the major product when ADS was incubated with 
analogue 170, 8-methoxy FDP (Section 4.3.6). The structural assignment of the major 
product produced in Section 4.3.6 was made via NMR spectroscopic analysis and 
therefore when comparing the mass spectra, there was firm evidence to suggest the 
formation of 8-hydroxy-g-humulene (261) (Figure 4.23). 
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Figure 4.23 Mass spectra of proposed 8-hydroxy-g-humulene (261) (top) and of identified 
8-methoxy-g-humulene (262) (bottom).
HO
261
O
262
105
4.3.5 8-Acetoxy FDP (167)
Figure 4.24 8-Acetoxy FDP (167)
8-Acetoxy FDP (167, Figure 4.24) was synthesised to test whether ADS would 
generate the same products with this analogue as it did with 8-hydroxy FDP (169, 
Section 4.3.4) by analogy with the fact that ADS created the same enzymatic products 
when incubated with 12-hydroxy FDP (168) and 12-acetoxy FDP (166) (4.3.1 and 
4.3.2). 
Incubation of ADS with 8-acetoxy FDP produced nine pentane extractable 
products (Figure 4.25). Six of those peaks correlated to the products generated from 8-
hydroxy FDP (Section 4.3.4). There are three additional peaks observed in the GC that 
were not observed with 8-hydroxy FDP but these peaks were not further investigated. 
Figure 4.25 Overlaid gas chromatograms of the pentane extractable products from 
incubations of ADS with 8-hydroxy FDP (blue) and 8-acetoxy FDP (red).
Although additional products were generated, the gas chromatograms show that ADS 
produced the same products with substrates 8-acetoxy FDP and 8-hydroxy FDP (169). 
This observation implied that to achieve the same product profile, it did not matter 
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which carbon the hydroxyl and acetoxyl groups were placed on. This could also 
suggest that the same product profiles are due to the specific catalysis performed by 
the ADS enzyme, because other sesquiterpene synthases studied in the Allemann 
group did not generate the same compounds when tested with these two analogues.
4.3.6 8-Methoxy FDP (170)
Figure 4.26 8-Methoxy FDP (170)
The methoxy group, positioned on C8, was based on the idea that in that position the 
additional group would hopefully not interfere with the synthesis of artemisinin, if the 
corresponding amorphadiene derivative was generated. 
Incubation of ADS with 8-methoxy FDP (170, Figure 4.26) generated two
pentane extractable products, when analysed by GC-MS, with mass spectra of each 
product revealing a molecular ion with m/z = 234 (Figure 4.27).
Figure 4.27 A: Total ion chromatogram of the pentane extractable products from 
incubation of ADS and 8-methoxy FDP (170). B-C: Mass spectra of the two major eluted 
compounds.
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Since there were only two major enzymatic products, this incubation was carried out on 
a preparative scale for analysis by NMR spectroscopy. 
1H NMR spectroscopy (Figure 4.28) was carried out on the two compounds as 
a mixture and then they were separated using silica chromatography (95:5, hexane: 
ethyl acetate) and once separated, 1H NMR spectroscopy was again carried out on the 
major product (Figure 4.29). Unfortunately, there was not enough of the minor product 
to give a useful 600 MHz 1H NMR spectrum, however by subtracting the resonances 
belonging to the major product, from the spectrum with both compounds, the structure 
of the minor product was deciphered. After studying the 1H, 13C, HSQC and HMBC 
NMR spectra, it was concluded that the major product was 8-methoxy-g-humulene 
(262) (Table 4.1). To our knowledge, there are no 1H NMR spectra of g-humulene 
reported in literature to compare these spectra with.
The identity of the minor product was established as 8-methoxy-E-b-farnesene 
(263). In addition to making this identification by studying the 1H NMR spectroscopy, it 
was also confirmed by incubating 8-methoxy FDP with EBFS. Overlaid gas 
chromatograms of both incubations proved the presence of 8-methoxy-E-b-farnesene 
(263) (Figure 4.30). In addition to this, the mass spectra of farnesene 263, generated 
by ADS and EBFS, are identical in their fragmentation patterns (Figure 4.31).
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Figure 4.28. 1H NMR spectrum (600 MHz, CDCl3) of the enzymatic products generated 
from incubation of ADS with 8-methoxy FDP (170). The peaks belonging to the minor 
product, 8-methoxy-E-b-farnesene (263) are shown in blue.
Figure 4.29. 1H NMR spectrum (600 MHz, CDCl3) of the major product, 8-methoxy-g-
humulene (262), generated from incubation of ADS with 8-methoxy FDP (170), with peak 
assignments in red.
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Table 4.1 Complete assignment of 8-methoxy-g-humulene (262). Chemical shifts are 
reported relative to TMS in ppm.
Figure 4.30 Overlaid gas chromatograms of pentane extractable products from an 
incubation of EBFS (blue) and ADS (red) with 8-methoxy FDP. Both chromatograms 
show the same compound eluting at 15.79 min.
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Figure 4.31 Mass spectra of the identified 8-methoxy-E-b-farnesene (263) generated from 
incubation of ADS (top) and EBFS (bottom) with 8-methoxy FDP.
The exact mechanism by which 8-methoxy-g-humulene (262) and 8-methoxy-E-b-
farnesene (263) are formed is unknown, however a mechanism can be proposed 
(Scheme 4.12). It is assumed that the nucleophilic oxygen attacks at C10 or C1 in a 
1,11- or 1,8-cyclisation, respectively, at a faster rate than the formation of an NDP 
analogue, which facilitates the more usual 1,6-cyclisation. In the case of a 1,11-
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cyclisation of cation 264, the resulting cation 265 undergoes a [1,3]-hydride shift to 
form 266, which is followed by a deprotonation at C15 to afford 8-methoxy-g-humulene 
(262) (Scheme 4.12 A, blue pathway). For the minor product, once a 1,8-cyclisation 
takes place to form 267, a deprotonation at C15 cleaves the 9-membered ring and 
forms the E-b-farnesene derivative, 263 (Scheme 4.12 B, blue pathway).
Alternatively the oxygen might not be involved in the catalysis at all and instead, 
after the diphosphate is eliminated, a subsequent deprotonation at C15 of 264 forms 
farnesene 263 (Scheme 4.12 B, red pathway). Similarly, for the formation of the 
humulene derivative 262, 8-methoxy FDP might be bound in an orientation in the active 
site that facilitates the 1,11-cyclisation over the initial 1,6 cyclisation observed for FDP, 
which generates cation 268. A [1,3]-hydride shift to cation 266, followed by subsequent 
deprotonation at C15 again would allow for the formation of humulene 262 (Scheme 
4.12 A, red pathway).
Scheme 4.12 Proposed mechanism for the formation of 8-methoxy-g-humulene (262) and 
8-methoxy-E-b-farnesene (263) from incubation of ADS and 8-methoxy FDP (170).
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4.3.7 12-Methoxy FDP (171)
Figure 4.32 12-Methoxy FDP (171)
Incubation of ADS with 12-methoxy FDP (171, Figure 4.32) generated two pentane 
extractable products. Both products had a molecular weight with m/z = 234 (Figure 
4.33).
The mass spectra for the two products both obtain base peaks at m/z = 118, 
with similar fragmentation patterns. This could imply that unlike 8-methoxy FDP 
(Section 4.3.6), 12-methoxy FDP is possibly converted into two sesquiterpenoids with 
the same terpenoid frame. This incubation was carried out on a preparative scale for 
analysis by NMR spectroscopy. 
Figure 4.33 A: Total ion chromatogram of the pentane extractable products from 
incubation of ADS and 12-methoxy FDP (171). B-C: Mass spectra of the eluted 
compounds.
NMR spectroscopic analysis was carried out on the mixture of products because 
attempts at separation of the two compounds by chromatography were not successful. 
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The 1H NMR spectrum (Figure 4.34) of the mixture instantly clarified that the two 
products produced were not analogues of amorphadiene. This was concluded from the 
presence of an excessive number of olefinic peaks observed in the region dH = 4.7 - 5.2 
ppm. Although it was found that the bicyclic hydrocarbon frame had not been made, 
the pair of doublets found at 0.85 and 0.87 ppm suggested that ADS still carried out a 
1,6-ring closure for both enzymatic products as these doublets corresponded to the 
methyl group at C14 of both compounds. The two singlets observed at dH = 3.27 and 
3.78 ppm, with integrations of 3 and 2, respectively, have a similar chemical shift to 
that observed in the 1H NMR spectrum of 12-methoxy FDP (Section 7). These singlets 
represent C12 and C16. This indicates that both products retain the methoxy group in 
the same position, and preclude the possibility of a methoxy group migration. The 13C 
DEPT-135 (Figure 4.34) spectrum contained a negative peak at ~109 ppm, implying 
the presence of an olefinic CH2. Through logical elimination of other possible locations, 
it was concluded that this CH2 was positioned on C15 and this correlates with the two 
overlapped doublets observed at dH = 4.74 ppm. The integration of these singlets were 
measured as 2 protons and so that meant that this exocyclic alkene was present in 
only one of the products. Since one of the olefinic protons in the substrate, 8-methoxy 
FDP, was left intact in the products it was concluded that ADS catalysed a 1,6 ring 
closure of this substrate, but did not follow with the second 1,10 ring closure. The triplet 
found at dH = 5.39 ppm with an integration of 2 protons, representing a proton at C10 
for each product, is consistent with this theory. By piecing together the assignments 
made for distinct peaks in both the 1H NMR and 13C NMR spectra, it was concluded 
that the enzymatic products were 12-methoxy-b-sesquiphellandrene (269) and 12-
methoxy-zingiberene (270). The stereochemistry of the zingiberene is unknown and 
therefore it can either be a zingiberene or a 7-epi-zingiberene derivative. The predicted 
structures were in agreement with NMR spectra found in literature of b-
sesquiphellandrene, zingiberene and 7-epizingiberene.[54,210–212] A proposed 
mechanism (Scheme 4.13) was predicted to explain the formation of each compound. 
It is assumed that the catalysis of 12-methoxy FDP begins in the same manner as the 
natural substrate FDP. An isomerisation of the FDP analogue to the corresponding 
NDP analogue 271 allows for the rotation of the terminal alkene bond. Ionisation of this 
compound forms 272 which subsequently undergoes the initial 1,6 ring closure, seen 
with FDP, to generate 273. A [1,3]-hydride shift affords cation 274. With the natural 
substrate, FDP, a 1,10-ring closure would follow, however the identification of the 
monocyclic products proved that this second cyclisation does not follow in this case. 
There are two suggestions as to why a 1,10-ring cyclisation cannot follow. Either the 
nucleophilic oxygen attacks at C1 of cation 274 at a faster rate, forming intermediate 
275. Alternatively the methoxy group could just force an orientation of the distal alkyl 
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group that prevents the second ring closure. Accordingly, deprotonation at C15 
(Scheme 4.13, blue pathway) and C4 (Scheme 4.13, red pathway) of either 
intermediate 274 or 275 allows the formation of 12-methoxy-b-sesquiphellandrene 
(269) and 12-methoxy-zingiberene (270).
Figure 4.34 1H NMR (600 Hz, CDCl3) (top) and 13C DEPT-135 NMR (125 Hz, CDCl3) (bottom) 
of the enzymatic products formed from incubation of ADS with 12-methoxy FDP (171).
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Scheme 4.13 Proposed mechanism for the formation of 12-methoxy-b-
sesquiphellandrene (269) and 12-methoxy-zingiberene (270) from incubation of ADS and 
12-methoxy FDP (171). 
 
4.4 Nitrogen containing FDP analogues
4.4.1 12-Acetamido FDP (184)
Figure 4.35 12-Acetamido FDP (184).
12-acetamido FDP (184, Figure 4.35) was designed in attempt to generate a nitrogen 
containing amorphadiene. With a similar structure to 12-acetoxy FDP it was thought 
that if the enzyme treated 12-acetamide FDP in a similar manner to 12-acetoxy FDP, it 
might convert the substrate into an aza-analogue of dihydroartemisinic aldehyde (276, 
Figure 4.36).
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Figure 4.36 Top: Enzymatic conversion of 12-acetoxy FDP (166) with ADS. Bottom: 
Predicted enzymatic conversion of 12-acetamido FDP (184) with ADS.
Incubation of ADS with 12-acetamido FDP generated no pentane extractable products,
with nothing visible by GC-MS analysis. It is proposed that due to the similar sizes of 
both 12-acetamide FDP and 12-acetoxy FDP, analogue 184 is still capable of entering 
the active site of ADS, but instead of acting as a substrate it behaves as an inhibitor. 
This could be demonstrated in future work by carrying out inhibition studies using 12-
acetamide FDP with ADS and tritiated FDP.[207] Alternatively the analogue could be a 
suicide substrate. 12-acetamide FDP could enter the active site and form a covalent 
bond with a residue in the enzyme and block its activity.[213] This has been previously 
reported for aristolochene synthase, where a vinyl analogue of FDP was found to be an 
effective mechanism-based inactivator of the enzyme.[214] The last possibility would be 
that the analogue does not enter the active site at all, either because it does not fit, 
which would support the idea discussed earlier (Section 4.3.2) of 12-acetoxy FDP 
being de-acetylated before it enters the active site, or because the nitrogen reacts with 
an amino acid outside of the active site, preventing it from entering. 
4.4.2 12-Amino FDP (185)
Figure 4.37 12-Amino FDP (185)
After observing an absence of products from an incubation of ADS with 12-acetamido 
FDP (184), 12-amino FDP (185, Figure 4.37) was synthesised. This compound was not 
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an ADS substrate either, with nothing visible in the pentane extractable products as 
judged by GC-MS. Initially it was thought that pH 8, which is the pH that the 
incubations were carried out in, was too low for this specific analogue. The pKa of a 
protonated amine is between 10 and 11 and therefore the substrate in the normal 
incubation buffer would exist in the protonated form. This could prevent the enzyme 
accepting it as a substrate due to the positive charge on the nitrogen and therefore the 
incubation was repeated at pH values of 9, 10, 11, and 12. Unfortunately no product 
was observed at any of those pH values either. The structure of the enzyme was 
studied by CD spectroscopy (Section 2.6.3) to examine whether the protein was still 
folded in the characteristic a-helical form when ADS was exposed to a high pH value. 
The stability profile for ADS was monitored over 20 minutes, measuring CD spectra 
every 10 minutes. It was clearly observed that the a-helical structure of ADS was 
unfolded at pH 12 due to the lack of minima at 208 and 220 nm (Figure 4.38).
Figure 4.38 CD spectra of ADS at different pH values (pH 10-12). Spectra were recorded 
at 0, 10 and 20-minute intervals.
4.5 Summary
To conclude, ADS was incubated with a variety of FDP analogues to test the extent of 
the enzymes promiscuity. Each analogue incubated with ADS proved to be a substrate 
of the enzyme, except for the aza-FDP derivatives, 12-acetamido FDP (184) and 12-
amino FDP (185). 14-Methyl FDP (130) was transformed into one enzymatic product 
pH 10 pH 11
pH 12
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that gave sufficient evidence via NMR spectroscopic and GCMS analysis to be 
identified as an amorphadiene analogue. Interestingly, 12-acetoxy (166) and 12-
hydroxy FDP (168) were converted by ADS into the same products, generating two 
epimers of dihydroartemisinic aldehyde (49). The methoxylated analogues, 8-methoxy 
FDP (170) and 12-methoxy FDP (171) were catalysed by ADS through a different 
mechanism to the natural substrate, FDP. These analogues, combined, generated 
derivatives of a farnesene, humulene, zingiberene and sesquiphellandrene. These 
results demonstrate that ADS can be defined as promiscuous and has the capability of 
accepting substrates with additional functional groups in various locations.
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Chapter 5. Three-step formal chemoenzymatic total 
synthesis of dihydroartemisinic aldehyde
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5.1 Preface
Artemisinin (6) and its derivatives in combination therapy are the world’s number one 
treatment against malaria, but with resistance arising, methodology for producing novel 
and active analogues is a constant need. In addition to this, there is also a requirement 
to find an alternative method to source artemisinin, to combat the unreliable and 
fluctuating methods that are present today.[215] Here is presented a 3-step synthesis to 
dihydroartemisinic aldehyde (49), a precursor of artemisinin, starting from farnesyl 
chloride (127). Optimised conditions were developed for preparation of 12-hydroxy 
FDP (168), and for the conversion of this FDP analogue with ADS. The results 
demonstrate a highly efficient route to dihydroartemisinic aldehyde (49), bypassing 
several of the chemical steps previously required for artemisinin synthesis.
Previously, in Section 1, the various methods for sourcing artemisinin were 
discussed. To our knowledge, there are three main approaches to supplying 
artemisinin and its analogues; extracting the compound from the dry plant material,[129–
132] total synthesis of the compound[135,136] and a combination of a biosynthetic and 
synthetic route that exploits the use of important biocatalysts to create the complex, 
chiral scaffold of the immediate precursor, dihydroartemisinic acid (50) (Section 
1.3.3).[137–141] With the high demand for artemisinin, other routes to production remain 
active lines of research. Here it is reported how a biosynthetic approach can also be 
employed using a recombinant ADS in vitro to produce artemisinin precursors. In 
contrast to in vivo production using a full biosynthetic pathway, carrying out in vitro
incubations gives the advantage of employing substrate analogues that may be 
converted by the enzyme to, ultimately, artemisinin analogues that may have improved 
efficacy over current treatments.
When using an in vitro biosynthetic approach, with the use of ADS, FDP is 
converted into amorphadiene, and then is further converted to artemisinin through a 
series of chemical steps (Scheme 5.1). The series of chemical steps, that have been 
previously reported by other research groups, begin with a selective hydroboration of 
the external double bond using 9-BBN or wilkinsons catalyst. The resulting 
dihydroartemisinic alcohol (277) can then be further oxidised to the corresponding 
dihydroartemisinic aldehyde (49) by using SO3-pyridine complex. Finally, this is 
followed by treatment of the aldehyde with the oxidant NaClO2 in DMSO to form 
dihydroartemisinic acid (50).[137] Once the acid is formed, the continuation of the 
pathway can involve the same procedures as described in Section 1.3.3 when the 
production of artemisinin via the biosynthetic method was discussed.[139] In brief, an 
esterification of the carboxylic acid moiety of 50 yields the methyl ester derivative, 74
and subsequent treatment with singlet oxygen generates the hydroperoxide moiety on 
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75. An acid catalysed Hock cleavage of 75 and rearrangement forms artemisinin (6) in 
the presence of triplet oxygen (Section 1.3.3, Scheme 1.11).[139,141]
Using the knowledge that sesquiterpene synthases are capable of accepting 
novel substrates,[143,148] 12-hydroxy FDP was synthesised (168, Scheme 5.1). 12-
Hydroxy FDP was constructed with the alcohol group positioned on the w-carbon, 
where the first chemical oxidation would take place following formation of 
amorphadiene in A. annua. This created the potential of forming a precursor further 
down the schematic pathway to the final compound, thus reducing the overall number 
of steps required to form artemisinin. 12-Hydroxy FDP proved to be a substrate of ADS 
and the enzymatic products formed were identified as two epimers of 
dihydroartemisinic aldehyde (11R-49 and 11S-49, Section 4.3.1) – an advanced
precursor in the chemical synthesis of artemisinin. By incubating ADS with 12-hydroxy 
FDP a reduction in the number of chemical steps required to produce artemisinin was 
demonstrated (Scheme 5.1).
Scheme 5.1 Chemoenzymatic pathway to artemisinin starting with FDP (36, A) and the 
shortened pathway starting with 12-hydroxy FDP (168, B).
5.2 Optimisation of 12-hydroxy FDP synthesis 
To ensure that this new in vitro approach to artemisinin production was efficient, every 
step to make dihydroartemisinic aldehyde (49) was optimised to give the shortest and 
highest yielding pathway. The initial methodology used to prepare 12-hydroxy FDP 
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consisted of a seven-step synthesis (Section 3.5.2, Scheme 3.9). A new pathway 
reducing the number of steps to just two was devised (Scheme 5.2).[216,217]
Scheme 5.2 Shortened optimised synthesis of 12-hydroxy FDP (168).
The first step, hydroxylation of the farnesyl chloride chain in the w-position, was carried 
out with selenium dioxide and salicylic acid, and various reaction condition parameters
were varied to obtain an optimal yield. Our results showed that controlling the molar 
equivalents of reagents used gave the biggest improvement in yields (Table 5.1). Using 
between 0.3 and 0.5 molar equivalents of both selenium dioxide and salicylic acid gave
12-hydroxy farnesyl chloride (278) in the best yield of 62%. Reducing the equivalents
of oxidant gave insufficient turnover of the starting material farnesyl chloride (127, 
Scheme 5.2), whereas anything above 0.5 molar equivalents produced more of the 
corresponding over-oxidized aldehyde. 
Table 5.1 Optimisation of conditions for the preparation of 12-hydroxy farnesyl chloride 
(278).
Entry Molar equivalents Yield (%)
SeO2 H+ t-BuOOH
1 0.1 0.1 5 47
2 0.2 0.2 5 53
3 0.3 0.3 5 62
4 0.5 0.5 5 57
5 1 1 5 8
The diphosphorylation of 12-hydroxy farnesyl chloride was carried out with 
tris(tetrabutylammonium) hydrogen diphosphate salt (TBDP, 121) under anhydrous 
conditions (Table 5.2). Variables changed in this reaction step were molar equivalents 
of TBDP used and the reaction time. It was found that the use of 2 molar equivalents of 
TBDP and a reaction time of 48 h gave the best results. An average yield of 32% was 
obtained over the two steps.
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Table 5.2 Optimisation of conditions for the preparation of 12-hydroxy FDP (168).
Entry TBDP (molar equivalents) Time (h) Yield (%)
1 1.5 24 34
2 2 24 47
3 2 48 51
5.3 Optimisation for the catalytic conversion 12-hydroxy FDP to 
dihydroartemisinic aldehyde 
Once the synthesis of the novel analogue, 12-hydroxy FDP was improved, the 
optimisation of the catalytic turnover of 12-hydroxy FDP to dihydroartemisinic aldehyde 
had to be accomplished. To obtain the optimal conditions for the catalytic turnover, 
analytical incubations of 12-hydroxy FDP with ADS at different substrate 
concentrations and with different organic solvents, overlaid for product extraction, were 
carried out (Table 5.3). 
Table 5.3 Analytical incubations of 12-hydroxy FDP (168) with ADS.
The optimal enzyme concentration for substrate turnover was previosuly determined as 
1 µM. This was determined by incubating ADS (between 1 to 20 µM) with FDP (400 
µM). These incubations were overlaid with pentane and left for 24 h. Gas 
chromatography with flame ionisation detection (GC-FID) was used to measure the 
Entry 168 (µM) Solvent overlay
Conversion (%) Second extraction
calibration 
curve
internal 
standard Solvent
Conversion
(%)
1 100 Pentane 65.4 67.0 Pentane 4.3
2 200 Pentane 63.7 63.6 Pentane 1.9
3 300 Pentane 65.1 67.6 - -
4 400 Pentane 62.0 59.3 - -
5 200 Pentane 62.8 66.5 EtOAc 2.8
6 200 Pentane 71.9 73.3 DCM 4.6
7 200 EtOAc 15.1 17.9 - -
8 200 DCM 10.1 10.3 - -
9 200 No overlay - EtOAc 19.6
10 200 No overlay - DCM 21.6
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product formation of amorphadiene in the solvent overlays and the enzymatic 
conversion was calculated by using an internal standard, commercially available a-
humulene (Table 5.4 and Figure 5.1). It was assumed that the optimal enzyme 
concentration to give the maximum yield of amorphadiene would also apply when 
using novel FDP analogues. Therefore this parameter was not changed. 
Table 5.4 Conversion (%) of FDP (36) to amorphadiene (45) with varying concentrations 
of ADS.
ADS (µM) FDP (µM) Conversion (%)
1 400 47.4
2 400 44.0
3 400 36.2
4 400 37.5
6 400 33.5
9 400 32.1
12 400 30.8
15 400 24.2
20 400 22.5
Figure 5.1 Conversion (%) of FDP (36) to amorphadiene (45) with varying concentrations 
of ADS.
The conversions of 12-hydroxy FDP to dihydroartemisinic aldehyde were also
measured using GC-FID to analyse the solvent overlays. All incubations with ADS and 
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the novel analogue were carried out in parallel to identical incubations of ADS with the 
natural substrate, FDP, to compare the reaction efficiency.
All conversions were measured using calibration curves calculated with an 
analytical standard. Farnesal (279) was used as the standard for measuring the 
conversion of 12-hydroxy FDP to dihydroartemisinic aldehyde. FID response was 
recorded for concentrations of farnesal in the range 10 µM to 4 mM. Farnesal was 
synthesised from commercially available farnesol (126) with the use of manganese 
dioxide with a yield of 70% (Section 7.2.16). Farnesal was chosen as it has the same 
molecular weight and chemical formula as dihydroartemisinic aldehyde, hence likely to 
give a similar response in the flame ionization detector. The conversions of 12-hydroxy 
FDP to dihydroartemisinic aldehyde were measured using the calibration curve (Figure 
5.2). For the analytical incubations, in addition to the calibration curve, farnesal was 
also used as an internal standard. The results using both internal and external 
standards were complementary, with a maximum discrepancy of ca. 4%. Similarily, to 
measure the conversions of the natural substrate FDP to amorphadiene, commercially 
available a-humulene was used as a standard, with concentrations also ranging from 
10 µM to 4 mM (Figure 5.2). This was also used as an internal and external standard 
for the analytical incubations, also providing consistent results.
The results from analytical incubations showed that varying substrate 
concentration between 100 µM and 400 µM for both 12-hydroxy FDP and FDP showed 
no increase in the conversion rates. No tests were carried out using in excess of 400 
µM substrate as concentrations higher than this have been observed previously to 
cause FDP precipitation.[171,218] The change in the solvent for the overlay of the 
incubations however was important. Pentane was found to be the most efficient at 
extracting the products (Table 5.3). The majority of the enzymatic products were 
extracted from the initial overlay, and less than 1% further material was present in the 
third extraction. The optimal incubation time was 24 h, with no improvement observed 
with extended incubations. Once the most favourable conditions on an analytical scale 
were found, they were repeated on larger scales consisting of 50 mg of substrate and 
200 mg of substrate, to examine robustness and reproducibility.
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Figure 5.2 Calibration curves showing FID response for various concentrations of 
farnesal (top) and a-humulene (bottom). 
The highest conversion rates obtained for 12-hydroxy FDP, when using the analytical 
incubations, were in the range 60 to 70%. When the same conditions were used for the 
incubation of the natural substrate, FDP, an average of 71% conversion was recorded. 
It was clear that the enzyme could convert, reproducibly, both the natural and unnatural 
substrate to a similar extent within a 24 h period. On a 50 mg scale, the conversion of 
12-hydroxy FDP was still comparable to that of FDP, providing conversions of 77% and 
79% respectively. Reproducing this yield on a 200 mg scale required an additional day
of incubation. As the mass of substrate increased, so did the buffer volume, decreasing 
the ratio of extraction solvent overlay relative to the buffer. A typical 200 mg incubation 
contained 500 mL of buffer and was overlaid with only 20 mL of pentane. The method 
of extraction was less efficient, in contrast to the analytical 250 µL buffers overlaid with 
1 mL of pentane. The increased relative quantity of buffer posed a problem as the 
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dihydroartemisinic aldehyde tautomerizes with the corresponding enol which is more 
soluble in the neutral aqueous buffer. To tackle this issue an additional night of 
incubation was performed with the pH adjusted to 10. In basic conditions, the 
equilibrium shifted to favour the aldehyde and therefore increased the percentage of 
product extracted by the pentane. There was a clear increase, where the conversion 
rate increased from 53 to 65% when pH was increased (Figure 5.3). The isolated yield 
for the mixture of epimers (11R-49 and 11S-49) was recorded as 35% after purification 
was carried out by flash chromatography on silica gel (9:1, hexane: ethyl acetate).
Figure 5.3 Gas chromatograms (FID) of pentane extractable products generated from 
incubations of ADS with 12-hydroxy FDP after 24 h at pH 7.5 (top) and after an additional 
24 h at pH 10 (bottom).
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5.4 Organic synthesis of (11R)-dihydroartemisinic aldehyde (49)
With the knowledge that only the (R)-epimer (11R-49) is the desired precursor to 
artemisinin,[114,162] a standard of (11R)-dihydroartemisinic aldehyde was synthesised to 
confirm which epimer was the dominant product from enzymatic incubations of ADS 
with 12-hydroxy FDP. (11R)-Dihydroartemisinic aldehyde was synthesised from 
commercially available (11R)-dihydroartemisinic acid (50) via two steps (Scheme 5.3). 
The first step was an esterification of the acid moiety of 50.[139] This was carried out via 
an acyl chloride intermediate, which was treated with methanol to afford 
dihydroartemisinic methyl ester (88) with a yield of 78%. DIBAL reduction of the methyl 
ester 88 afforded the reduced products, dihydroartemisinic aldehyde (49) and 
dihydroartemisinic alcohol (277), both with yields of 31%. 
Scheme 5.3 Synthesis of (11R)-dihydroartemisinic aldehyde (49).
Overlaid gas chromatograms of the synthesised (11R)-dihydroartemisinic aldehyde 
and the pentane extractable products from an incubation of ADS with 12-hydroxy FDP 
clearly showed that the (11R)-epimer was the minor product (20%) formed by the 
enzymatic incubations (Figure 5.4). In addition to this observation, the 1H NMR 
spectrum of the authentic sample of (11R)-dihydroartemisinic aldehyde displayed a 
doublet at dH = 9.57 ppm, showing that the minor epimer observed in the 1H NMR 
spectrum of the mixture of epimers from the enzymatic incubation was (11R)-
dihydroartemisinic aldehyde (Figure 5.5).
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Figure 5.4 Overlaid gas chromatograms of chemically synthesised (11R)-
dihydroartemisinic aldehyde (red) and pentane extractable products from an incubation 
of ADS with 12-hydroxy FDP (black).
Figure 5.5 1H NMR spectra (500 MHz, CDCl3) of authentic (11R)-dihydroartemisinic 
aldehyde (top) and the pentane extractable products from incubation of ADS with 12-
hydroxy FDP (bottom). 
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5.5 Conclusions
Here is reported the efficient turnover of a novel FDP analogue, 12-hydroxy FDP, to a 
3:2 mixture of dihydroartemisinic aldehydes using ADS. Also reported is a novel 
efficient synthesis for this substrate from farnesyl chloride. ADS proved to be partially
promiscuous with this substrate giving two epimeric aldehydes as products but it is 
clear that sesquiterpene synthases which naturally produce only hydrocarbon products 
can be challenged with heteratom substituted substrates, including the nucleophilic 
(and potentially carbocation quenching) OH group to produce sesquiterpenoid 
analogues that may be useful for drug discovery or agrochemical purposes. Since a
short series of chemical steps is required to convert dihydroartemisinic aldehyde to 
artemisinin, here is provided an efficient chemoenzymatic strategy for the synthesis of 
this valuable antimalarial. This strategy may prove useful for the production of further 
artemisinin analogues with functionality introduced at positions in its skeletal framework 
that are hard to achieve without extensive total synthesis.
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Chapter 6. Conclusions and Future work
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6.1 Overview
This project describes the investigation of the promiscuity of amorphadiene synthase. 
This was accomplished by testing the enzyme with novel FDP analogues. FDP 
analogues were designed with various functional groups in several positions on the 
FDP backbone to bring diversity to any resulting terpenoid structures. In addition to 
synthesising a selection of FDP analogues, and testing these with ADS, mutants of the 
enzyme were also designed and produced. Mutants of ADS were created to study the 
effect and contribution of the ‘silent’ N-terminal domain to the catalytic mechanism and 
structure of ADS.
ADS proved to be partially promiscuous with the library of analogues 
synthesised in this research but it is clear that sesquiterpene synthases which naturally 
produced only hydrocarbon products can be challenged with heteratom substituted 
substrates including the nucleophilic (and potentially carbocation quenching) OH group 
to produce potentially useful sesquiterpenoid analogues that may be useful for drug 
discovery or agrochemical purposes. The advantage of using this approach is that it is 
easier to decorate a linear isoprenyl diphosphate chain than the cyclic and 
stereoselective product produced once the diphosphate is incubated with a terpene 
synthase. This approach can be tested with other classes of terpenes and their 
respective synthases as it is not only specific to sesquiterpenes.
Since it is only a short set of chemical steps from dihydroartemisinic aldehyde 
to artemisinin, an efficient chemoenzymatic strategy for the synthesis of this valuable 
antimalaria is provided. This strategy may prove useful for the production of further 
artemisinin analogues with functionality introduced at positions in its skeletal framework 
that are hard to achieve without extensive total synthesis.
6.2 Synthesis of amorphadiene derivatives
Within the library of FDP analogues synthesised in this work, there is sufficient 
evidence, particularly from 1H NMR spectroscopy, to confirm that 14-methyl FDP (130) 
is converted to the corresponding 14-methyl amorphadiene derivative (211) (Section 
4.2.3). With the formation of 14-methyl amorphadiene (211), future work involves 
carrying out the remaining chemical steps, using procedures that are already published 
by Newman and co-workers,[139] and Paddon and co-workers,[137] to produce the 
corresponding artemisinin derivative, 14-methyl artemisinin (212) (Scheme 6.1). 
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Scheme 6.1 Proposed synthetic pathway to form 14-methyl artemisinin (212) from 14-
methyl amorphadiene (211).
In addition to successfully creating an analogue of amorphadiene, this project also
included the formation of FDP analogues that proved to be substrates of ADS, forming 
sesquiterpenoids that do not possess the amorphadiene scaffold. 8-Methoxy FDP 
(170) was transformed into an acyclic sesquiterpenoid, 8-methoxy-E-b-farnesene 
(263), as well as an 11-membered monocyclic sesquiterpenoid, 8-methoxy-g-humulene 
(262) (Section 4.3.6). 12-Methoxy FDP (171) was converted to two 6-membered 
monocyclic sesquiterpenoids, 12-methoxy-b-sesquiphellandrene (269) and 12-methoxy 
zingiberene (270) (Section 4.3.7). All four products were characterised by GC-MS and 
NMR spectroscopy (Figure 6.1). These findings demonstrate that ADS is capable of 
accepting heteroatom substituted FDP analogues, however due to the additional 
oxygenated groups, they are converted through different mechanisms, compared to the 
natural substrate FDP, to produce other novel sesquiterpenoids. The formation of 
these specific products by ADS was not surprising as Brodelius and co-workers[127]
report the formation of g-humulene (58), E-b-farnesene (59), b-sesquiphellandrene (63) 
and zingiberene (115) as minor products resulting from incubation of ADS and FDP. 
Although these minor products are not observed in this project, the identification of 
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them reported from another research group shows that the catalysis carried out by 
ADS is achievable.
Figure 6.1 Enzymatic products produced from incubations of ADS and 8-methoxy FDP 
(170, A), 12-methoxy FDP (171, B) and FDP (36, C) reported by Brodelius and co-workers.
6.3 Synthesis of additional FDP analogues
Future work following the completion of this project could involve the synthesis of 
additional FDP analogues. ADS was capable of catalysing the conversion of 12-
acetoxy FDP (166) and 12-hydroxy FDP (168), into dihydroartemisinic aldehyde (49), 
which was very valuable as it provides the shortest pathway to date for artemisinin (6) 
(Section 5, Scheme 5.1). The mechanism by which ADS converts 12-acetoxy FDP 
(166) and 12-hydroxy FDP (168) into the same product is still unclear. Two FDP 
analogues that could help better understand what happens to the acetoxyl moiety 
could be 12-formyl FDP (280) and [17-13C]-12-acetoxy FDP (281) (Figure 6.2). By 
incubating 12-formyl FDP with ADS, it can be observed whether ADS can form the 
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same product as 12-acetoxy FDP and 12-hydroxy FDP by removing the formyl moiety. 
If de-formylation occurs, there will be greater evidence to suggest that the enzymatic 
catalysis is responsible for removing the acetoxyl/formyl moieties. 
The use of 13C labelling on the acetyl group (C17) of 12-acetoxy FDP enables 
the use of 13C NMR spectroscopy to identify whether ADS de-acetylates the acetyl 
group before the enzymatic catalysis begins or whether an acyl-enzyme derivative is 
formed. In addition to the NMR spectroscopy technique, liquid chromatography-mass 
spectrometry (LCMS) can also be used to detect an increase in the molecular weight of 
the enzyme. If the enzyme gets acetylated during the formation of dihydroartemisinic 
aldehyde, then this increase can be observed by LCMS. 
Figure 6.2 12-Formyl FDP (281) and ([17-13C]-12-acetoxy FDP) (282)
To further exploit this promiscuity of ADS, the synthesis of a second-generation 
analogue, defined by the addition of two functional groups onto the FDP skeleton, is 
something to consider in additional work stemming from this project. The preferred 
second-generation analogue requires the hydroxyl group on C12, in addition to a 
second group, such as methyl, attached elsewhere. 14-Methyl FDP (Section 4.2) 
proved to transform into enzymatic products through the same mechanism as the 
natural substrate FDP, and therefore it was predicted that ‘methylated’ 12-hydroxy FDP 
analogues have the biggest probability of converting to derivatives of 
dihydroartemisinic aldehyde through ADS mediated catalysis. The synthesis of ‘8-
methyl-12-hydroxy FDP’ (282, Scheme 6.2) was attempted but was not completed by 
the end of this project. It is proposed that this analogue has the potential of being 
converted to ‘8-methyl’ dihydroartemisinic aldehyde (283, Scheme 6.3). The formation 
of this analogue, coupled with published synthetic steps from (11R)-dihyroartemisinic 
aldehyde to artemisinin, combines the two objectives of this project; to successfully 
synthesise an artemisinin derivative and to find an efficient and alternative method to 
supply artemisinin. 
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Scheme 6.2 Proposed synthesis of 8-methyl-12-hydroxy FDP (216). Intermediates in blue 
have been successfully prepared. Intermediates in black are the proposed remaining 
steps required to generate the product. 
Scheme 6.3 Potential formation of 8-methyl dihydroartemisinic aldehyde (282) from 
incubation of ADS with 8-methyl-12-hydroxy FDP (283).
6.4 Inhibition studies
Analogues, 12-acetamido FDP (184) and 12-amino FDP (185), did not prove to be 
substrates of ADS as no pentane extractable products were observed by GC-MS after 
incubation (Section 4.4). Therefore further work could include carrying out inhibition 
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studies with these two analogues. If they are indeed shown to be inhibitors and hence, 
are accepted into the active site then mutagenesis of the protein may enable their 
conversion using ADS mutants as has been observed for conversion of 14,15-dimethyl 
FDP by a mutant of germacrene D synthase.[219]
6.5 The contribution of the N-terminal domain to the catalytic activity and 
structure of ADS
ADS mutants were designed in this project to study the effect(s) of the N-terminal 
domain on the catalysis and structure of ADS. Mutants ADS-M8 and ADS-F24A were 
created because of the results observed with analogous mutations on similar 
sesquiterpene synthases studied within the research group (Section 2.7).[96] ADS-M8, a 
mutant created by truncating the first 8 residues from the N-terminus, exhibited a KM
almost half the value and a kcat 3.2 fold less, compared to the wild type (ADS-WT). This 
resulted in the catalytic efficiency of the enzyme, kcat/KM being almost half of that of 
ADS-WT. The reduced catalytic constant and catalytic efficiency of ADS-M8 led to the 
conclusion that the N-terminal domain, although previously considered as a ‘silent’ 
domain, plays a part in the structural contribution to the enzymes catalysis.[96]
Previous work also show that the single point mutations, F30A in EBFS and 
F36A in DCS have a substantial 4-fold increase in kcat and a small reduction in KM, 
compared to the wild type. When combined, these parameters gave a 7-fold 
enhancement of the catalytic efficiency for both enzymes (unpublished data).[96] This 
observation could imply that this phenylalanine residue is likely to be part of the 
structural determinant responsible for the product release, which is suggested to be the 
rate limiting step during the catalysis of sesquiterpene synthases.[166] The analogous 
mutant, ADS-F24A surprisingly did not follow the trend shown by EBFS and DCS but 
instead a kcat that had decreased by more than 10-fold and a slightly larger KM were 
found. This combination resulted in a 14-fold decrease in catalytic efficiency relative to 
wild type ADS. 
6.6 Chemo-enzymatic approach to the production of dihydroartemisinic 
aldehyde allows for a possible one-pot synthesis of dihydroartemisinic acid.
Section 5 presented an efficient turnover of a novel FDP analogue, 12-OH FDP, to a 
mixture of dihydroartemisinic aldehydes using ADS. ADS proved to be promiscuous 
with this substrate endorsing the hypothesis that sesquiterpene synthases which 
naturally produce only hydrocarbon products can be challenged with heteratom 
substituted substrates to produce sesquiterpenoid analogues that may be useful for 
drug discovery or agrochemical purposes. 
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To exploit the chemoenzymatic approach for sourching the artemisinins, further 
work could be steered towards designing a one pot synthesis for dihydroartemisinic 
acid (50). This was attempted before the research for this thesis came to an end. 
Paddon and co-workers[137] report a succesful oxidation of dihydroartemisinic aldehyde 
to the corresponding acid with the use of sodium chlorite. The reported reaction was 
carried out in an aqueous buffer and therefore it was predicted that the same 
conditions could be adopted for the conversion of dihydroartemisinic aldehyde (49) to 
dihydroartemisinic acid (50) immediately after the 24 hour enzymatic incubation of ADS 
with 12-hydroxy FDP. An analytical incubation was set up with no organic overlay so 
the generated aldehyde would remain trapped in the aquoues buffer, then the synthetic 
procedure reported by Paddon and co-workers could be carried out with no 
requirement for a work up or purification of aldehyde 49. Unfortunately the presence of 
dihydroartemisinic acid was not observed by the means of GC-MS. 
Since the end of this project, Dr. Xiaoping Tang has repeated the sodium 
chlorite oxidation reaction with some modifications. The incubation containing ADS and 
12-hydroxy FDP was set up with a toluene overlay. After 24 h of incubation, the toluene 
was removed and the sodium chlorite was added to the organic extract. This 
successfully saw the formation of dihydroartemisinic acid (50). 
Another approach to creating a one pot synthesis of dihydroartemisinic acid is 
with the use of an additional enzyme. 
Dr. Veronica Gonzalez is attempting to carry out the oxidation by using an 
aldehyde dehydrogenase (ALDH). ALDH is an NAD+ dependent enzyme.[220] The 
catalytic mechanism begins with a nucleophilic attack on the adehyde moeity by a 
cysteine residue in the enzymes active site, in the form of a thiolate. This nucleophilic 
attack provides for a hydride transfer from the resulting hemithioacetal intermediate to 
the pyridine ring of NAD+. Hydrolysis of the thioester intermediate, followed by a 
dissociation of the reduced cofactor affords acid 50 (Scheme 6.4). The use of a second 
enzyme is predicted to allow for a one pot synthesis of dihydroartemisinic acid as long 
as a buffer that enables both enzymes, ADS and ALDH, to function is used. If this one 
pot synthesis is successful, dihydroartemisinic acid will be efficiently produced in three 
steps starting from commercially available farnesyl chloride. 
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Scheme 6.4 Mechanism of NAD+ dependant aldehyde dehydrogenase (ALDH) to catalyse 
the formation of dihydroartemisinic acid (50) from dihydroartemisinic aldehyde (49).
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Chapter 7. Materials and Methods
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7.1 Biological methods
7.1.1 General Materials and methods
The gene, codon optimised for expression in E. coli, encoding for amorphadiene 
synthase (ADS) from Artemisia annua was obtained from the GenBank (Acc. No. 
JF951730.1). The gene was supplied in a pTrc99a vector. 
Restriction enzymes, Pfu DNA polymerase, unstained protein marker (14.4 kDa 
to 116.0 kDa) and amicon membranes were purchased from Fisher Scientific. The 
DNA ladder (high range) was purchased from Melford, the spin columns for DNA 
minipreps were purchased from Epoch and dialysis membrane was purchased from 
Medicell. Nickel beads used for nickel affinity chromatography were purchased from 
Expedion. The DNA sequencing service, to confirm successful SDM or PCR products, 
were carried out by Eurofins. Oligonucleotide primers and all other chemicals were 
purchased from Sigma Aldrich.
GC-MS analyses were measured on a Waters GCT Premier with a time of flight 
mass spectrometer detecting in the range m/z 50-800 in EI+ mode. The column used 
was an Agilent J&W DB-35MS (30 m x 0.25 mm internal diameter). 10 µL samples 
were injected with a 5:1 split. Two methods were used for the elution of enzymatic 
products;
Method 1: Injector temperature was set to 100 °C and the initial oven 
temperature was 80 °C. A temperature gradient of 80 °C (1 min hold) to 180 °C (4 °C 
min-1, 2 min hold) was used.
Method 2: Injector temperature was set to 100 °C and the initial oven 
temperature was 80 °C. A temperature gradient of 80 °C (1 min hold) to 180 °C (4 °C 
min-1, 15 min hold) to 250 °C (20 °C min -1, 4 min hold) was used.
DNA bands that were separated in agarose gel electrophoresis were visualized 
using a Syngene GeneFlash UV light box (Syngene, Cambridge, UK).
DNA concentration was measured using a nanodrop (Nanodrop 3300 
Fluorospectrometer, Thermo scientific).
UV spectroscopy was measured using a Jasco V-660 spectrophotometer.
Size exclusion chromatography was carried out using a Superdex 75 10/300 GL 
pre-packed size exclusion column (24 mL) using an ÅKTA FPLC system.
CD experiments were carried out on an Applied PhotoPhysics Chirascan 
Spectrometer. CD spectra were measured in the range 190 nm to 300 nm in a 1 mm 
quartz cuvette. Spectra were recorded with a 50 nm/min scan speed, 0.5 nm data 
pitch, 1 nm bandwith and 0.5 s response time. 
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7.1.2 Bacterial strains
Two strains of E. coli were used in this project. The XL1-Blue cloning strain was used 
for the cloning of plasmid DNA and transformation of SDM products, whereas the 
BL21-(DE3)-Codon Plus RP (BL21-RP) expression strain was used for the expression 
of ADS and ADS mutants.[221]
7.1.3 Growth media
Luria-Bertani (LB) medium
Sodium chloride (10 g), tryptone (10 g) and yeast (5 g) were dissolved in deionised 
water (1 L). The solution was autoclaved (121 °C, 20 min) prior to use.[222]
LB agar plates
To LB medium (500 mL), agar (7.5 g) was added and the solution was autoclaved (121 
°C, 20 min). The resulting mixture was stirred until the temperature cooled down to 
room temperature. Ampicillin (100 g/mL) was added and the resulting mixture was 
poured (c.a. 50 mL for each) into sterile petri dishes. Once the agar had set, plates 
were stored at 4 °C.
7.1.4 Buffers 
TAE buffer (50X): Tris-base (242 g, 2 M), glacial acetic acid (57.1 mL, 1 M) and EDTA 
(100 mL, 5 mM) was added to deionised water (900 mL). The pH was adjusted to 8 
and the total volume was made up to 1 L with deionised water.
DNA Loading buffer: Glycerol (3 mL, 4 M) and 0.5% bromophenol blue solution (2 µL) 
were added to deionised water (7 mL).
NE Buffer 3.1: NaCl (0.58 g, 100 mM), Tris-HCl (0.8 g, 50 mM), MgCl2 (96 mg, 10
mM), BSA (100 µg/ml) were dissolved in deionised water (100 mL). The pH was 
adjusted to 7.9.
QIAquick gel extraction buffers;
QG: Guanidine thiocyanate (65 g, 5.5 M) and Tris-HCl (32 mg, 2 mM) were dissolved in 
deionised water (100 mL). The pH was adjusted to 6.6.
PE: NaCl (117 mg, 20 mM) and Tris-HCl (32 mg, 2 mM) were added to a mixture of 
deionised water (20 mL) and ethanol (80 mL). The pH was adjusted to 7.5.
EB: Tris-HCl (0.3 g, 10 mM) was dissolved in deionised water (200 mL) and the pH 
was adjusted to 8.5.
QIAprep® spin miniprep buffers;
P1: Tris-HCl (3.94 g, 50 mM) and EDTA (1.86 g, 10 mM) was added to deionised water 
(450 mL). Once fully dissolved, the pH was adjusted to 8 and RNase A (25.0 mg, 1.82 
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µM) was added before the total volume was made up to 500 mL with deionised water. 
This buffer was stored at 4 °C.
P2: NaOH (0.8 g, 0.2 M) and SDS (1.00 g, 1% w/v, 34.7 mM) were dissolved in 
deionised water (100 mL). 
N3: Guanidine hydrochloride (38.2 g, 4 M) and potassium acetate (4.90 g, 500 mM) 
were dissolved in deionised water (90 mL). The pH was adjusted to 4.2 and the total 
volume was made up to 100 mL with deionised water.
PB: Guanidine hydrochloride (47.8 g, 5 M) and Tris-HCl (300 mg, 20 mM) were added 
to deionised water (62 mL) and the pH was adjusted to 7.5. Ethanol (38 mL) was 
added last.
PE: NaCl (117 mg, 20 mM) and Tris-HCl (32.0 mg, 2.00 mM) were added to deionised 
water (20 mL) and the pH was adjusted to 7.5. Ethanol (80 mL) was added last.
EB: Tris-HCl (300 mg, 10 mM) was dissolved in deionised water (170 mL) and the pH 
was adjusted to 8.5. The total volume was then made up to 200 mL with additional 
deionised water.
Cell lysis buffer 1: Disodium hydrogenphosphate (30.5 mL, 20 mM), Monosodium 
dihydrogenphosphate (19.5 mL, 20 mM), NaCl (29.2 g, 50 mM), MgCl2 (476 mg, 5.00 
mM), glycerol (100 mL, 10% v/v), were all dissolved in deionised water (1 L) and the 
pH was adjusted to 7.
Cell lysis buffer 2: Tris-HCl (15.8 g, 100 mM), PMSF (174 mg, 1 mM), MgCl2 (476 mg, 
5 mM), glycerol (100 mL, 10% v/v), were all dissolved in deionised water (1 L) and the 
pH was adjusted to 8.
Cell lysis buffer 3: Tris-Base (6.06 g, 50 mM), NaCl (29.2 g, 50 mM), imidazole (340 
mg, 5 mM), b-ME (1.40 mL, 20 mM), glycerol (100 mL, 10% v/v), were all dissolved in 
deionised water (1 L) and the pH was adjusted to 8.
Resolving buffer: Acrylamide/Bis-acrylamide, 30% solution (4 mL), 1.5 M tris buffer
(2.5 mL, pH 8.8), and 10% SDS (100 µL) were dissolved in deionised water (3.4 mL). 
Stacking buffer: Acrylamide/Bis-acrylamide, 30% solution (1.7 mL), 0.5 M tris buffer 
(2.5 mL, pH 6.8) and 10% SDS (100 µL) were dissolved in deionised water (5.7 mL). 
10% APS (100 µL) and TEMED (20 µL) were added to both buffers as setting reagents 
when they were ready to be used. The resolving buffer was poured first into the 
templates and once this was set the stacking buffer was poured on top, followed 
immediately by a gel comb to create the wells. The comb was removed when the gel 
was set.
Electrode running buffer: Tris base (30.3 g, 250 mM) and glycine (150 g, 2 M) were 
dissolved in deionised water (600 mL). Once dissolved, SDS (10% w/v, 10 g) was 
added and left to stir to dissolve. Once fully dissolved, the final volume was brought up 
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to 1 L in deionised water. This buffer was diluted 10-fold with deionised water prior to 
use.
SDS sample buffer: 0.5 M Tris HCl (1.25 mL, pH 6.8), glycerol (2.5 mL), 0.6% (w/v) 
bromophenol blue (200 µL), 10% SDS (2 mL) and b-mercaptoethanol (500 µL) were 
dissolved in deionised water (3.55 mL). 
SDS-PAGE stain buffer: Coomassie brilliant blue G-250 (0.25 g, 3 mM) was added to 
a mixture of ethanol and water (90 mL, 1:1). Glacial acetic acid (10 mL, 10% v/v) was 
added to the resulting mixture.
SDS-PAGE de-stain buffer: Ammonium sulphate (50 g, 0.76 mM) was added to a 
mixture of phosphoric acid (50 mL, 1.92 M) and deionised water (50 mL) and stirred. 
Once fully dissolved, Comassie brilliant blue G-250 (60 mg, 0.15 mM) was added and 
the solution was made up to 400 ml with deionised water before the addition of 
methanol (100 mL).
Dialysis buffer: HEPES (26.0 g, 25 mM), NaCl (23.4 g, 100 mM), and DTT (618 mg, 1
mM) were dissolved in deionised water (4 L) and the pH was adjusted to pH 7.5.
BSA (1 mg/ml): BSA (10 mg) was dissolved in deionised water (10 mL). 1 mL aliquots 
of this solution were stored at -20 °C until required. 
Bradford reagent: Brilliant blue G250 (20 mg, 0.12 mM) was dissolved in ethanol (2 
mL) and phosphoric acid (80%, 20 mL) was added. The final volume was brought up to 
200 mL with deionised water and stored in the dark at 4 °C.
Size exclusion buffer: 0.2 M disodium hydrogenphosphate (76.3 mL, 50 mM), 0.2 M 
monosodium dihydrogenphosphate (48.8 mL, 50 mM) and b-mercaptoethanol (0.35 µL, 
5 mM) were dissolved in deionised water (1L) and the pH was adjusted to 7.
CD spectroscopy buffers;
Sodium acetate-acetic acid buffer solutions (20 mM) for pH 4-5: 0.2M sodium acetate 
(1mL, 20 mM) and 0.2 M acetic acid (9 mL, 20 mM) were added to deionised water 
(1L) and the pH was adjusted to required value (pH 4-5).
Tris-HCl buffer solutions (20 mM) for pH 6-9: Tris-HCl (3.2 g, 20 mM) was dissolved in 
deionised water (1 L) and the pH was adjusted to the required value (pH 6-9).
Sodium phosphate buffer solutions (20 mM) for pH 10-12: Disodium 
hydrogenphosphate (30.5 mL, 20 mM) and monosodium dihydrogenphosphate (19.5 
mL, 20 mM) were dissolved in deionised water (1 L) and the pH was adjusted to the 
required value (pH 10-12).
Incubation buffer: HEPES (20 mM), MgCl2 (5 mM) and DTT (1 mM) were all 
dissolved in deionised water and the pH was adjusted to 7.5.
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7.1.5 Cloning of ADS gene into pET21d vector
Restriction site digestion
Both pTrc99a-ADS and pET21d-GDS plasmids were, separately, double digested with 
NcoI and BamHI restriction endonucleases (1 µL of each enzyme, 5 µL of NEBuffer
3.1, 10 µL of plasmid) following the manufacturer’s guidelines. The mixtures were left 
to incubate for 4 h at 37 °C.
Agarose gel electrophoresis
Agarose gels were prepared using TAE buffer (50 mL) with a 1% w/v ratio of agarose 
(0.5 g).[223] Electrophoresis was carried out in the same TAE buffer. DNA samples (10 
µL) were mixed with DNA loading buffer (5 µL) and inserted into the gel wells. A DNA 
molecular weight ladder was also placed on the same gel to help identify the size of the 
fragments. Electrophoresis was carried out at a constant voltage of 80 mA for 80 min 
before being placed into a solution of ethidium bromide for 10 min. DNA fragments that 
corresponded to an open pET21d vector (5443 bp) and ADS gene (1634 bp), by 
comparison with the molecular weight ladder, were cut out of the gel and purified using 
a QIAquick gel extraction kit protocol. 
Ligation of ADS gene into pET21d vector
The ADS gene and the open pET21d vector were ligated using T4 DNA ligase 
following the manufacturer’s protocol (1:2 molar ratio of vector: insert, enzyme (1 µL), 
buffer (2 µL), sterile deionised water to make the total volume up to 20 µL). The 
resulting mixture was incubated using a PCR machine with the cycle as described in 
the Table 1. The cycle lasted for 50 min after which ligated plasmid was ready for 
effective transformation of competent E. coli XL1 Blue cells.
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Table 7.1 PCR ligation cycle.
Temperature (°C) Time (s) Steps
4 20 4
22 20
5 20
21 20
6 20
20 20
7 20
19 20
8 20
18 20
9 20
17 20
10 20
16 20
11 20
15 20
12 20
13 20
14 20
4 20 1
Transformation of competent XL1-Blue cells 
Super-competent E. coli XL1-Blue cells were used when cloning of DNA was required. 
Once the plasmid and cell had both gently thawed over ice, plasmid solution (5 µL) was 
added to the cell suspension (50 µL). The resulting mixture was stored on ice (30 min) 
before being heat shocked in a water bath (42 °C, 30-45 s) and placed back into ice (2 
min). LB medium (1 mL) was added and the solution was incubated (60 min, 37 °C, 
3300 g). The cells were harvested by centrifugation (1 min, 13000 g) and spread on an 
agar plate containing ampicillin (100 µg/mL) after re-suspending in a minimum amount 
of LB medium. Inverted plates were incubated overnight (37 °C). 
QIAprep® Miniprep DNA extraction and purification.
A single colony from the agar plate harbouring the required transformed cells was used 
to inoculate LB medium (10 mL) containing ampicillin (100 µg/mL). The culture was 
shaken overnight (37 °C, 3300 g) and the following day centrifuged (3220 g, 10 min). 
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The pellet was purified using a QIAprep Spin Miniprep Kit (QIAprep Miniprep protocol). 
Confirmation of successful ligation was determined by DNA sequencing.
7.1.6 Site directed mutagenesis: Introduction of C-terminal hexa-histidine tag 
into the ADS gene
A single nucleotide deletion was required to bring the hexa-histidine coding sequence 
of pET21d in frame with the ADS coding sequence. A Quickchange site-directed 
mutagenesis kit was used to introduce the desired deletion according to the 
manufacturer’s instructions (Table 2 and 3). The primers used for the deletion were: 
5'- CGATGTCCATCTGTCCCGGGGATCC -3' and 
5'- GGATCCCCGGGACAGATGGACATCG -3'. 
Table 7.2 SDM reaction mixture.
Mixture component (stock concentration) Volume
Parent plasmid 0.5 µL and 1 µL
Forward primer (10 µM) 2 µL
Reverse primer (10 µM) 2 µL
dNTP mix (10 mM) 1 µL
Pfu buffer with MgSO4 5 µL
Pfu DNA polymerase 0.5 µL
Deionised water 38 µL
Table 7.3 SDM method: 
Step Temperature (°C) Time Number of cycles
Initial Denaturation 95 3 1
Denaturation 95 1
20Annealing 55 2
Extension 72 10
Final extension 72 10 1
Once the SDM program was complete, samples were digested with DpnI restriction 
enzyme (1 µL, 1 h, 37 °C).[151–153] Transformation, DNA extraction and measurement of 
the DNA concentration all followed the same procedures as stated above in Section 
7.1.5. DNA sequencing was used to confirm successful SDM. 
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7.1.7 ADS mutants
Site directed mutagenesis
When site directed mutagenesis was carried out to create mutants of ADS, the same 
SDM reaction mixture and SDM method was used as in Section 7.1.6. The primers 
used for each mutant are as follows:
F24A 
Forward 5’- CTATCTGGGGTGACCAGGCCCTGATCTACGAAAAG -3’ 
Reverse 5’- CTTTTCGTAGATCAGGGCCTGGTCACCCCAGATAG- 3’
I9M/R10G
Forward 5' GAAGAGAAACCCATGGGCCCGATCGCTAAC 3' 
Reverse 5' GTTAGCGATCGGGCCCATGGGTTTCTCTTC 3'
I9M/G10R
Forward 5’ CGAAGAGAAACCCATGCGTCCGATCGCTAACTTCC 3’
Reverse 5’ GGAAGTTAGCGATCGGACGCATGGGTTTCTCTTCG 3’
M8-ADS G2R
Forward 5’ GAGATATACCATGCGCCCGATCGCTAAC 3’
Reverse 5’ GTTAGCGATCGGGCGCATGGTATATCTC 3’
Truncation of the first 8 amino acid residues of ADS (ADS-M8)
Once the production of mutant I9M/R10G was confirmed by sequencing, XL1 Blue 
cells were transformed to clone and increase the concentration of the variant. 
I9M/R10G (50 µL, 0.5 µg/mL) was diluted with fast digest buffer (10 µL) and to this was 
added NcoI (2 µL). The digestion was left at 37 °C for 4 h. The mixture was lyophilized 
to concentrate the sample, which was then separated on an agarose gel. It is worth 
noting that the length of the fragment cut from the plasmid is too small to witness a 
significant difference in the position of the band in the gel, from the wild type. Therefore 
the gel was not to confirm if the digestion was successful but to simply separate the 
plasmid from the isolated gene fragment. Purification of the open plasmid by gel 
extraction, and ligation of the open plasmid followed the same procedures as Section 
7.1.5. To confirm if the ligation was successful and that the truncation of the enzyme 
was successful, transformation of XL1 blue cells, followed by DNA extraction by 
miniprep were carried out as described in Section 7.1.5. DNA sequencing proved that 
the truncation was a success.
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7.1.8 Transformation and gene expression of ADS
Transformation of super-competent BL21 RP cells
E. coli BL21-RP cells were used for protein production. Once the plasmid and cell had 
both gently thawed over ice, plasmid solution (1 µL) was added to the cell suspension 
(50 µL). The resulting mixture was stored on ice (30 min) before being heat shocked in 
a water bath (42 °C, 30-45 s) and placed back into the ice (2 min). LB medium (1 mL) 
was added and the solution was incubated (1 h, 37 °C, 3300 g). The cells were 
harvested by centrifugation (3300 g, 1 min) and spread on an agar plate containing 
ampicillin (100 µg/mL) after re-suspending them in a minimum amount of LB medium. 
Inverted plates were incubated overnight (37 °C). 
Test expression of ADS
To optimise the over-expression of ADS, the temperature and the length of expression 
were both varied (Table 4). Test incubations in 500 mL cultures were carried out. A
single colony from the agar plate harbouring the required transformed cells was used 
to inoculate LB medium (100 mL) containing ampicillin (100 µg/mL). The culture was 
shaken overnight (37 °C, 3300 g) and the following day the resulting cell suspension 
was used to inoculate LB medium (3 x 500 mL, 10 mL of cell suspension in each flask) 
containing ampicillin (100 µg/mL).
Table 7.4 Optimisation of the over-expression of ADS.
Flask Temperature of expression (°C) Length of expression (h)
1 35 4
2 20 6
3 16 21
1 mL samples were removed at hourly intervals after induction, including one sample 
immediately prior to induction. The cells were harvested by centrifugation (3300 g, 1 
min) and the pellets were re-suspended in SDS sample buffer and analysed by SDS-
PAGE (Section 7.1.9.).
Expression of ADS
A single colony from the agar plate harbouring the required transformed cells was used 
to inoculate LB medium (100 mL) containing ampicillin (100 µg/mL). The culture was 
shaken overnight (37 °C, 3300 g) and the following day the resulting cell suspension 
was used to inoculate LB medium (6 x 500 mL, 10 mL of cell suspension in each flask) 
containing ampicillin (100 µg/mL). The cells were incubated (37 °C, 3300 g) until the 
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optical density at 600 nm (OD600) reached 0.5. Isopropyl b-D-1-thiogalactopyranoside 
(IPTG) (48 mg, 0.40 mM) was added to each culture and shaking continued (20 °C, 
3300 g, 6 h). The cells were harvested by centrifugation (4500 g, 10 min) and the 
resulting pellets were stored at -20 °C.
7.1.9 Purification of ADS
Cell lysis buffers 
To optimize the extraction of protein process, from the cell pellets, three different 
protocols were followed (Table 5).[125,127,154] Each protocol used a cell lysis buffer with 
different compositions. It is worth noting that the protocol used for the extraction of the 
protein from the cell lysate was not varied so that the only factor being investigated 
was the composition of the buffers.
Table 7.5 Optimisation of protein extraction
Protocol Buffer composition Reducing 
agent
Detergent
Brodelius and co-
workers[127]
(Buffer 1)
20 mM sodium phosphate, 10% 
(v/v) glycerol, 0.5 M NaCl, 5 mM 
MgCl2, pH 7
No No
Kim and co-
workers[125]
(Buffer 2)
100 mM Tris-HCl, 10% (v/v) 
glycerol, 1 mM PMSF, 5 mM 
MgCl2, pH 8
No No
Noel and co-
workers[154]
(Buffer 3)
50 mM Tris-HCl, 10% (v/v) 
glycerol, 0.5 M NaCl, 5 mM MgCl2, 
5 mM imidazole, pH 8
20 mM 
b-ME
1% (v/v) 
Tween 20
Nickel affinity chromatography
Cell pellets were re-suspended in cell lysis buffer 3 (50 mL). Lysozyme (0.5 mg/mL) 
was added and the mixture was left to stir for 1 h at 5 °C. Cells were disrupted by 
sonication at 4 °C (38% amplitude for 3 min with 5 s on/10 s off cycles), the resulting 
suspension was centrifuged (17000 g, 30 min, 5 °C) and the resulting supernatant 
solution was loaded onto a Ni SepharoseTM 6 Fast Flow column (12 mL, under gravity 
controlled drip flow).[224] The flow through was eluted and the column was washed with 
cell lysis buffer 3 (10 CV) followed by a stepped gradient from 20 to 300 mM imidazole; 
buffer 3 with 20 mM imidazole (5 CV), 40 mM imidazole (5 CV), 100 mM imidazole (10 
CV) and 300 mM imidazole (10 CV).
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SDS-PAGE
Fractions eluted from the Ni2+ column were analysed by sodium dodecylsulfate-
polyacrylamide gel electrophoresis (SDS-PAGE).[225] SDS polyacrylamide gels were 
prepared with a combination of stacking and resolving buffers. Electrophoresis was 
carried out in electrode running buffer (50 mL) using a Mini-PROTEAN system from 
Bio-Rad. Fraction samples (10 µL) were mixed with SDS sample buffer (10 µL) and 
inserted into the gel wells. A protein molecular weight ladder was also placed in the 
same gel to help identify the size of the bands. Electrophoresis was carried out (150 V, 
60 min) before being stained in SDS gel stain (30 min). The gel was de-stained using 
gel de-stain buffer (30 min) until bands were visible. Protein bands that corresponded 
to a relative molecular mass of ~ 66 200 were pooled.
Dialysis and concentration of ADS
Purified protein was dialysed (MWCO 30000) overnight in dialysis buffer (4 L dialysis 
buffer: 100 mL protein) to remove the imidazole. The dialysed protein was then 
concentrated to a final volume of ~ 20 mL using an AMICON system (MWCO 30000). 
Concentrated solutions were stored at 4 °C. 
Bradford assay 
The concentration of ADS was determined using the Bradford assay.[155] A range of 
concentrations of bovine serum albumin protein (BSA) in water; 0.01 to 0.1 µg/mL were 
used as the calibration standard and the Bradford reagent (Coomassie Brilliant Blue 
dye) was used for the detection (Table 6).
Table 7.6 Preparation of the Bradford assay standards.
1 mg/mL stock of 
BSA (µL)
dH20 (µL) Bradford reagent (µL) Concentration of 
Sample (µg/mL)
2 198 800 0.01
5 195 800 0.025
8 192 800 0.04
10 190 800 0.05
12 188 800 0.06
15 185 800 0.075
18 182 800 0.09
20 180 800 0.1
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The absorbance shift of the dye was measured by UV spectrophotometry using a 
Jasco V-660 spectrophotometer.  The ratio of absorbance at 590 nm and 450 nm was
calculated and used to plot a standard curve.[156] The same procedure was carried out 
for samples of ADS. The concentration of ADS was calculated using the extrapolated 
calibration curve equation.
7.1.10 Size exclusion chromatography
Samples of various proteins were prepared by dissolving 1-2 mg of each protein in 
NaXPO4 buffer (pH 7.5, 1 mL). The resulting solution was injected (500 µl injection) and 
eluted through the column with 1.5 CV of size exclusion buffer at a rate of 0.8 mL/min. 
UV absorbance was monitored at 280 nm. [157]
7.1.11 Circular dichroism spectroscopy
Samples of ADS (10 µM) were prepared in buffers dependent on the pH under
investigation.[86,100,158–160] For spectra measured at pH 4 and 5, NaOAc-AcOH buffer (20 
mM) was used. For pH values of 6-9, Tris.HCl buffer (20 mM) was used. For pH values 
of 10-12, NaxPO4 buffer (20 mM) was used. The pH was adjusted with the addition of 
HCl (1M) and NaOH (1M). Each buffer (382 µL) was mixed with 77 µM ADS (52 µL) to 
give the concentration required. For each given pH, measurements were carried out at 
0, 10 and 20 min to see if there was any change to the structure of the enzyme over 
time. 
The spectra obtained from the CD spectrometer were converted to mean residue
ellipticity (MRE) using the following equation:
Equation 1:
Where,
q = molar ellipticity in millidegrees,
n = number of peptide bonds in the protein, 
c = molar concentration of protein in the sample, 
l = pathlength in cm
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7.1.12 Steady state kinetics
Optimisation
The procedure for optimising incubation time involved the incubation of 6 samples of 
[1-3H]-FDP (10 mM, specific activity 3.11 mCi/mmol) with ADS (100 nM) in incubation 
buffer. The reaction mixtures containing buffer, FDP and ADS were prepared on ice in 
a total volume of 250 µL and were overlaid with hexane (1 mL).  Assays were initiated 
by the addition of enzyme (2 µL, 12.5 µM stock solution) to the assay mixture. The 
assay mixtures were incubated at 30 °C for varying times; 5, 10, 15, 20, 25, and 30 
min. Each reaction was quenched with EDTA (200 µL, 100 mM), briefly vortexed and 
ice-cooled. The hexane overlay and 2 additional hexane extracts (2 x 750 µL) were 
passed through a short silica gel column in a Pasteur pipette (~1 g). The column was 
then eluted with additional hexane (2 x 750 µL). The pooled hexane extracts/eluents
were emulsified with EcoscintTM O fluid (15 mL) and radioactivity was detected using a 
scintillation counter (Packard 2500 TRTM) in 3H mode for 4 min per sample.
After verifying that 10 min assays were optimal (section 2.6.4), in turn, enzyme 
concentration, magnesium ion concentration and pH values were all varied in order to 
maximise product concentration.  Assays were carried out with 50, 100, 150, 200, 300 
and 500 nM enzyme, 0, 2, 5, 10, 15 and 20 mM MgCl2 and at pH values of 6.0, 6.5, 7.0, 
7.5, 8.0, 8.5 and 9.0. Measurements were made in triplicate. The enzyme and Mg2+
concentrations that gave optimal rates were 100 nM and 5 mM, respectively, and the 
optimal pH was 7.5.  
Michaelis-Menten kinetics
Steady state kinetic parameters for ADS were measured using the optimized assay 
conditions described above and variation of [1-3H]-FDP concentration by fitting of the 
data to the Michaelis-Menten equation by nonlinear least squares regression in 
conjunction with the graphical procedures developed by Lineweaver-Burk using the 
commercial SigmaPlot package.[226–228] Assays (final volume 250 µL) were initiated with 
the addition of ADS (12.5 µM, 2 µL) to [1-3H]-FDP (240000 dpm/nmol) with 
concentrations of FDP ranging from 0.2 to 12 µM. The buffer and protocol used was
the same as what was used for the optimisation tests above.
The Michaelis Menten equation, Equation 2, was used to fit the raw data so that 
parameters kcat and KM could be deduced. 
Equation 2:
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Using the calculated Vmax from the equation above, kcat was calculated with Equation 3:
Equation 3:
Where,
Vmax = maximum rate of the enzyme catalysed reaction. At this point every active site is 
saturated.
[ETOT] = total concentration of enzyme.
kcat = turnover number.
KM = Michaelis constant.
[S] = substrate concentration.
7.1.13 Calculation of errors
Standard errors of the weighted mean 
The estimate for the true value of KM and kcat was calculated as the weighted average. 
This is because each set of measurements for the same experiment was carried out 
separately and independently.
The weighted average mean (Xwav) was calculated using the following equation:
Equation 4
Where xi is each value in the sample and wi are the reciprocal squares of each 
measurements individual uncertainty, calculated with the following equation:
Equation 5
The errors in this work are expressed as the standard error of the weighted mean (swav) 
that is defined by the following equation: 
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Equation 6
Propagation of the errors
Propagation of errors was performed where appropriate using the following equations: 
Equation 7
Where X and Y are the experimentally measured values, X and Y are their 
respective errors; Z is the calculated value and Z the propagated error.
7.1.14 Normalisation
Where data has been normalised it has been performed using unity-based 
normalisation using the following equation:
Equation 8
Where X’ is the normalised value, X is the original value and Xmin and Xmax are the 
minimum and maximum values in the dataset, respectively.
7.2 Synthetic procedures
7.2.1 General methods and materials
1H NMR, 13C NMR, 31P NMR and 19F NMR spectra were measured on a Bruker Avance 
III 600, Bruker Avance 500, Bruker Avance III HD 400 and a Bruker Fourier 300 NMR 
spectrometer. The spectra are reported as chemical shifts in parts per million, 
downfield from tetramethylsilane (1H and 13C) and phosphoric acid (31P), multiplicity (s 
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– singlet, d – doublet, t – triplet, q – quartet, m – multiplet, dd - doublet of doublet, dq -
doublet of quartet), coupling (to the nearest 0.5 Hz) and assignment, respectively. 
Assignments are made to the limitations of COSY, DEPT 90/135, gradient HSQC, and 
gradient HMBC spectra.
Mass spectra were measured on a Waters GCT Premier time of flight mass 
spectrometer and a Waters LCT time of flight mass spectrometer. The methods used 
are the same as described in Section 7.1.1.
Thin layer chromatography (TLC) was performed on pre-coated aluminium 
plates of silica G/UV254. TLC visualisations were performed with 4.2% ammonium 
molybdate and 0.2% ceric sulfate in 5% H2SO4 (Hanessian’s stain) or UV light. 
Ion-exchange chromatography was performed using ion-exchange resin (Amberlyst 
131 wet, H+ form) pre-equilibrated with ion-exchange buffer (25 mM NH4HCO3
containing 2% isopropanol, 2 CV).
Reverse phase HPLC was performed on a system comprising of a Dionex P680 
pump and a Dionex UVD170U detector unit. The column used was a 150 x 21.2 mm 
Phenomenex Luna C-18 column. Crude diphosphates were eluted under isocratic 
conditions with 10% B for 20 min, a linear gradient to 60% B over 25 min, then a linear 
gradient to 100% B over 5 min and finally with 100% B for 10 min; solvent B: 
acetonitrile; solvent A: 25 mM ammonium bicarbonate in water, flow rate 5.0 cm3 min-1, 
detection at 220 nm. 
All chemicals were purchased from Sigma-Aldrich, Alfa Aesar, or Fisher 
Scientific unless otherwise stated. Anhydrous tetrahydrofuran (THF), diethyl ether, 
toluene and acetonitrile were obtained from a MBraun SPS800 solvent purification 
system. Dichloromethane (DCM) and triethylamine were distilled from calcium hydride 
and potassium hydroxide under nitrogen respectively. 
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7.2.2 Index of synthetic compounds
Number Name Page
36 (2E, 6E)-3, 7, 11-Trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate 161
45 Amorphadiene 211
11R-49 (R)-2-((1R, 4R, 4aS, 8aS)-4, 7-dimethyl-1, 2, 3, 4, 4a, 5, 6, 8a-
octahydronaphthalen-1-yl) propanal
210/212
11S-49 (S)-2-((1R, 4R, 4aS, 8aS)-4, 7-dimethyl-1, 2, 3, 4, 4a, 5, 6, 8a-
octahydronaphthalen-1-yl) propanal
212/213
11R-88 (R)-2-((1R, 4R, 4aS, 8aS)-4, 7-dimethyl-1, 2, 3, 4, 4a, 5, 6, 8a-
octahydronaphthalen-1-yl) propanoate
209
121 Tris (tetrabutylammonium) hydrogendiphosphate 160
127 (2E, 6E)-1-Chloro-3, 7, 11-trimethyl dodeca-2, 6, 10-triene 160
128 (2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl 
diphosphate
167
129 (2E, 6E, 10Z)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl diphosphate 174
130 (2E, 6E)-7-Ethyl-3, 11-dimethyl dodeca-2, 6, 10-trien-1-yl diphosphate 182
131 2-(((2E, 6E)-3, 7, 11-Trimethyl dodeca-2, 6, 10-trien-1-yl) oxy) 
tetrahydro-2H-pyran
162
132 2-(((2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl) oxy) 
tetrahydro-2H-pyran (134)
163
133 2-(((2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10, 12-tetraen-1-yl) 
oxy) tetrahydro-2H-pyran
164
134 2-(((2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl) oxy) 
tetrahydro-2H-pyran
165
135 (2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-ol 165
136 (2E, 6E, 10E)-1-Bromo-3, 7, 11-trimethyl trideca-2, 6, 10-triene 166
137 (6E, 10E)-2-Bromo-2, 6, 10-trimethyl-12-((tetrahydro-2H-pyran-2-yl) 
oxy) dodeca-6,10-dien-3-ol
167
138 2-(((2E, 6E)-9-(3, 3-Dimethyl oxiran-2-yl)-3, 7-dimethyl nona-2, 6-
dien-1-yl) oxy) tetrahydro-2H-pyran
168
139 (4E, 8E)-4, 8-Dimethyl-10-((tetrahydro-2H-pyran-2-yl) oxy) deca-4, 8-
dienal
169
140 (2Z, 6E, 10E)-Ethyl-2, 6, 10-trimethyl-12-((tetrahydro-2H-pyran-2-yl) 
oxy) dodeca-2, 6, 10-trienoate
170
141 Ethyl 2-(bis (2, 2, 2 trifluoroethoxy) phosphoryl) propanoate 206
144 Ethyl 2-(diethoxyphosphoryl) propanoate 205
145 Ethyl 2-(dichlorophosphoryl) propanoate 206/207
146 Ethyl 2-(bis ((trimethylsilyl) oxy) phosphoryl) propanoate 207
149 (2Z, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) 171
158
dodeca-2, 6, 10-trien-1-ol
150 2-(((2E, 6E, 10Z)-12-Bromo-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-
yl) oxy) tetrahydro-2H-pyran
172
151 2-(((2E, 6E, 10Z)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl) oxy) 
tetrahydro-2H-pyran
172
152 (2E, 6E, 10Z)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-ol 173
155 Ethyl 7-methyl-3-oxooct-6-enoate 175
156 Ethyl (Z)-7-methyl-3-(((trifluoromethyl) sulfonyl) oxy) octa-2, 6-
dienoate
175
157 Ethyl (E)-3-ethyl-7-methylocta-2, 6-dienoate 176
158 (E)-3-Ethyl-7-methylocta-2, 6-dien-1-ol 177
159 (E)-1-Bromo-3-ethyl-7-methylocta-2, 6-diene 177
160 Ethyl (E)-7-ethyl-11-methyl-3-oxododeca-6, 10-dienoate 178
161 Ethyl (2Z, 6E)-3-((diethoxyphosphoryl) oxy)-7-ethyl-11-methyl 
dodeca-2, 6, 10-trienoate
179
162 Ethyl (2E, 6E)-7-ethyl-3, 11-dimethyl dodeca-2, 6, 10-trienoate 180
163 (2E, 6E)-7-Ethyl-3, 11-dimethyl dodeca-2, 6, 10-trien-1-ol 181
164 (2E, 6E)-1-Bromo-7-ethyl-3, 11-dimethyl dodeca-2, 6, 10-triene 181
165 (2E, 6E, 10Z)-12-Acetoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate
185
166 (2E, 6E, 10E)-12-Acetoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate
188
167 (2E, 6E)-8-Acetoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate
191
168 (2E, 6E, 10E)-12-Hydroxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate
189
169 (2E, 6E)-8-Acetoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate
191
170 (2E, 6E)-8-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate
194
171 (2E, 6E, 10E)-12-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate
197
172 (2Z, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) 
dodeca-2, 6, 10-trien-1-yl acetate
183
173 (2Z, 6E, 10E)-12-Hydroxy-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-yl 
acetate
183
174 (2Z, 6E, 10E)-12-Bromo-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-yl 
acetate
184
175 (2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) 
dodeca-2, 6, 10-trien-1-ol
185
159
176 (2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) 
dodeca-2, 6, 10-trien-1-yl acetate
186
177 (2E, 6E, 10E)-12-Hydroxy-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-yl 
acetate
187
178 (6E, 10E)-12-Chloro-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-5-ol 190
179 (6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) 
dodeca-2, 6, 10-trien-5-ol
192
180 2-(((2E, 6E)-8-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl) 
oxy) tetrahydro-2H-pyran
193
181 2-(((2E, 6E, 10E)-12-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-
1-yl) oxy) tetrahydro-2H-pyran
195
182 (2E, 6E)-8-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-ol 194
183 (2E, 6E, 10E)-12-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-ol 196
184 (2E, 6E, 10E)-12-Acetamido-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-
1-yl diphosphate
201
185 (2E, 6E, 10E)-12-Amino-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate
204
186 2-((2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) 
oxy) dodeca-2, 6, 10-trien-1-yl) isoindoline-1, 3-dione
198
187 (2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) 
dodeca-2, 6, 10-trien-1-amine
199
191 N-((2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) 
oxy) dodeca-2, 6, 10-trien-1-yl) acetamide
199
192 N-((2E, 6E, 10E)-12-Hydroxy-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-
1-yl) acetamide
200
193 N-((2E, 6E, 10E)-12-Bromo-2, 6, 10-trimethyldodeca-2, 6, 10-trien-1-
yl) acetamide
201
196 (9H-Fluoren-9-yl) methyl ((2E, 6E, 10E)-2, 6, 10-trimethyl-12-
((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6, 10-trien-1-yl) carbamate
202
197 (9H-Fluoren-9-yl) methyl ((2E, 6E, 10E)-12-hydroxy-2, 6, 10-trimethyl 
dodeca-2, 6, 10-trien-1-yl) carbamate
203
198 (9H-Fluoren-9-yl) methyl ((2E, 6E, 10E)-12-bromo-2, 6, 10-trimethyl 
dodeca-2, 6, 10-trien-1-yl) carbamate
204
211 14-Methyl amorphadiene 212
262 8-Methoxy-g-humulene 213
278 (2E, 6E, 10E)-12-Chloro-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-ol 189
279 (2E, 6E)-3, 7, 11-trimethyldodeca-2, 6, 10-trienal 208
284 (2E, 6E, 10E)-12-Bromo-1-methoxy-2, 6, 10-trimethyl dodeca-2, 6, 
10-triene
197
160
7.2.3Preparation of farnesyl diphosphate (FDP)
(2E, 6E)-1-Chloro-3, 7, 11-trimethyl dodeca-2, 6, 10-triene (127)[167]
To a cold suspension (0 °C) of farnesol (500 mg, 2.25 mmol), lithium chloride (1.5 g, 35 
mmol) and s-collidine (1.5 mL, 11 mmol) in dry dimethylformamide (DMF) (30 mL) was 
added methanesulfonyl chloride (0.80 mL, 9.6 mmol), via a syringe, under nitrogen. 
The mixture was stirred for 3 h and then poured into deionized water (100 mL). The 
biphasic layers were separated and the aqueous layer was extracted with hexane (4 x 
20 mL). Combined organic extracts were washed with saturated copper sulfate solution 
(3 x 40 mL), deionized water (2 x 40 mL) and saturated sodium bicarbonate solution (2 
x 40 mL) and dried over anhydrous magnesium sulfate. The resulting solution was 
filtered under gravity and concentrated under reduced pressure to give the title 
compound as light yellow oil (540 mg, 99%).
1H NMR (500 MHz, CDCl3): d 5.48 (1 H, t, JH,H = 8.0, C=CHCH2Cl), 5.11 (2 H, t, JH,H = 
7.0, 2 x C=CHCH2CH2), 4.10 (2 H, d, JH,H = 8.0, CH2Cl), 2.14-1.95 (8 H, m, 2 x 
CH2CH2), 1.73, 1.68 and 1.60 (2 x 3 H and 1 x 6 H, 3 x s, 4 x CH3).
13C NMR (125 MHz, CDCl3): d 143.0, 135.8 and 131.5 (3 x CH3CCHCH2), 124.5, 123.6 
and 120.4 (3 x CH3CCHCH2), 41.39 (CH2Cl), 39.86 and 39.62 (2 x CCHCH2CH2), 
26.87 and 26.28 (2 x CCHCH2CH2), 25.91, 17.89, 16.31 and 16.23 (4 x CH3). 
Tris (tetrabutylammonium) hydrogendiphosphate (121)[169]
Disodium dihydrogen diphosphate (3.3 g, 15 mmol) in 10% (v/v) aqueous ammonium 
hydroxide (15 mL) was passed through a cation-exchange resin (H+ form, amberlyst 
131 wet, 10 g). Free acid was eluted with deionized water (110 mL) and the resulting 
solution was titrated to pH 7.3 by slow addition of tetrabutylammonium hydroxide (40% 
w/w in aqueous solution). The solution was lyophilized to attain the hygroscopic 
product. 
The title compound was purified by recrystallization. The white solid was 
partially dried by treating with acetonitrile (75 mL) and by azeotropic removal of the 
water/solvent by reduced pressure to yield a tacky solid. The material was warmed to 
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40 °C in ethyl acetate (50 mL) before being filtered under vacuum to remove insoluble 
inorganic contaminants. The clear colourless filtrate was concentrated to half the 
volume and cooled to -20 °C to give the title compound as crystals (5 g, 38%).
1H NMR (500 MHz, CDCl3): d 3.17-3.13 (24 H, m, 12 x NCH2CH2CH2CH3), 1.62-1.56
(24 H, m, 12 x NCH2CH2CH2CH3), 1.36-1.27 (24 H, m, 12 x NCH2CH2CH2CH3), 0.90 
(36 H, t, JH,H = 7.5, 12 x NCH2CH2CH2CH3).
31P NMR (121 MHz, D2O): d -7.93 (s).
HRMS (ES-): calculated for (C16H39NO7P2 - [H])-: 418.2124, found: 418.2134.
(2E, 6E)-3,7,11-Trimethyl dodeca-2,6,10-trien-1-yl diphosphate (36)[169]
(Bu4N)3+
To a stirred solution of 121 (4.0 g, 4.5 mmol) in anhydrous acetonitrile (10 mL) under 
nitrogen was added a solution of crude 127 (540 mg, 2.25 mmol) in acetonitrile (3 mL) 
via a syringe. This was left to stir for 24 h. The solvent was removed and the resulting 
oil was dissolved in a minimum amount of ion-exchange buffer (25 mM ammonium 
bicarbonate solution containing 2% isopropanol). 
The crude compound in buffer was eluted through the NH4+-form cation 
exchange column with additional ion exchange buffer. Fractions that contained the 
diphosphate as judged by comparison with an authentic FDP standard by TLC (6:3:1,
isopropanol: water: ammonium hydroxide) were collected and lyophilized.
The resulting dry powder was re-dissolved in ion-exchange buffer and was 
purified by being passed through a reverse phase HPLC. Farnesyl diphosphate eluted 
at 35.7 min and fractions containing clean farnesyl diphosphate were pooled and 
lyophilized to give the title compound as a white powder (440 mg, 51%).
1H NMR (500 MHz, D2O): d 5.41 (1 H, t, JH,H = 7.0, CHCH2O), 5.18-5.10 (2 H, m, 2 x 
C=CHCH2CH2), 4.41 (2 H, t, JH,H = 6.5, CHCH2O), 2.11-1.94 (8 H, m, 2 x CHCH2CH2), 
1.67, 1.63 and 1.57 (2 x 3 H and 1 x 6 H, 3 x s, 4 x CH3).
31P NMR (121 MHz, D2O): d -6.49 (d, JP,P = 22), -10.25 (d, JP,P = 22).
LRMS (ES-) m/z: 381.12 (100%, [M - H]-), 301.17 (53).
HRMS (ES-): calculated for (C15H28O7P2 – [H])-: 381.1232, found: 381.1232.
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7.2.4 Preparation of 12-methyl-farnesyl diphosphate (12-Methyl FDP, 128)[170,172–
175]
2-(((2E, 6E)-3, 7, 11-Trimethyl dodeca-2, 6, 10-trien-1-yl) oxy) tetrahydro-2H-pyran 
(131)
To a stirred solution of farnesol (5.00 g, 22.5 mmol) in DCM (25 mL) was added to 3,4-
dihydropyran (8.10 mL, 88.8 mmol) and left to stir for 10 min. Pyridinium p-
toluenesulfonate (0.6 g, 2.4 mmol) was added and the mixture was stirred for 1 h 
whereupon TLC analysis (8:2, hexane: ethyl acetate) showed full consumption of 
starting material. DCM was removed under reduced pressure and the residual crude 
product was dissolved in diethyl ether (50 mL). The organic solution was washed with 
saturated aqueous sodium bicarbonate solution (3 x 20 mL) and brine (20 mL), before 
being dried over anhydrous magnesium sulfate, filtered under gravity and concentrated 
under reduced pressure to give the title compound as a colourless oil (6.5 g, 93%). The 
product was judged by 1H NMR spectroscopy to be sufficiently pure to carry forward 
without further purification.[172]
1H NMR (300 MHz, CDCl3): d 5.36 (1 H, t, JH,H = 6.5, CHCH2O), 5.10-5.13 (2 H, m, 2 x 
CCHCH2CH2), 4.63 (1 H, t, JH,H = 4.0, OCHO), 4.24 (1 H, dd, JH,H= 12.0 and 6.5, 
CCHCHAO), 4.06 (1 H, dd, JH,H= 12.0 and 7.5, CCHCHBO), 3.93-3.47 (2 H, m, 
OCH2CH2), 2.16-1.94 (8 H, m, 2 x CCHCH2CH2), 1.89-1.50 (6 H, m, OCHCH2CH2CH2), 
1.68 and 1.60 (2 x 6 H, 2 x s, 4 x CH3). 
13C NMR (75 MHz, CDCl3): d 140.5, 135.4 and 131.5 (3 x CH3CCH), 124.5, 124.1 and 
120.7 (3 x CH3CCH), 97.98 (OCHO), 63.83 and 62.48 (2 x CHOCH2), 39.89 and 39.82
(2 x CH3CCH2), 30.90 (OCHCH2), 26.90 and 26.47 (2 x CCHCH2CH2), 25.90
(OCH2CH2), 25.69 (OCH2CH2CH2), 19.82, 17.88, 16.62 and 16.20 (4 x CH3).
LRMS (ES+) m/z: 329.24 (100%, [M + Na]+).
HRMS (ES+): calculated for (C20H34O2 + [Na])+: 329.2457, found: 329.2463.
O O
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(2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6,
10-trienal (132)
Selenium dioxide (593 mg, 5.39 mmol), salicylic acid (752 mg, 5.39 mmol) and t-butyl 
hydroperoxide (5.10 mL, 539 mmol) were stirred in DCM (100 mL) for 30 min. 131
(3.30 g, 10.9 mmol) was added and the reaction was left to stir for 6 h. DCM was
removed under reduced pressure. t-Butyl hydroperoxide was removed by co-
evaporation with toluene (2 x 20 mL) under reduced pressure. The crude residue was 
dissolved in diethyl ether (20 mL) and washed with saturated aqueous sodium 
bicarbonate solution (50 mL). The layers were separated and the aqueous layer was 
further extracted with diethyl ether (5 x 20 mL). The combined organic layers were 
washed with brine (20 mL) and dried over anhydrous magnesium sulfate before being 
filtered under gravity. The solvent was removed under reduced pressure and the crude 
oil was purified by flash chromatography on silica gel (9:1, hexane: ethyl acetate) to 
give the title compound as a colourless oil (0.8 g, 23%).[173,174]
1H NMR (500 MHz, CDCl3): d 9.38 (1 H, s, CHO), 6.46 (1 H, t, JH,H = 7.0, CHC=CHO), 
5.36 (1 H, t, JH,H = 6.5, CCHCH2O), 5.16 (1 H, t, JH,H = 7.0, CH2CH2CHCCH2), 4.62 (1
H, m, OCHO), 4.24 (1 H, dd, JH,H= 12.0 and 6.5, CCHCHAO), 4.02 (1 H, dd, JH,H= 12.0 
and 7.5, CCHCHBO), 3.91-3.50 (2 H, m, OCH2CH2), 2.45 (2 H, m, CCHCH2CH2), 2.17-
2.11 (4 H, m, CCHCH2CH2), 2.06-2.03 (2 H, m, CCHCH2CH2), 1.77-1.51 (6 H, m, 
OCHCH2CH2CH2), 1.74, 1.68 and 1.63 (9 H, 3 x s, 3 x CH3).
13C NMR (125 MHz, CDCl3): d 195.5 (CH3CCHO), 154.7, 140.1 and 139.5 (3 x 
CH3CCH), 133.8, 125.5 and 121.0 (3 x CH3CCH), 98.07 (OCHO), 63.85 and 62.51 (2 x 
CHOCH2), 39.64 and 38.15 (2 x CH3CCH2), 30.90 (OCHCH2), 27.59 and 26.39 (2 x 
CCHCH2CH2), 25.67 (OCH2CH2), 19.82 (OCH2CH2CH2), 16.61, 16.11 and 9.42 (3 x 
CH3).
LRMS (ES+) m/z: 343.22 (100%, [M + Na]+).
HRMS (ES+): calculated for (C20H32O3 + [Na])+: 343.2249, found: 343.2232.
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2-(((2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10, 12-tetraen-1-yl) oxy) 
tetrahydro-2H-pyran (133)
To a stirred solution of methyl triphenyl phosphonium bromide (2.0 g, 5.6 mmol) in 
anhydrous THF (20 mL) was added n-butyl lithium (2.5 M in hexanes, 2.3 mL, 5.6 
mmol) at -10 °C. This solution was left to stir for 30 min before 132 (600 mg, 1.87
mmol) was added. The reaction was allowed to warm to room temperature and left to 
stir for 48 h. The reaction was quenched with the addition of saturated aqueous 
ammonium chloride solution (20 mL) and the organic layer was separated. The 
aqueous layer was extracted with diethyl ether (5 x 20 mL). The organic layers were 
combined and washed with saturated aqueous sodium bicarbonate solution (2 x 20 
mL) and brine (20 mL). The organic solution was dried over anhydrous magnesium 
sulfate, filtered under gravity and concentrated under reduced pressure. The crude oil 
was purified by flash chromatography on silica gel (9:1, hexane: ethyl acetate) to give 
the title compound as a colourless oil (350 mg, 56%).[175]
1H NMR (300 MHz, CDCl3): d 6.36 (1 H, dd, JH,H = 17.5 and 10.5, CHCCHCH2CH2), 
5.46 (1 H, t, JH,H = 7.0, CH3CCH), 5.36 (1 H, t, JH,H = 7.5, CH3C=CH), 5.13 (1 H, t, JH,H = 
6.0, CH3C=CH), 5.07 (1 H, d, JH,H = 17.5, CH3CCHCHAO), 4.92 (1 H, d, JH,H = 10.0, 
CH3CCHCHBO), 4.63 (1 H, t, JH,H = 3.5, OCHO), 4.24 (1 H, dd, JH,H= 12.0 and 6.5, 
CCHCHA), 4.02 (1 H, dd, JH,H= 12.0 and 6.5, CCHCHB), 3.93-3.47 (2 H, m, OCH2CH2), 
2.26-2.01 (8 H, m, 2 x CCHCH2CH2), 1.88-1.50 (6 H, m, OCHCH2CH2CH2), 1.73, 1.68 
and 1.60 (9 H, 3 x s, 3 x CH3).
13C NMR (75 MHz, CDCl3): d 141.8, 140.4 and 135.0 (3 x CH3CCH), 134.1, 133.1,
124.5 and 120.8 (4 x CH3CCH), 110.6 (CH3CCHCH2), 97.99 (OCHO), 63.84 and 62.48
(2 x CHOCH2), 39.76 and 39.39 (2 x CH3CCH2), 30.89 (OCHCH2), 27.02 and 26.44 (2 
x CCHCH2CH2), 25.68 (OCH2CH2), 19.81 (OCH2CH2CH2), 16.61, 16.18 and 11.86 (3 x 
CH3). 
LRMS (ES+) m/z: 341.25 (100%, [M + Na]+).
HRMS (ES+): calculated for (C21H34O2 + [Na])+: 341.2457, found: 341.2469.
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2-(((2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl) oxy) tetrahydro-2H-
pyran (134)
To a stirred solution of 133 (350 mg, 1.10 mmol) in toluene (10 mL) was added 
Wilkinson’s catalyst (102 mg, 0.110 mmol). The air in the sealed round bottom flask 
was evacuated using a vacuum pump and replaced with hydrogen contained in a 
balloon. This procedure was repeated 5 times to ensure the atmosphere in the round 
bottom flask was solely made up of hydrogen. The reaction was left to stir for 5 h and 
quenched with saturated aqueous sodium bicarbonate solution (20 mL). The layers 
were separated and the aqueous layer was extracted with diethyl ether (5 x 10 mL). 
The organic layers were combined and washed with saturated aqueous sodium 
bicarbonate solution (10 mL) and brine (10 mL) before being dried over anhydrous 
magnesium sulfate and filtered under gravity. The solvent was removed using reduced 
pressure and the crude product was purified by flash chromatography on silica gel (9:1, 
hexane: ethyl acetate) to give the title compound as a colourless oil (250 mg, 71%).[176]
1H NMR (300 MHz, CDCl3): d 5.36 (1 H, t, JH,H = 7.0, CHCH2O), 5.12-5.05 (2 H, m, 2 x 
CCHCH2CH2), 4.62 (1 H, t, JH,H = 3.5, OCHO), 4.23 (1 H, dd, JH,H= 12.0 and 6.5, 
CCHCHAO), 4.03 (1 H, dd, JH,H = 12.0 and 6.5, CCHCHBO), 3.92-3.49 (2 H, m, 
OCH2CH2), 2.14-1.90 (10 H, m, 2 x CCHCH2CH2 and CH3CCH2CH3), 1.68 (3 H, s, 
CHCCH3), 1.62-1.51 (6 H, m, OCHCH2CH2CH2), 1.59 (6 H, s, 2 x CHCCH3) and 0.97 
(3 H, t, JH,H = 7.5, CH3CCH2CH3).
13C NMR (125 MHz, CDCl3): d 140.5, 137.0 and 135.5 (3 x CH3CCH), 124.1, 122.9 and 
120.7 (3 x CH3CCH), 97.98 (OCHO), 63.84 and 62.47 (2 x CHOCH2), 39.93, 39.84 and 
32.52 (3 x CH3CCH2), 30.91 (OCHCH2), 26.75 and 26.48 (2 x CCHCH2CH2), 25.69
(OCH2CH2), 19.82 (OCH2CH2CH2), 16.62, 16.21, 16.09 and 13.00 (4 x CH3). 
LRMS (ES+) m/z: 343.26 (100%, [M + Na]+).
HRMS (ES+): calculated for (C21H36O2 + [Na])+: 343.2613, found: 343.2602.
(2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-ol (135)
To a stirred solution of 134 (230 mg, 0.780 mmol) in methanol (5 mL) was added p-
toluene sulfonic acid (13 mg, 0.078 mmol) and left to stir for 1 h. Once TLC analysis 
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(8:2, hexane: ethyl acetate) confirmed that all the starting material had been 
consumed, the methanol was removed under reduced pressure. The crude residual oil 
was dissolved in diethyl ether (10 mL) and washed with saturated aqueous sodium 
bicarbonate solution (20 mL). The separated aqueous layer was extracted with diethyl 
ether (5 x 10 mL). The organic layers were combined and washed with saturated 
aqueous sodium bicarbonate solution (20 mL) and brine (20 mL), before being dried 
over anhydrous magnesium sulfate and filtered under gravity. The solvent was 
removed under reduced pressure to give the title compound as a colourless oil (160 
mg, 94%). The product was judged by 1H NMR spectroscopy to be sufficiently pure to 
carry forward without further purification.[177]
1H NMR (300 MHz, CDCl3): d 5.42 (1 H, t, JH,H = 7, CHCH2OH), 5.13-5.06 (2 H, m, 2 x 
C=CHCH2CH2), 4.15 (2 H, d, JH,H = 7, C=CHCH2OH), 2.13-1.90 (10 H, m, 2 x 
C=CHCH2CH2 and CH2CH3), 1.68 (3 H, s, CH3C=CH), 1.60 (6 H, s, 2 x CH3C=CH) and 
0.97 (3 H, t, JH,H = 7.5, CH3CCH2CH3).
13C NMR (125 MHz, CDCl3): d 140.1, 137.1 and 135.6 (3 x CH3CCH), 124.0, 123.5 and
122.9 (3 x CH3CCH), 59.61 (CHCH2OH), 39.91 and 39.74 and 32.52 (3 x CH3CCH2), 
26.74 and 26.48 (2 x CCHCH2CH2), 16.47, 16.21, 16.09, 12.99 (4 x CH3). 
LRMS (EI+) m/z: 218.20 (56%, [M – H2O]+), 189.17 (48), 161.13 (50), 119.09 (100), 
93.07 (81).
HRMS (EI+): calculated for (C16H28O – [H2O])+: 218.2041, found: 218.2035. 
 
(2E, 6E, 10E)-1-Bromo-3, 7, 11-trimethyl trideca-2, 6, 10-triene (136)
To a stirred solution of 135 (160 mg, 0.677 mmol) in anhydrous THF (5 mL) was added 
phosphorous tribromide (31.8 µL, 335 µmol). The reaction was left to stir for 30 min 
under argon. Once TLC analysis (8:2, hexane: ethyl acetate) confirmed full 
consumption of the starting material, THF and phosphorous tribromide were removed 
under reduced pressure. The residual oil was dissolved in diethyl ether (20 mL) and the 
organic solution was washed with saturated aqueous sodium bicarbonate solution (20 
mL). The layers were separated and the aqueous layer was extracted with additional 
diethyl ether (3 x 10 mL). The combined organic layers were washed with brine (20 
mL), dried over anhydrous magnesium sulfate and filtered under gravity. The solvent 
was removed under reduced pressure to give the title compound as a yellow oil (180 
mg, 89%). The product was judged by 1H NMR spectroscopy to be sufficiently pure to 
carry forward without further purification.[168]
Br
167
1H NMR (300 MHz, CDCl3): d 5.53 (1 H, t, JH,H = 8.5, CHCH2Br), 5.13-5.03 (2 H, m, 2 x 
C=CHCH2CH2), 4.02 (2 H, d, JH,H = 8.5, CH2Br), 2.18-1.87 (10 H, m, 2 x C=CHCH2CH2
and CH2CH3), 1.73 (3 H, s, CH3C=CH), 1.60 (6 H, s, 2 x CH3C=CH) and 0.98 (3 H, t, 
JH,H = 7.5, CH2CH3).
(2E, 6E, 10E)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl diphosphate (128)
(Bu4N)3+
A stirred solution of 136 (180 mg, 0.604 mmol) in anhydrous acetonitrile (10 mL) was 
treated with 121 (1.1 g, 1.2 mmol). The reaction was left for 48 h to stir under nitrogen. 
The solvent was removed under reduced pressure and the resulting crude oil was 
purified by flash chromatography on silica gel (6:2.5:0.5, isopropanol: water: 
ammonium hydroxide). Fractions that contained the diphosphate as judged by 
comparison with an authentic FDP standard by TLC (6:3:1, isopropanol: water: 
ammonium hydroxide) were collected. The isopropanol was removed under reduced 
pressure and the remaining solution was lyophilized to give the title compound as 
colourless oil (0.12 g, 51%).[169]
1H NMR (500 MHz, CDCl3): d 5.46 (1 H, t, JH,H = 6.5, CHCH2O), 5.25-5.16 (2 H, m, 2 x 
CCHCH2CH2), 4.48 (2 H, t, JH,H = 6.5, CHCH2O), 3.22-3.18 (24 H, m, 12 x 
NCH2CH2CH2CH3), 2.21-1.91 (10 H, m, 2 x CCHCH2CH2 and CH3CCH2CH3), 1.73-1.63 
(33 H, m, 12 x NCH2CH2CH2CH3 and 3 x CHCCH3), 1.41-1.32 (24 H, m, 12 x 
NCH2CH2CH2CH3), 0.99-0.93 (39 H, m, 12 x NCH2CH2CH2CH3 and CH3CCH2CH3).
31P NMR (121 MHz, D2O): d -9.59 (d, JP,P = 18), -10.82 (d, JP,P = 18).
HRMS (ES-): calculated for (C16H30O7P2 – [H])-: 395.1389, found: 395.1371.
7.2.5 Preparation of 13-methyl farnesyl diphosphate (13-Methyl FDP, 129)
(6E, 10E)-2-Bromo-2, 6, 10-trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-
6,10-dien-3-ol (137)[179]
N-bromosuccinimide (1.90 g, 10.7 mmol) was added in small portions to a stirred 
solution of 131 (3.0 g, 9.8 mmol) in a mixture of THF (100 mL) and water (40 mL) at 5 
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°C. Additional water was added drop-wise when needed to retain the cloudiness of the 
solution. Once TLC analysis (8:2, hexane: ethyl actetate) confirmed that there was no 
starting material left, the reaction was quenched with brine (50 mL). The layers were 
separated and the aqueous layer was extracted with diethyl ether (5 x 20 mL). Pooled 
diethyl ether extracts were washed with saturated aqueous sodium bicarbonate 
solution (20 mL), brine (30 mL), dried over anhydrous magnesium sulfate, filtered
under gravity and concentrated under reduced pressure. The crude oil was purified by 
flash chromatography on silica gel (4:1, hexane: ethyl acetate) to give the title 
compound as a colourless oil (2.3 g, 67%).[178]
1H NMR (400 MHz, CDCl3): d 5.36 (1 H, t, JH,H = 6.5, CHCH2O), 5.20 (1 H, t, JH,H = 6.5, 
CH3CCHCH2CH2), 4.63 (1 H, t, JH,H = 3.5, OCHO), 4.24 (1 H, dd, JH,H = 12 and 6.5, 
CCHCHAO), 4.03 (1 H, dd, JH,H = 12 and 7.5, CCHCHBO), 3.97 (1 H, dt, JH,H = 11.5 and
1.5, OHCHCH2), 3.92-3.49 (2 H, m, OCH2CH2), 2.35-2.04 (8 H, m, 2 x CCHCH2CH2), 
1.86-1.51 (6 H, m, OCHCH2CH2CH2), 1.68, 1.59, 1.34, 1.33 (4 x 3 H, 4 x s, 4 x CH3).
13C NMR (125 MHz, CDCl3): d 139.4 and 133.5 (2 x CH3C=CH), 125.9 and 120.9 (2 x 
CH3C=CH), 97.98 (OCHO), 94.85 (CHOH), 63.87 and 62.52 (2 x CHOCH2), 39.65
(CH3CBr), 38.31 and 32.23 (2 x CH3CCH2), 30.88 (OCHCH2), 26.72 and 26.39 (2 x 
C=CHCH2CH2), 26.03 and 25.66 (2 x OHCHCCH3), 25.41 (OCH2CH2), 19.80
(OCH2CH2CH2), 16.63 and 16.03 (2 x CH2CCH3). 
LRMS (ES+) m/z: 425.17 (100%, [C20H35O379Br + Na]+), 427.17 (91, [C20H35O381Br + 
Na]+).
HRMS (ES+): calculated for (C20H35O379Br + [Na])+: 425.1667, found: 425.1660.
2-(((2E, 6E)-9-(3, 3-Dimethyl oxiran-2-yl)-3, 7-dimethyl nona-2, 6-dien-1-yl) oxy)
tetrahydro-2H-pyran (138)[179]
To a stirred solution of potassium carbonate (2.40 g, 17.4 mmol) in methanol (50 mL)
was added 137 (3.5 g, 8.7 mmol). The mixture was stirred for 1 h at room temperature. 
The methanol was removed and the residual oil was dissolved in diethyl ether (20 mL). 
A solution of saturated aqueous sodium bicarbonate solution (80 mL) was added to 
dilute the solution. The layers were separated and the aqueous layer was washed with 
additional diethyl ether (5 x 20 mL). Combined ether extracts were washed with brine 
(20 mL), dried over anhydrous magnesium sulfate, filtered under gravity and 
concentrated under reduced pressure. The crude oil was purified by flash 
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chromatography on silica gel (4:1, hexane: ethyl acetate) to give the title compound as 
a colourless oil (2.3 g, 81%).[178]
1H NMR (300 MHz, CDCl3): d 5.36 (1 H, t, JH,H = 7.0, CHCH2O), 5.15 (1 H, t, JH,H = 6.5, 
CH3CCHCH2CH2), 4.62 (1 H, t, JH,H = 3.5, OCHO), 4.24 (1 H, dd, JH,H = 12.0 and 6.5, 
CCHCHAO), 4.01 (1 H, dd, JH,H = 12.0 and 7.5, CCHCHBO), 3.92-3.47 (2 H, m, 
OCH2CH2), 2.70 (1 H, t, JH,H = 6.0, COCH), 2.15-1.80 (8 H, m, 2 x CCHCH2CH2), 1.72 -
1.49 (6 H, m, OCHCH2CH2CH2), 1.67, 1.61, 1.29 and 1.25 (4 x 3 H, 4 x s, 4 x CH3).
13C NMR (125 MHz, CDCl3): d 140.3 and 134.5 (2 x CH3CCH), 124.7 and 120.8 (2 x 
CH3CCH), 98.02 (OCHO), 64.37, 63.83, 62.48 and 58.52 (2 x OCH and 2 x OCH2), 
39.72 and 36.48 (2 x CH3CCH2), 30.89 (OCHCH2), 27.61 and 26.45 (2 x CCHCH2CH2), 
25.67 (OCH2CH2), 25.08 (OCCH3), 19.81 (OCH2CH2CH2), 18.93 (OCCH3), 16.61 and 
16.19 (2 x CH2CCH3). 
LRMS (ES+) m/z: 345.24 (100%, [M + Na]+), 309.17 (25), 250.14 (7).
HRMS (ES+): calculated for (C20H34O3 + [Na])+: 345.2406, found: 345.2393.
(4E, 8E)-4, 8-Dimethyl-10-((tetrahydro-2H-pyran-2-yl) oxy) deca-4, 8-dienal (139)
A stirred solution of 138 (330 mg, 1.02 mmol) in a mixture of THF (10 mL) and water (1 
mL) at 0 °C was treated sequentially with sodium periodate (130 mg, 0.610 mmol) and 
periodic acid (260 mg, 1.14 mmol). The resulting biphasic solution was stirred at 0 °C 
for 10 min and was then allowed to warm to room temperature. After 1 h at room 
temperature, the reaction was quenched with saturated aqueous sodium bicarbonate
solution (25 mL) and poured into brine (25 mL). The layers were separated and the 
aqueous layer was extracted with diethyl ether (5 x 20 mL). Combined organic layers 
were washed with brine (20 mL), dried over anhydrous magnesium sulfate, filtered 
under gravity and concentrated under reduced pressure. The resulting oil was purified 
by flash chromatography on silica gel (4:1, hexane: ethyl acetate) to give the title 
compound as a colourless oil (250 mg, 87%).[179]
1H NMR (300 MHz, CDCl3): d 9.75 (1 H, t, JH,H = 2.0, CCH2CH2CHO), 5.34 (1 H, t, JH,H = 
6.5, CHCH2O), 5.13 (1 H, t, JH,H = 6.5, CCHCH2CH2), 4.62 (1 H, t, JH,H = 4.0, OCHO),
4.24 (1 H, dd, JH,H = 12.0 and 6.5, CCHCHAO), 4.01 (1 H, dd, JH,H = 12.0 and 7.5, 
CCHCHBO), 3.93-3.47 (2 H, m, OCH2CH2), 2.54-2.48 (2 H, m, OCHCH2CH2C), 2.31 (2
H, t, JH,H = 7.5, OCHCH2CH2C), 2.13-2.03 (4 H, m, CCHCH2CH2), 1.75-1.50 (6 H, m, 
OCHCH2CH2CH2), 1.67 and 1.61 (2 x 3 H, 2 x s, 2 x CH3).
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13C NMR (125 MHz, CDCl3): d 202.9 (CCH2CH2CHO), 140.1 and 133.4 (2 x CH3CCH), 
125.2 and 121.0 (2 x CH3CCH), 98.05 (OCHO), 63.83 and 62.50 (2 x CHOCH2), 42.33 
(CCH2CH2CHO), 39.57 and 31.99 (2 x CH3CCH2), 30.90 (OCHCH2), 26.34 
(CCHCH2CH2), 25.67 (OCH2CH2), 19.81 (OCH2CH2CH2), 16.58 and 16.29 (2 x CH3). 
LRMS (ES+) m/z: 303.19 (100%, [M + Na]+), 227.13 (10).
HRMS (ES+): calculated for (C17H28O3 + [Na])+: 303.1936, found: 303.1943.
(2Z, 6E, 10E)-Ethyl-2, 6, 10-trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-
2, 6, 10-trienoate (140)
To a stirred solution of 141 (123 mg, 0.355 mmol) in anhydrous THF (5 mL) was added 
18-crown-6 (400 µL, 1.88 mmol) and the solution was cooled to -78 °C. Potassium 
bis(trimethylsilyl)amide (KHMDS) (1 M in THF, 360 µL, 0.360 mmol) was added drop-
wise over 5 min and then was left to stir for 15 min. 139 (100 mg, 0.357 mmol) was 
dissolved in a minimal amount of anhydrous THF (5 mL) and added slowly over 5 min
to the reaction. The reaction was stirred for 1 h before being quenched with saturated 
aqueous ammonium chloride solution (20 mL). The layers were separated and the 
aqueous layer was extracted with diethyl ether (3 x 20 mL). Combined ether extracts 
were washed with brine (10 mL), dried over magnesium sulfate, filtered under gravity 
and concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (9:1, hexane: ethyl acetate) to give the title compound as 
a colourless oil (36 mg, 41%).
1H NMR (300 MHz, CDCl3): d 5.90 (1 H, t, JH,H = 7.5, EtO2CC=CH), 5.36 (1 H, t, JH,H = 
6.5, CHCH2O), 5.13 (1 H, t, JH,H = 6.5, CCHCH2CH2), 4.62 (1 H, t, JH,H = 4.0, OCHO), 
4.27-4.16 (3 H, m, CCHCHAO and COCH2CH3), 4.19 (2 H, q, JH,H = 7.0, COCH2CH3), 
4.02 (1 H, dd, JH,H = 12.0 and 7.5, CCHCHBO), 3.93-3.47 (2 H, m, OCH2CH2), 2.59-2.51 
(2 H, m, 2 x C=CHCH2CH2), 2.16-2.03 (6 H, m, C=CHCH2CH2 and 2 x C=CHCH2CH2),
1.88 and 1.68 (2 x 3 H, 2 x s, 2 x CH3), 1.64-1.49 (6 H, m, OCHCH2CH2CH2), 1.59 (3
H, s, CH3), 1.30 (3 H, t, JH,H = 7.0, CH2CH3).
13C NMR (75 MHz, CDCl3): d 168.4 (COCH2CH3), 142.8, 140.4 and 134.7 (3 x 
CH3CCH), 127.3, 124.7 and 120.8 (3 x CH3CCH), 98.01(OCHO), 63.84 and 62.48 (2 x 
CHOCH2), 60.23 (COCH2CH3), 39.78 and 39.30 (2 x CH3CCH2), 30.90 (OCHCH2), 
28.14 and 26.46 (2 x CCHCH2CH2), 25.68 (OCH2CH2), 20.84 (OCCCH3), 19.81
(OCH2CH2CH2), 16.62 and 16.05 (2 x CH2CCH3), 14.49 (COCH2CH3). 
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LRMS (AP+) m/z: 387.25 (100%, [M + Na]+), 347.26 (21, [M-OH]+).
HRMS (AP+): calculated for (C22H36O4 + [Na])+: 387.2511, found: 387.2514.
(2Z, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6,
10-trien-1-ol (149)
To a stirred solution of 140 (0.20 g, 0.55 mmol) in anhydrous THF (5 mL) at 78 °C was 
added, drop-wise, DIBAL-H (1 M in toluene, 1.7 mL, 1.7 mmol) and the reaction was 
left to stir until TLC analysis (8:2, hexane: ethyl acetate) showed full consumption of 
starting material (ca. 1 h). The reaction was quenched with saturated aqueous sodium 
bicarbonate solution (30 mL) and left to stir for 1 h. The layers were separated and the
aqueous layer was washed with diethyl ether (3 x 10 mL), brine (10 mL) and dried over 
anhydrous magnesium sulfate before being filtered under gravity and concentrated 
under reduced pressure. The crude oil was purified by flash chromatography on silica 
gel (4:1, hexane: ethyl acetate) to give the title compound as a colourless oil (110 mg, 
62%).[145]
1H NMR (300 MHz, CDCl3): d 5.36 (1 H, t, JH,H = 7.0, CHCH2O), 5.28 (1 H, t, JH,H = 7.0, 
OHCH2CCH), 5.10 (1 H, t, JH,H = 6.5, CCHCH2CH2), 4.63 (1 H, t, JH,H = 4.0, OCHO), 
4.24 (1 H, dd, JH,H= 12.0 and 6.5, CCHCHAO), 4.11 (2 H, s, OHCH2), 4.03 (1 H, dd, 
JH,H= 12.0 and 7.5, CCHCHBO), 3.93-3.48 (2 H, m, OCH2CH2), 2.18-1.96 (8 H, m, 2 x 
CCHCH2CH2), 1.79 and 1.68 (2 x 3 H, 2 x s, 2 x CH3), 1.61-1.48 (6 H, m, 
OCHCH2CH2CH2), 1.59 (3 H, s, CH3).
13C NMR (75 MHz, CDCl3): d 140.3, 135.0 and 134.6 (3 x CH3CCH), 128.4, 124.7 and
120.8 (3 x CH3CCH), 98.00 (OCHO), 63.84 and 62.49 (2 x CHOCH2), 61.79 (OHCH2), 
39.99 and 39.75 (2 x CH3CCH2), 30.89 (OCHCH2), 26.39 and 25.67 (2 x CCHCH2CH2), 
21.47 (OCH2CH2), 19.80 (OCH2CH2CH2), 16.60, 16.23 and 14.32 (3 x CH3). 
LRMS (ES+) m/z: 345.24 (100%, [M + Na]+).
HRMS (ES+): calculated for (C20H34O3 + [Na])+: 345.2406, found: 345.2390.
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2-(((2E, 6E, 10Z)-12-Bromo-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl) oxy)
tetrahydro-2H-pyran (150)
To a stirred solution of 149 (400 mg, 1.24 mmol) in anhydrous THF (12 mL) at -45 °C 
was added anhydrous triethylamine (0.50 mL, 3.5 mmol) followed by methanesulfonyl 
chloride (140 µL, 1.81 mmol) and the reaction was left to stir for 15 min. Lithium 
bromide (121 mg, 1.40 mmol) was added and the solution was warmed to room 
temperature. The reaction was left to stir until TLC analysis (8:2, hexane: ethyl acetate) 
showed full consumption of starting material (ca. 2 h). The reaction was quenched with 
saturated brine (10 mL) and the biphasic layers were separated. The aqueous layer 
was washed with diethyl ether (3 x 10 mL), 1 M hydrochloric acid (2 x 10 mL) and brine 
(10 mL). The resulting solution was dried over anhydrous magnesium sulfate, filtered
under gravity, and concentrated under reduced pressure to give the title compound as 
an orange oil (450 mg, 97%). The product was judged by 1H NMR spectroscopy to be 
sufficiently pure to carry forward without further purification.
1H NMR (300 MHz, CDCl3): d 5.36 (2 H, t, JH,H = 7.0, CHCH2O and CHCH2Br), 5.12 (1
H, t, JH,H = 7.0, CCHCH2CH2), 4.63 (1 H, t, JH,H = 4.0, OCHO), 4.24 (1 H, dd, JH,H= 12.0 
and 6.5, CCHCHAO), 4.03 (1 H, dd, JH,H= 12.0 and 7.5, CCHCHBO), 3.98 (2 H, s, 
CH2Br), 3.93-3.48 (2 H, m, OCH2CH2), 2.17-2.01 (8 H, m, 2 x CCHCH2CH2), 1.82 and 
1.68 (2 x 3 H, 2 x s, 2 x CH3), 1.63-1.52 (6 H, m, OCHCH2CH2CH2), 1.61 (3 H, s, CH3).
2-(((2E, 6E, 10Z)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl) oxy) tetrahydro-2H-
pyran (151)
Copper iodide (475 mg, 2.49 mmol) and methyl lithium (1.6 M in diethyl ether, 3.5 mL, 
5.0 mmol) were mixed together at 0 °C for 30 min. An initial yellow precipitate formed 
which turned into a colourless solution (presence of lithium dimethylcuprate). 150 (480 
mg, 1.25 mmol) in minimal anhydrous diethyl ether (5 mL) was added and the 
temperature was reduced to -78 °C. Once TLC analysis (8:2, hexane: ethyl acetate) 
showed full consumption of starting material, ammonia (10 mL) was added to quench 
the reaction and the solution was left stirring overnight for the phases to separate. The 
biphasic layers were separated and the aqueous layer was washed with diethyl ether 
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(4 x 10 mL). Combined organic layers were washed with brine (10 mL), dried over 
anhydrous magnesium sulfate, filtered under gravity and concentrated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (4:1, 
hexane: ethyl acetate) to give the title compound as a colourless oil (240 mg, 60%).
1H NMR (400 MHz, CDCl3): d 5.36 (1 H, t, JH,H = 6.5, CHCH2O), 5.13-5.04 (2 H, m, 2 x 
CCHCH2CH2), 4.62 (1 H, t, JH,H = 4.0, OCHO), 4.24 (1 H, dd, JH,H= 12.0 and 6.5, 
CCHCHAO), 4.03 (1 H, dd, JH,H= 12.0 and 7.5, CCHCHBO), 3.92-3.49 (2 H, m, 
OCH2CH2), 2.14-1.79 (10 H, m, 2 x CCHCH2CH2 and CH3CH2C), 1.68 (3 H, s, CCH3), 
1.61-1.50 (6 H, m, OCHCH2CH2CH2), 1.59 (6 H, s, 2 x CCH3), 0.96 (3 H, t, JH,H = 7.5, 
CH2CH3).
13C NMR (100 MHz, CDCl3): d 140.4, 134.6 and 131.6 (3 x CH3CCH), 131.6, 124.8 and
120.8 (3 x CH3CCH), 98.02 (OCHO), 63.86 and 62.49 (2 x CHOCH2), 39.76, 39.21 and 
32.69 (3 x CH3CCH2), 30.91 (OCHCH2), 26.78 and 26.46 (2 x CCHCH2CH2), 25.69
(OCH2CH2), 22.06 (CH3CH2CCH3), 19.83 (OCH2CH2CH2), 16.63, 16.20 and 14.32 
(CH3). 
HRMS (EI+): calculated for C21H36O2+: 320.2715, found: 320.2732.
(2E, 6E, 10Z)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-ol (152) 
 
To a stirred solution of 151 (110 mg, 340 µmol) was added pyridinium p-
toluenesulfonate (8.0 mg, 30 µmol) in methanol (25 mL) and stirred at room 
temperature overnight. The reaction mixture was heated to 50 °C for 1 h before being 
quenched with triethylamine (10 mL). The solvent was removed under reduced 
pressure and the residual oil was dissolved with diethyl ether (20 mL) and washed with 
saturated sodium bicarbonate solution (2 x 10 mL) and brine (10 mL). The resulting 
solution was dried over anhydrous magnesium sulfate, filtered under gravity and 
concentrated under reduced pressure to give the title compound as a colourless oil (40 
mg, 49%). The product was judged by 1H NMR spectroscopy to be sufficiently pure to 
carry forward without further purification.[177]
1H NMR (300 MHz, CDCl3): d 5.42 (1 H, t, JH,H = 7.0, CHCH2O), 5.12-5.04 (2 H, m, 2 x 
CCHCH2CH2), 4.15 (2 H, d, JH,H = 7.0, CH2OH), 2.15-1.87 (10 H, m, 2 x CCHCH2CH2
and CH3CH2C), 1.68 (6 H, s, 2 x CH3), 1.60 (3 H, s, CH3), 1.01-0.93 (3 H, m, CH2CH3).
13C NMR (75 MHz, CDCl3): d 140.0, 137.3 and 135.5 (3 x CH3CCH), 124.1, 124.0 and 
123.5 (3 x CH3CCH), 59.57 (CH2OH), 40.18, 39.72 and 39.54 (CH3CCH2), 26.47 and 
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26.45 (2 x CCHCH2CH2), 23.04 (CH3CH2CCH3), 16.46 and 16.20 (2 x CCH3), 13.00
(CH2CH3). 
HRMS (EI+): calculated for C16H28O+: 236.2140, found: 236.2150.
(2E, 6E, 10Z)-3, 7, 11-Trimethyl trideca-2, 6, 10-trien-1-yl diphosphate (129)
(NH4)3+
To a cold suspension (0 °C) of 152 (40 mg, 0.17 mmol), lithium chloride (115 mg, 2.71
mmol) and s-collidine (134 µL, 1.03 mmol) in anhydrous DMF (10 mL) was added 
methanesulfonyl chloride (26.2 µL, 340 µmol), under nitrogen. The mixture was stirred 
for 3 h. The solution was poured into ice-cold water (30 mL) and extracted with diethyl 
ether (4 x 15 mL). Combined organic extracts were washed with saturated aqueous 
copper sulfate solution (3 x 20 mL), water (2 x 20 mL) and saturated aqueous 
ammonium bicarbonate solution (2 x 20 mL), dried over anhydrous magnesium sulfate, 
filtered under gravity and concentrated under reduced pressure to give the crude 
chloride intermediate.
To a stirred solution of 121 (46 mg, 0.52 mmol) in anhydrous acetonitrile (5 mL) 
under N2 was added the crude chloride in acetonitrile (3 mL). This was left for 24 h at 
room temperature. The solvent was removed under reduced pressure and the resulting 
oil was dissolved in a minimum amount of ion-exchange buffer (25 mM ammonium 
bicarbonate solution containing 2% isopropanol).
The crude compound in buffer was then eluted through the NH4+-form cation exchange 
column with additional ion exchange buffer. Fractions that contained the diphosphate 
as judged by comparison with an authentic FDP standard by TLC (6:3:1 isopropanol: 
water: ammonium hydroxide) were collected and lyophilized. The resulting dry powder 
was purified by methanol precipitation to give the title compound as a colourless oil (27 
mg, 36%).
1H NMR (500 MHz, D2O): d 5.44 (1 H, t, JH,H = 6.5, CH3CCHCH2O), 5.20 (1 H, t, JH,H = 
6.5, CH3CCH), 5.14 (1 H, t, JH,H = 6.5, CH3CCH), 4.46 (2 H, m, CHCH2O), 2.16-1.91 
(10 H, m, 2 x CCHCH2CH2 and CH3CH2C), 1.70, 1.67 and 1.60 (3 x 3 H, 3 x s, 3 x 
CCH3), 0.93 (3 H, t, JH,H = 7.5, CH2CH3).
31P NMR (121 MHz, D2O): d -10.64 (m).
HRMS (ES-): calculated for (C16H30O7P2 – [H])-: 395.1389, found: 395.1401.
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7.2.6 Preparation of 14-methyl farnesyl diphosphate (14-Methyl FDP, 130)
Ethyl 7-methyl-3-oxooct-6-enoate (155)
To a stirred suspension of sodium hydride (3.2 g, 60% in mineral oil, 80 mmol) in 
anhydrous THF (50 mL) at 0 °C, was added ethyl acetoacetate (5.2 g, 40 mmol) and 
then n-butyllithium solution (2.2 M in hexane, 20 mL, 49 mmol). The solution was left to 
stir for 30 min. A cooled solution of 3,3-dimethylallyl bromide (2.0 g, 15.4 mmol) in 
anhydrous THF (10 mL) was added via syringe drop-wise. After 3 h the solution was 
quenched with saturated aqueous ammonium chloride solution (50 mL) and the 
biphasic layers were separated. The aqueous layer was washed with additional diethyl 
ether (3 x 50 mL). Combined organic layers were washed with water (10 mL), brine (10 
mL), dried over anhydrous magnesium sulfate, filtered under gravity and concentrated 
under reduced pressure. The crude oil was purified by flash chromatography on silica 
gel (4:1, hexane: ethyl acetate) to give the title compound as a colourless oil (1.7 g, 
64%).
1H NMR (300 MHz, CDCl3): d 5.05 (1 H, t, JH,H = 7.0, CCHCH2), 4.19 (2 H, q, JH,H = 7.0, 
OCH2CH3), 3.43 (2 H, s, CH2CO), 2.56 (2 H, t, JH,H = 7.5, CCHCH2CH2), 2.31-2.20 (2 H, 
m, CCHCH2CH2), 1.67 (3 H, s, CCH3), 1.61 (3 H, s, CCH3), 1.28 (3 H, t, JH,H = 7, 
CH2CH3).
13C NMR (75 MHz, CDCl3): d 202.9 (OCO), 167.4 (OCCH2), 133.3 (CH3CCH), 122.4 
(CH3CCH), 61.54 (OCH2CH3), 49.58 (OCCH2CO), 43.22 (OCCH2CH2), 25.86
(OCCH2CH2), 22.37 and 17.84 (2 x CHCCH3), 14.28 (CH2CH3). 
LRMS (EI+): 198.13 (16, M+), 180.11 (43), 152.08 (37), 130.06 (44), 82.08 (100), 
67.05 (55).
HRMS (EI+): calculated for C11H18O3+: 198.1256, found: 198.1257.
Ethyl (Z)-7-methyl-3-(((trifluoromethyl) sulfonyl) oxy) octa-2, 6-dienoate (156)
To a stirred solution of 155 (2.0 g, 10 mmol) in anhydrous DCM (150 mL) at 0 °C was 
added lithium trifluoromethane sulfonate (1.9 g, 12 mmol) and freshly distilled 
triethylamine (2.0 mL, 13 mmol). After 1 h, trifluoromethane sulfonic anhydride (2.0 mL, 
12 mmol) was added and the resulting orange solution was left for an additional 2 h. 
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The reaction was quenched with saturated aqueous ammonium chloride solution (100 
mL). The biphasic layers were separated and the aqueous layer was washed with 
additional DCM (3 x 50 mL). The combined organic layers were washed with saturated 
aqueous sodium bicarbonate solution (3 x 40 mL), brine (50 mL), dried over anhydrous 
magnesium sulfate, filtered under gravity and concentrated under reduced pressure. 
The crude oil was purified by flash chromatography on silica gel (9.7:0.3, hexane: ethyl 
acetate) to give the title compound as a colourless oil (2.7 g, 80%).
1H NMR (300 MHz, CDCl3): d 5.74 (1 H, s, OCCH), 5.04 (1 H, t, JH,H = 7.0, CH3CCH), 
4.24 (2 H, q, JH,H = 7.0, OCH2CH3), 2.42-2.22 (4 H, m, CHCH2CH2), 1.70 (3 H, s, 
CCH3), 1.61 (3 H, s, CCH3), 1.30 (3 H, t, JH,H = 7.0, OCH2CH3).
13C NMR (75 MHz, CDCl3): d 189.3 (OCCH), 162.7 (OCO), 158.7 (CF3), 134.7
(CH3CCH), 120.9 (CH3CCH), 112.2 (OCCH), 61.43 (OCH2CH3), 34.76 (CH2CH2), 25.84
(CCH3), 24.66 (CH2CH2), 17.86 (CCH3), 14.21 (OCH2CH3). 
HRMS (EI+): calculated for C12H17O5F3S+: 330.0749, found: 330.0700.
Ethyl (E)-3-ethyl-7-methylocta-2, 6-dienoate (157)
To a stirred suspension of copper iodide (3.4 g, 18 mmol) in anhydrous THF (60 mL) at 
0 °C was added ethyl magnesium bromide (6.7 mL, 18 mmol) and the resulting black 
solution was left to stir for 30 min. The solution was cooled to -78 °C and a solution of 
156 (1.0 g, 3.0 mmol) in anhydrous THF (10 mL) was added via syringe. This was left 
to stir for 1 h before being quenched with saturated aqueous ammonium chloride 
solution (50 mL). 35% ammonium hydroxide (20 mL) was added and left to stir for 1 h
to allow the copper salts, formed during the quenching, to dissolve. The biphasic layers 
were separated and the blue aqueous layer was washed with diethyl ether (3 x 40 mL). 
The combined organic layers were washed with 10% ammonium hydroxide (2 x 20 
mL), water (2 x 20 mL), and brine (50 mL). The resulting solution was dried over 
anhydrous magnesium sulfate, filtered under gravity and concentrated under reduced 
pressure. The crude oil was purified by flash chromatography on silica gel (9:1, 
hexane: ethyl acetate) to give the title compound as a colourless oil (510 mg, 80%).
1H NMR (300 MHz, CDCl3): d 5.61 (1 H, s, OCCH), 5.09 (1 H, m, CH3CCH), 4.14 (2 H, 
q, JH,H = 7, OCH2CH3), 2.61 (2 H, q, JH,H = 7.5, CH3CH2C), 2.16 (4 H, m, CHCH2CH2), 
1.69 (3 H, s, CCH3), 1.60 (3 H, s, CCH3), 1.28 (3 H, t, JH,H = 7, OCH2CH3), 1.07 (3 H, t, 
JH,H = 7.5, CCH2CH3).
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13C NMR (75 MHz, CDCl3): d 166.7 (OCO), 165.8 (CH3CH3C), 132.6 (CH3CCH), 123.3
(CH3CCH), 115.0 (CCHC), 59.65 (OCH2CH3), 38.13 (CCH2CH2), 26.41 (CCH2CH2), 
25.87 (CCH2CH3), 25.52 and 17.90 (2 x CCH3), 14.50 (OCH2CH3), 13.17 (CCH2CH3). 
HRMS (EI+): calculated for C13H22O2+: 210.1620, found: 210.1590.
(E)-3-Ethyl-7-methylocta-2, 6-dien-1-ol (158)
To a stirred solution of 157 (0.75 g, 3.6 mmol) in anhydrous toluene (30 mL) at -78 °C, 
was added diisobutylaluminium hydride (DIBAL-H) (1 M in THF, 7.1 mL, 7.1 mmol) 
drop-wise and the resulting solution was left to stir for 1 h whereupon TLC analysis
(8:2, hexane: ethyl acetate) showed full consumption of the starting material. Methanol 
(10 mL) was added drop-wise and stirred whilst the reaction warmed to room 
temperature. Saturated aqueous ammonium chloride solution and hydrochloric acid (1 
M) (80 mL; 1: 1) was added and stirred for 30 min. The biphasic layers were separated 
and the aqueous layer was extracted with diethyl ether (3 x 20 mL). The combined 
organic layers were washed with water (2 x 20 mL), brine (25 mL), dried over 
anhydrous magnesium sulfate, filtered under gravity and concentrated under reduced 
pressure to give the title compound as a colourless oil (528 mg, 88%). The product was 
judged by 1H NMR spectroscopy to be sufficiently pure to carry forward without further 
purification.
1H NMR (300 MHz, CDCl3): d 5.37 (1 H, t, JH,H = 7.0, CHCH2OH), 5.13-5.08 (1 H, m, 
CHCH2CH2), 4.16 (2 H, d, JH,H = 7.0, CHCH2OH), 2.13-2.05 (6 H, m, CHCH2CH2 and 
CCH2CH3), 1.68 (3 H, s, CCH3), 1.61 (3 H, s, CCH3), 0.99 (3 H, t, JH,H = 7.5, CH2CH3).
13C NMR (75 MHz, CDCl3): d 145.9 (CH3CH2C), 131.9 (CH3CCH), 124.2 (CHCH2OH), 
122.9 (CHCH2CH2), 59.30 (CHCH2OH), 36.56 (CCH2CH2), 26.77 (CCH2CH2), 25.88
(CCH2CH3), 23.69 and 17.90 (2 x CCH3), 13.89 (CCH2CH3). 
HRMS (EI+): calculated for C11H20O+: 168.1514, found: 168.1527.
(E)-1-Bromo-3-ethyl-7-methylocta-2, 6-diene (159)
To a stirred solution of 158 (0.45 g, 2.7 mmol) in anhydrous THF (15 mL) at -45 °C was 
added freshly distilled triethylamine (1.1 mL, 7.9 mmol) and methanesulfonyl chloride 
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(0.4 mL, 5.3 mmol). After 45 min, lithium bromide (1.0 g, 10.7 mmol) was added and 
the solution was warmed to 0 °C and left for 2 h whereupon TLC analysis (8:2, hexane: 
ethyl acetate) showed full consumption of the starting material.
The solution was diluted with hexane and quenched with saturated ammonium 
chloride solution (20 mL). The biphasic layers were separated and the aqueous layer 
was washed with hexane (4 x 20 mL). Combined organic layers were washed with 
saturated sodium bicarbonate solution (20 mL), water (20 mL) and brine (20 mL). The 
solution was dried over anhydrous magnesium sulfate, filtered under gravity and 
concentrated with reduced pressure to give the title compound as a colourless oil (610 
mg, 99%). The product was judged by 1H NMR spectroscopy to be sufficiently pure to 
carry forward without further purification.
1H NMR (300 MHz, CDCl3): d 5.49 (1 H, t, JH,H = 8.5, CHCH2Br), 5.08 (1 H, m, 
CHCH2CH2), 4.04 (2 H, d, JH,H = 8.5, CHCH2Br), 2.19-2.07 (6H, m, CHCH2CH2 and 
CCH2CH3), 1.68 (3H, s, CCH3), 1.60 (3H, s, CCH3), 1.03 (3H, t, JH,H = 7.5, CH2CH3).
13C NMR (75 MHz, CDCl3): d 149.3 (CH3CH2C), 132.2 (CH3CCH), 123.8 (CHCH2OH), 
120.2 (CHCH2CH2), 36.59 (CHCH2Br), 29.55 (CCH2CH2), 26.56 (CCH2CH2), 25.88
(CCH2CH3), 23.37 and 17.92 (2 x CCH3), 13.13 (CCH2CH3). 
Ethyl (E)-7-ethyl-11-methyl-3-oxododeca-6, 10-dienoate (160)
To a stirred suspension of sodium hydride (1.2 g, 30.6 mmol) in anhydrous THF (50 
mL) at 0 °C, was added ethyl acetoacetate (19.7 mL, 15.3 mmol) and then n-
butyllithium (2.5 M in hexane, 7.2 mL, 17.9 mmol). The solution was stirred for 30 min. 
A cooled solution of 159 (1.2 g, 5.1 mmol) in dry THF (10 mL) was added and left to stir 
until TLC analysis (8:2, hexane: ethyl acetate) showed complete consumption of the 
starting material. The reaction was quenched with saturated aqueous ammonium 
chloride solution (20 mL) and the biphasic layers were separated. The aqueous layer 
was washed with hexane (4 x 20 mL). Combined organic layers were washed with 
water (2 x 10 mL) and brine (10 mL) and then dried over anhydrous magnesium 
sulfate. The resulting solution was filtered under gravity and concentrated under 
reduced pressure. The crude oil was purified by flash chromatography on silica gel 
(8:2, hexane: ethyl acetate) to give the title compound as a colourless oil (800 mg, 
56%).
1H NMR (300 MHz, CDCl3): d 5.12-4.98 (2 H, m, 2 x CCH), 4.19 (2 H, q, JH,H = 7,0, 
OCH2CH3), 3.43 (2 H, s, OCCH2CO), 2.57 (2 H, t, JH,H = 7.5, CH2CH2), 2.34-2.26 (2 H, 
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m, CH2CH2), 2.07-1.97 (6 H, m, CH3CH2 and CH2CH2), 1.68 (3 H, s, CCH3), 1.59 (3 H, 
s, CH3), 1.28 (3 H, t, JH,H = 7.0, OCH2CH3), 0.95 (3 H, t, JH,H = 7.5, CCH2CH3).
13C NMR (125 MHz, CDCl3): d 202.8 (OCO), 167.4 (OCCH2CH2), 142.9 (CCHCH2), 
131.6 (CCHCH2), 124.5 (CCHCH2), 121.8 (CCHCH2), 61.54 (OCH2CH3), 49.62
(OCCH2CO), 43.57 (OCCH2CH2), 36.64 (CH2), 27.02 (CH2), 25.87 (OCCH2CH2), 23.32 
(CH2), 22.00 and 17.88 (2 x CCH3), 14.29 (OCH2CH3), 13.37 (CCH2CH3). 
LRMS (ES+) m/z: 303.19 (100%, [M + Na]+), 242.28 (31).
HRMS (ES+): calculated for C17H28O3[Na]+: 303.1936, found: 303.1932.
Ethyl (2Z, 6E)-3-((diethoxyphosphoryl) oxy)-7-ethyl-11-methyl dodeca-2, 6, 10-
trienoate (161)
To a stirred suspension of sodium hydride (200 mg, 8.33 mmol) at 0 °C in anhydrous 
diethyl ether (10 mL) was added 160 (412 mg, 1.47 mmol) and the resulting solution 
was stirred for 30 min. Diethyl chlorophosphate (434 µL, 3.00 mmol) was added and 
after TLC analysis (8:2, hexane: ethyl acetate) showed complete consumption of 
starting material the reaction was quenched with saturated aqueous ammonium 
chloride solution (10 mL). The product was extracted with diethyl ether (3 x 10 mL) and 
the combined organic layers were washed with saturated aqueous ammonium 
bicarbonate solution (2 x 10 mL) and brine (10 mL). The resulting solution was dried 
over anhydrous magnesium sulfate, filtered under gravity and concentrated under 
reduced pressure. The crude oil was purified by flash chromatography on silica gel 
(gradient from 8:2, hexane: ethyl acetate; to 100% ethyl acetate) to give the title
compound as a colourless oil (368 mg, 62%)
1H NMR (300 MHz, CDCl3): d 5.35 (1 H, s, OCCH), 5.11-5.02 (2 H, m, 2 x CCHCH2), 
4.28 (2 H, q, JH,H = 7.0, POCH2CH3), 4.25 (2 H, q, JH,H = 7.0, POCH2CH3), 4.14 (2 H, q, 
JH,H = 7.0, COCH2CH3), 2.46 (2 H, t, JH,H = 7.5, CCH2CH2), 2.28 (2 H, m, CCH2CH2), 
2.09-1.95 (6 H, m, CH2 and CH2CH2), 1.67 (3 H, s, CCH3), 1.59 (3 H, s, CCH3), 1.36 (3
H, t, JH,H = 7.0, POCH2CH3), 1.36 (3 H, t, JH,H = 7.0, POCH2CH3), 1.27 (3 H, t, JH,H = 7.0, 
COCH2CH3), 0.95 (3 H, t, JH,H = 7.5, CCH2CH3).
13C NMR (125 MHz, CDCl3): d 164.0 (OCCH), 161.2 (OCO), 143.1 (CCHCH2), 131.6
(CCHCH2), 124.5 (CCHCH2), 121.5 (CCHCH2), 105.5 (OCCH), 66.05 (POCH2CH3), 
66.00 (POCH2CH3), 60.04 (COCH2CH3), 36.59 (CCH2CH2), 35.72 (CCH2CH2), 27.02
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(CH2), 25.84 (CH2), 24.74 (CH2), 23.36 and 17.86 (CCH3), 15.93 (POCH2CH3), 15.87
(POCH2CH3), 14.41 (COCH2CH3), 13.29 (CCH2CH3). 
31P NMR (121 MHz, D2O): d -8.76 (s).
LRMS (AP+) m/z: 417.24 (100%, [M + H]+), 155.45 (36), 120.02 (37).
HRMS (AP+): calculated for (C21H37O6P + [H])+: 417.2406, found: 417.2387.
Ethyl (2E, 6E)-7-ethyl-3, 11-dimethyl dodeca-2, 6, 10-trienoate (162)
To a stirred solution of copper iodide (0.29 g, 1.5 mmol) in anhydrous diethyl ether (5 
mL), was added methyl lithium (1.6 M in diethyl ether, 2.0 mL, 3.0 mmol) and the 
reaction was left to stir for 20 min at 0 °C under argon. The reaction was cooled to -78 
°C before 161 (0.32 g, 0.76 mmol) in anhydrous diethyl ether (5 mL) was added drop-
wise. After 2 h the reaction was warmed to -45 °C and methyl iodide (0.27 g, 1.9 mmol) 
was added. The reaction was left to stir for an additional 45 min. The reaction was 
quenched with saturated aqueous ammonium chloride solution (10 mL). Stirring the 
reaction overnight with the addition of ammonium hydroxide (20 mL) dissolved the 
copper salts formed. The biphasic layers were separated and the aqueous layer was 
washed with diethyl ether (4 x 10 mL). The combined organic layers were washed with 
10% ammonium hydroxide (3 x 10 mL), water (2 x 10 mL) and brine (10 mL). The 
resulting solution was dried over anhydrous magnesium sulfate, filtered under gravity 
and concentrated under reduced pressure. The crude oil was purified by flash 
chromatography on silica gel (9:1, hexane: ethyl acetate) to give the title compound as 
a colourless oil (100 mg, 47%).
1H NMR (300 MHz, CDCl3): d 5.67 (1 H, s, CCHC), 5.12-5.02 (2 H, m, 2 x CCHCH2), 
4.14 (2 H, q, JH,H = 7.0, OCH2CH3), 2.16-1.95 (13 H, 2 x m, CCH3, CCH2CH3 and 2 x 
CHCH2CH2), 1.60 (3 H, s, CCH3), 1.55 (3 H, s, CCH3), 1.25 (3 H, t, JH,H = 7.0, 
OCH2CH3), 0.95 (3 H, t, JH,H = 7.5, CCH2CH3).
13C NMR (125 MHz, CDCl3): d 167.1 (OCO), 160.1 (CH3CCH2), 142.2 (CH3CH2C),
131.6 (CH3CCHCH2), 124.5 (CCHCH2), 122.6 (CCHCH2), 115.8 (CCHC), 59.65
(COCH2CH3), 41.49 (CH3CCH2), 36.63 (CH3CCH2), 27.03 and 25.89 (CCHCH2CH2), 
25.79 (CCH2CH3), 23.32, 19.04 and 17.89 (3 x CCH3), 14.52 (COCH2CH3), 13.40
(CCH2CH3). 
HRMS (EI+): calculated for C18H30O2+: 278.2246, found: 278.2238.
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(2E, 6E)-7-Ethyl-3, 11-dimethyl dodeca-2, 6, 10-trien-1-ol (163)
To a stirred solution of 162 (0.1 g, 0.4 mmol) in anhydrous toluene (5 mL) at -78 °C
was added DIBAL-H (1 M in toluene, 0.72 mL, 0.72 mmol) drop-wise and the reaction 
was left to stir for 1 h. After TLC analysis (8:2, hexane: ethyl acetate) confirmed 
complete consumption of starting material, methanol (5 mL) was added drop-wise 
while the reaction was allowed to warm to room temperature. Saturated aqueous 
ammonium chloride solution and hydrochloric acid (1 M) (1:1; 10 mL) was added and 
stirred for 30 min. The biphasic layers were separated and the aqueous layer was 
washed with diethyl ether (4 x 10 mL). The combined organic layers were washed with 
water (10 mL) and brine (10 mL). The resulting solution was dried over anhydrous 
magnesium sulfate, filtered under gravity and concentrated under reduced pressure to 
give the title compound as a colourless oil (73 mg, 86%).
1H NMR (300 MHz, CDCl3): d 5.42 (1 H, t, JH,H = 7, CHCH2OH), 5.12-5.05 (2 H, m, 2 x 
CHCH2CH2), 4.15 (2 H, d, JH,H = 7, CHCH2OH), 2.16-1.99 (10 H, m, CH2CH3 and 2 x 
CH2CH2), 1.68 (6 H, s, 2 x CCH3), 1.60 (3 H, s, CCH3), 0.95 (3 H, t, JH,H = 7.5, 
CH2CH3).
13C NMR (125 MHz, CDCl3): d 141.49, 140.09 and 138.11 (3 x CCH), 129.28, 124.62 
and 123.48 (3 x CCH), 59.62 (CH2OH), 40.09 and 36.68 (2 x CCH2), 27.11, 26.14 and
25.90, 23.35 (2 x CCH2CH2 and CCH2CH3), 17.91 and 16.52 (2 x CCH3), 13.44
(CH2CH3). 
HRMS (EI+): calculated for (C16H28O - [H2O])+: 218.2035, found: 218.2038.
(2E, 6E)-1-Bromo-7-ethyl-3, 11-dimethyl dodeca-2, 6, 10-triene (164)
To a stirred solution of 163 (0.1 g, 0.4 mmol) in anhydrous THF (5 mL) at -10 °C, was 
added phosphorous tribromide (20 µL, 0.2 mmol), and this was left to stir for 1 h. When 
TLC analysis (8:2, hexane: ethyl acetate) confirmed complete consumption of starting 
material, the phosphorous tribromide and THF were removed under reduced pressure. 
The residual product was diluted in diethyl ether (10 mL) and washed with saturated 
aqueous ammonium bicarbonate solution (3 x 20 mL) and brine (10 mL). The resulting 
solution was dried over anhydrous magnesium sulfate, filtered under gravity and 
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concentrated under reduced pressure to give the title compound as a colourless oil 
(118 mg, 94%).[168]
1H NMR (300 MHz, CDCl3): d 5.34 (1 H, t, JH,H = 8.5, CHCH2Br), 5.12-5.02 (2 H, m, 2 x 
CHCH2CH2), 4.03 (2 H, d, JH,H = 8.5, CHCH2Br), 2.15-1.98 (10 H, m, 2 x CH2CH2 and 
CH2CH3), 1.73 (3 H, s, CCH3), 1.68 (3 H, s, CCH3), 1.60 (3 H, s, CCH3), 0.95 (3 H, t, 
JH,H = 7.5, CH2CH3).
(2E, 6E)-7-Ethyl-3, 11-dimethyl dodeca-2, 6, 10-trien-1-yl diphosphate (130)
(Bu4N)3+
To a stirred solution of 164 (60 mg, 0.20 mmol) in anhydrous acetonitrile (10 mL) was 
added 121 (0.37 g, 0.40 mmol). The reaction was left for 48 h to stir under nitrogen. 
After 48 h, the solvent was removed under reduced pressure and the resulting crude oil 
was purified by flash chromatography on silica gel (6:2.5:0.5, isopropanol: water:
ammonium hydroxide). Fractions that contained the diphosphate as judged by 
comparison with an authentic FDP standard by TLC (6:3:1, isopropanol: water: 
ammonium hydroxide) were collected. The isopropanol was removed under reduced 
pressure and the remaining solution was lyophilized to give the title compound as 
colourless oil (100 mg, 44%).[169,170]
1H NMR (500 MHz, D2O): d 5.46 (1 H, m, CHCH2O), 5.20-5.16 (2 H, m, 2 x 
CHCH2CH2), 4.48 (2 H, m, CHCH2O), 3.20-3.17 (24 H, m, 12 x NCH2CH2CH2CH3), 
2.18-2.04 (10 H, m, 2 x CCHCH2CH2 and CCH2CH3), 1.72-1.62 (33 H, m, 12 x 
NCH2CH2CH2CH3 and 3 x CHCCH3), 1.37-1.33 (24 H, m, 12 x NCH2CH2CH2CH3), 0.94 
(39 H, m, 12 x NCH2CH2CH2CH3 and CH2CH3).
31P NMR (121 MHz, D2O): d -10.38 (d, JP,P = 17.5), -6.51 (d, JP,P = 17.5).
LRMS (ES-) m/z: 395.14 (100%, [M - H]-), 315.20 (24).
HRMS (ES-): calculated for (C16H30O7P2 – [H])-: 395.1389, found: 395.1406.
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7.2.7 Preparation of 13-acetoxy farnesyl diphosphate (13-Acetoxy FDP, 165)
(2Z, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6,
10-trien-1-yl acetate (172)
To a stirred solution of 149 (0.11 g, 0.34 mmol) in DCM (5 mL), was added acetic 
anhydride (0.13 mL, 1.4 mmol) and pyridine (0.11 mL, 1.4 mmol). The reaction was left 
to stir at room temperature for 24 h and quenched with saturated aqueous sodium 
bicarbonate solution (10 mL). The biphasic layers were separated and the aqueous 
layer was washed with diethyl ether (4 x 10 mL). The combined organic layers were 
washed with brine (5 x 10 mL) and dried over anhydrous magnesium sulfate before 
being filtered under gravity. The solvent was removed under reduced pressure and the 
crude oil was purified by flash chromatography on silica gel (8:1, hexane: ethyl acetate) 
to give the title compound as a colourless oil (119 mg, 96%).
1H NMR (300 MHz, CDCl3): d 5.40-5.34 (2 H, m, 2 x CHCH2O and OCH2CCH), 5.11 (1
H, t, JH,H = 6.5, CCHCH2CH2), 4.62 (1 H, t, JH,H = 4.0, OCHO), 4.57 (2 H, s, OCH2CCH), 
4.24 (1 H, dd, JH,H = 12.0 and 6.5, CCHCHAO), 4.02 (1 H, dd, JH,H = 12.0 and 7.5, 
CCHCHBO), 3.93-3.47 (2 H, m, OCH2CH2), 2.19-1.96 (8 H, m, 2 x CCHCH2CH2), 2.07 
(3 H, s, OCCH3), 1.75-1.49 (6 H, m, CHCH2CH2CH2), 1.74, 1.68 and 1.58 (3 x 3 H, 3 x 
s, 3 x CHCCH3).
13C NMR (75 MHz, CDCl3): d 171.4 (OCO), 140.4, 134.7 and 130.7 (3 x CCHCH2), 
129.9, 124.6 and 120.7 (3 x CCHCH2), 98.00 (OCHO), 63.83 (CCH2O), 63.42 and
62.47 (2 x CHOCH2), 39.76 and 30.88 (2 x CCHCH2CH2), 26.45 and 25.67 (2 x 
CCHCH2CH2), 24.72 (OCH2CH2CH2), 21.61 (OCH2CH2CH2), 21.18, 19.81, 16.62, 
16.14 (4 x CCH3). 
LRMS (ES+) m/z: 387.25 (100%, [M + Na]+).
HRMS (ES+): calculated for (C22H36O4 + [Na])+: 387.2511, found: 387.2506.
(2Z, 6E, 10E)-12-Hydroxy-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-yl acetate (173)
To a stirred solution of 172 (0.11 g, 0.30 mmol) in methanol (5 mL) was added p-
toluenesulfonic acid (6 mg, 0.03 mmol) and stirred at room temperature for 1 h until 
TLC analysis (8:2, hexane: ethyl acetate) confirmed complete consumption of starting 
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material. The solvent was removed under reduced pressure and the residual oil was 
dissolved with diethyl ether (10 mL) and washed with saturated aqueous sodium 
bicarbonate solution (3 x 10 mL) and brine (10 mL). The resulting solution was dried
over anhydrous magnesium sulfate, filtered under gravity and concentrated under 
reduced pressure to give the title compound as a colourless oil (84 mg, 99%). The 
product was judged by 1H NMR spectroscopy to be sufficiently pure to carry forward 
without further purification.
1H NMR (300 MHz, CDCl3): d 5.41 (1 H, t, JH,H = 7.0, OCH2CCH), 5.38 (1 H, t, JH,H = 
7.5, CCH), 5.11 (1 H, t, JH,H = 6.5, CCHCH2), 4.57 (2 H, s, OCH2C), 4.15 (2 H, d, JH,H = 
7.0, CHCH2O), 2.18-1.98 (8 H, m, 2 x CCHCH2CH2), 2.07 (3 H, s, OCCH3), 1.74, 1.68 
and 1.59 (3 x 3 H, 3 x s, 3 x CH2CCH3).
13C NMR (75 MHz, CDCl3): d 171.5 (OCO), 139.8, 134.9 and 130.7 (3 x CCHCH2), 
129.9, 124.4 and 123.7 (3 x CCHCH2), 63.43 (CH2OC), 59.59 (CH2OH), 39.75 and
39.64 (2 x CCHCH2CH2), 26.55 and 26.35 (2 x CCHCH2CH2), 21.61, 21.18, 16.44 and
16.19 (4 x CCH3). 
LRMS (ES+) m/z: 303.19 (100%, [M + Na]+), 261.19 (12), 210.03 (8).
HRMS (ES+): calculated for (C17H28O3 + [Na])+: 303.1936, found: 303.1930.
(2Z, 6E, 10E)-12-Bromo-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-yl acetate (174)
To a stirred solution of 173 (90 mg, 0.30 mmol) in anhydrous THF (5 mL) at -10 °C, 
was added phosphorous tribromide (15 µL, 0.20 mmol), and the reaction was left to stir 
for 1 h. When TLC analysis (8:2, hexane: ethyl acetate) confirmed complete 
consumption of starting material, the phosphorous tribromide and THF were removed 
under reduced pressure. The residual product was diluted in diethyl ether (10 mL) and 
washed with saturated aqueous ammonium bicarbonate solution (3 x 20 mL) and brine 
(10 mL). The resulting solution was dried over anhydrous magnesium sulfate, filtered 
under gravity and concentrated under reduced pressure to give the title compound as a 
colourless oil (40 mg, 36%).[168]
1H NMR (300 MHz, CDCl3): d 5.52 (1 H, t, JH,H = 8.5, CCH), 5.37 (1 H, t, JH,H = 7.0, 
CCH), 5.08 (1 H, t, JH,H = 8.0, CCHCH2), 4.57 (2 H, s, OCH2C), 4.02 (2 H, d, JH,H = 8.5, 
CHCH2Br), 2.19-1.96 (8 H, m, 2 x CCHCH2CH2), 2.07 (3 H, s, OCCH3), 1.74, 1.72 and 
1.58 (3 x 3 H, 3 x s, 3 x CHCCH3).
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(2E, 6E, 10Z)-12-Acetoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate 
(165)
(Bu4N)3+
To a stirred solution of 164 (40 mg, 0.10 mmol) in anhydrous acetonitrile (5 mL) was 
added 121 (0.21 g, 0.20 mmol). The reaction was left for 48 h to stir under nitrogen. 
The solvent was removed under reduced pressure and the resulting crude oil was 
purified by flash chromatography on silica gel (6:2.5:0.5, isopropanol: water: 
ammonium hydroxide). Fractions that contained the diphosphate as judged by 
comparison with an authentic FDP standard by TLC (6:3:1, isopropanol: water: 
ammonium hydroxide) were collected. The isopropanol was removed under reduced 
pressure and the remaining solution was lyophilized to give the title compound as 
colourless oil (30 mg, 20%).
1H NMR (500 MHz, D2O): d 5.49 (1 H, t, JH,H = 7.5, CCH), 5.45 (1 H, t, JH,H = 7.0, CCH), 
5.20 (1 H, t, JH,H = 6.5, CCHCH2), 4.62 (2 H, s, OCH2C), 4.48 (2 H, t, JH,H = 7.0, 
CHCH2O), 3.21-3.17 (24 H, m, 12 x NCH2CH2CH2CH3), 2.22-2.03 (11 H, m, 2 x 
CCHCH2CH2 and OCCH3), 2.03 (3 H, s, OCCH3), 1.73-1.61 (33 H, m, 12 x 
NCH2CH2CH2CH3 and 3 x CH2CCH3), 1.39-1.32 (24 H, m, 12 x NCH2CH2CH2CH3), 
0.94 (36 H, t, JH,H = 7, 12 x NCH2CH2CH2CH3).
31P NMR (121 MHz, D2O): d -10.21 (m), -10.73 (m).
LRMS (ES-) m/z: 439.13 (100%, [M - H]-), 397.11 (33), 359.16 (41).
HRMS (ES-): calculated for (C17H30O9P2 – [H])-: 439.1287, found: 439.1286.
7.2.8 Preparation of 12-acetoxy farnesyl diphosphate (12-Acetoxy FDP,166)
(2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6,
10-trien-1-ol (175)
Selenium dioxide (0.11 g, 1.0 mmol), salicylic acid (0.14 g, 1.0 mmol), and tert-butyl 
hydroperoxide (1.6 mL, 16.3 mmol) were stirred in DCM (20 mL) for 30 min at room 
temperature. The temperature was reduced to 0 °C before the addition of 131 (1.0 g, 
3.3 mmol). The reaction was left to stir for 24 h whilst remaining between 0 – 4 °C. 
DCM was removed using reduced pressure and t-Butyl hydroperoxide was removed by 
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co-evaporation with toluene (2 x 20 mL) under reduced pressure. The crude residue
was dissolved in diethyl ether (20 mL) and washed with saturated aqueous sodium 
bicarbonate solution (50 mL). The biphasic layers were separated and the aqueous 
layer was extracted with diethyl ether (5 x 20 mL). The combined organic layers were 
washed with brine (20 mL) and dried over anhydrous magnesium sulfate before being 
filtered under gravity. The solvent was removed under reduced pressure and the crude 
oil was purified by flash chromatography on silica gel (9:1, hexane: ethyl acetate) to 
give the title compound as a colourless oil (0.5 g, 48%).[173,174]
1H NMR (300 MHz, CDCl3): d 5.41-5.33 (2 H, m, 2 x CCHCH2), 5.11 (1 H, t, JH,H = 6.5, 
CCHCH2), 4.63 (1 H, t, JH,H = 4, OCHO), 4.23 (1 H, dd, JH,H = 12 and 6.5, CCHCHAO), 
4.01 (1 H, dd, JH,H = 12 and 7.5, CCHCHBO), 3.99 (2 H, s, OHCH2), 3.93-3.48 (2 H, m, 
OCH2CH2), 2.20-1.99 (8 H, m, 2 x CCHCH2CH2), 1.75-1.50 (6 H, m, CHCH2CH2CH2), 
1.68, 1.66 and 1.60 (3 x 3 H, 3 x s, 3 x CH3). 
13C NMR (75 MHz, CDCl3): d 140.2, 135.0 and 135.0 (3 x CH3CCH), 126.1, 124.5 and
121.0 (3 x CH3CCH), 97.96 (OCHO), 69.15 (OHCH2), 63.85 and 62.48 (2 x CHOCH2), 
39.77 and 39.45 (2 x CCH2CH2), 30.92 (OCCH2), 26.42 and 26.32 (2 x CCH2CH2), 
25.72 (OCH2CH2CH2), 19.81 (OCH2CH2CH2), 16.59, 16.18 and 13.87 (CCH3). 
LRMS (ES+) m/z: 345.24 (100%, [M + Na]+).
HRMS (ES+): calculated for (C20H34O3 + [Na])+: 345.2406, found: 345.2415.
(2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6,
10-trien-1-yl acetate (176)
To a stirred solution of 175 (1.3 g, 4.1 mmol) in DCM (20 mL), was added acetic 
anhydride (1.5 mL, 16.1 mmol) and pyridine (1.3 mL, 16.1 mmol). The reaction was left 
to stir at room temperature for 24 h and was quenched with saturated aqueous sodium 
bicarbonate solution (20 mL). The biphasic layers were separated and the aqueous 
layer was washed with diethyl ether (4 x 20 mL). The combined organic layers were 
washed with brine (5 x 20 mL) and dried over anhydrous magnesium sulfate before 
being filtered under gravity. The solvent was removed under reduced pressure and the 
crude oil was purified by flash chromatography on silica gel (8:1, hexane: ethyl acetate) 
to give the title compound as a colourless oil (1.4 g, 95%).
1H NMR (300 MHz, CDCl3): d 5.44 (1 H, t, JH,H = 6.5, CCHCH2), 5.36 (1 H, t, JH,H = 7.0, 
CCHCH2), 5.11 (1 H, t, JH,H = 7.0, CCHCH2), 4.62 (1 H, t, JH,H = 4.0, OCHO), 4.44 (2 H, 
s, CCH2O), 4.24 (1 H, dd, JH,H = 12.0 and 6.5, CCHCHAO), 4.02 (1 H, dd, JH,H = 12.0 
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and 7.5, CCHCHBO), 3.93-3.47 (2 H, m, OCH2CH2), 2.20-1.98 (8 H, m, 2 x 
CCHCH2CH2), 2.07 (3 H, s, OCCH3), 1.75-1.49 (6 H, m, CHCH2CH2CH2), 1.68, 1.65 
and 1.60 (3 x 3 H, 3 x s, 3 x CCH3). 
13C NMR (75 MHz, CDCl3): d 171.1 (CH3CO), 140.2, 134.7 and 130.0 (3 x CH3CCH), 
129.6, 124.3 and 120.6 (3 x CH3CCH), 97.83 (OCHO), 70.54 (CCH2O), 63.82 and
62.48 (2 x CHOCH2), 39.76 and 39.21 (2 x CCH2CH2), 30.89 (OCCH3), 26.54 and
26.45 (2 x CCH2CH2), 25.67 (OCH2CH2CH2), 19.81 (OCH2CH2CH2), 16.62, 16.17 and
14.15 (3 x CCH3). 
LRMS (AP+) m/z: 387.25 (100%, [M + Na]+).
HRMS (AP+): calculated for (C22H36O4 + [Na])+: 387.2511, found: 387.2501.
(2E, 6E, 10E)-12-Hydroxy-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-yl acetate (177)
To a stirred solution of 176 (0.93 g, 2.5 mmol) in methanol (20 mL) was added p-
toluenesulfonic acid (47 mg, 0.25 mmol) and stirred at room temperature for 1 h until 
TLC analysis (8:2, hexane: ethyl acetate) confirmed complete consumption of starting 
material (ca. 1 h). The solvent was removed under reduced pressure and the residual 
oil was dissolved with diethyl ether (20 mL) and washed with saturated aqueous 
sodium bicarbonate solution (3 x 10 mL) and brine (10 mL). The resulting solution was 
dried over anhydrous magnesium sulfate, filtered under gravity and concentrated under 
reduced pressure to give the title compound as a colourless oil (690 mg, 97%). The 
product was judged by 1H NMR spectroscopy to be sufficiently pure to carry forward 
without further purification.
1H NMR (300 MHz, CDCl3): d 5.46-5.39 (2 H, m, 2 x CCH), 5.11 (1 H, t, JH,H = 6.5, 
CCHCH2), 4.44 (2 H, s, OCH2C), 4.15 (2 H, d, JH,H = 7.0, CH2OH), 2.14-2.00 (8 H, m, 2 
x CCHCH2CH2), 2.07 (3 H, s, OCCH3), 1.68, 1.65 and 1.60 (3 x 3 H, 3 x s, 3 x 
CHCCH3). 
13C NMR (75 MHz, CDCl3): d 171.3 (CH3CO), 139.8, 135.0 and 130.1 (3 x CH3CCH), 
129.8, 124.4 and 123.6 (3 x CH3CCH), 70.56 (CCH2O), 59.56 (CH2OH), 39.66 and
39.18 (2 x CCH2CH2), 26.46 and 26.41 (2 x CCH2CH2), 21.23 (OCCH3), 16.46, 16.15 
and 14.17 (3 x CHCCH3). 
LRMS (ES+) m/z: 303.19 (100%, [M + Na]+), 291.17 (74), 242.25 (44), 203.16 (47), 
89.05 (44).
HRMS (ES+): calculated for (C17H28O3 + [Na])+: 303.1936, found: 303.1945.
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(2E, 6E, 10E)-12-Acetoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate 
(166)
(NH4)3+
To a stirred, cold suspension (0 °C) of 177 (900 mg, 3.20 mmol), lithium chloride (545 
mg, 12.9 mmol) and s-collidine (2.5 mL, 19.3 mmol) in anhydrous DMF (10 mL) was 
added methanesulfonyl chloride (0.5 mL, 6.4 mmol), under nitrogen. The solution was 
stirred for 3 h. The solution was poured into cold water (50 mL) and extracted with 
diethyl ether (4 x 20 mL). Combined organic extracts were washed with saturated 
aqueous copper sulfate solution (3 x 20 mL), water (2 x 20 mL) and saturated aqueous 
ammonium bicarbonate solution (2 x 20 mL), dried over anhydrous magnesium sulfate, 
filtered under gravity and concentrated under reduced pressure to give the crude 
chloride intermediate.
To a stirred solution of 121 (5.8 g, 6.4 mmol) in anhydrous acetonitrile (10 mL) 
under N2 was added the solution of the crude chloride in acetonitrile (5 mL). This was 
left for 24 h at room temperature. The solvent was removed under reduced pressure 
and the resulting oil was dissolved in a minimum amount of ion-exchange buffer (25 
mM ammonium bicarbonate solution containing 2% isopropanol).
The crude compound in buffer was then eluted through the NH4+-form cation 
exchange column with additional ion exchange buffer. Fractions that contained the 
diphosphate and therefore gave a spot with TLC (6:3:1 isopropanol: water: ammonium 
hydroxide) were collected and lyophilized. The resulting dry powder was purified by 
HPLC to give the title compound as a colourless oil (0.6 g, 35%).
1H NMR (500 MHz, D2O): d 5.51-5.46 (2 H, m, 2 x CCH), 5.22 (1 H, t, JH,H = 6.5, CCH), 
4.50 (2 H, s, CCH2O), 4.48 (2 H, t, JH,H = 6.5, CHCH2O), 2.25-2.03 (8 H, m, 2 x 
CCHCH2CH2), 2.10 (3 H, s, OCCH3), 1.73, 1.65 and 1.63 (3 x 3 H, 3 x s, 3 x CHCCH3).
31P NMR (121 MHz, D2O): d -10.33 (d, JP,P = 21.5), -6.57 (d, JP,P = 21.5)
LRMS (AP+) m/z: 439.13 (70%, [M - H]-), 359.17 (100).
HRMS (ES-): calculated for (C17H30O9P2 - [H])-: 439.1287, found: 439.1290.
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7.2.9 Preparation of 12-hydroxy farnesyl diphosphate (12-Hydroxy FDP, 168)
(2E, 6E, 10E)-12-Hydroxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate 
(168)
(NH4)3+
To a stirred solution of 166 (0.3 g, 0.6 mmol) in deuterated water (10 mL) was added 
ammonium hydroxide (2 mL) and left to stir for 24 h. The following day 1H NMR 
analysis continued to show the presence of the acetate group. Additional ammonium 
hydroxide (2 mL) was added and left for another 24 h. The following day the deuterated 
water and ammonium hydroxide was lyophilized to give the title compound as a 
colourless oil (290 mg, 97%).
1H NMR (500 MHz, D2O): d 5.41-5.33 (2 H, m, 2 x CCH), 5.15 (1 H, t, JH,H = 6.5, CCH), 
4.40 (2 H, t, JH,H = 6.5, CHCH2O), 3.88 (2 H, s, CH2OH), 2.16-1.96 (8 H, m, 2 x 
CCHCH2CH2), 1.65, 1.57 and 1.56 (3 x 3 H, 3 x s, 3 x CH3).
31P NMR (121 MHz, D2O): d -7.93 (d, JP,P = 17), -7.53 (m).
HRMS (ES-): calculated for (C15H28O8P2 - 2[H] + [Na])-: 419.1001, found: 419.0983.
(2E, 6E, 10E)-12-Chloro-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-ol (278)
Selenium dioxide (33 mg, 0.3 mmol), salicylic acid (41 mg, 0.3 mmol) and 90% t-butyl 
hydroperoxide (0.48 mL, 5 mmol) were dissolved in DCM (10 mL) and left to stir for 30 
min at room temperature. The solution was cooled to 0 ºC after which farnesyl chloride 
(220 mg, 1.0 mmol) in DCM (5 mL) was added and left to stir for 24 h at 0 ºC. The 
reaction was quenched with saturated aqueous sodium bicarbonate solution (20 mL). 
Hexane (20 mL) was added and DCM was removed under reduced pressure. t-Butyl 
hydroperoxide was removed by co-evaporation with toluene (2 x 20 mL) under reduced 
pressure. The crude oil was dissolved in diethyl ether (20 mL). The biphasic layers 
were separated and the aqueous layer was washed with additional diethyl ether (3 x 20 
mL). The organic extracts were combined, washed with brine (10 mL), dried over 
anhydrous sodium sulfate and filtered under gravity. The solvent was removed under 
reduced pressure. The crude oil was purified by flash chromatography on silica gel 
(9.5:0.5, hexane: ethyl acetate) to give the title compound as a yellow oil (145 mg, 
62%).
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1H NMR (300 MHz, CDCl3): d (ppm) 5.47-5.36 (2 H, m, 2 x C=CH), 5.10 (1 H, t, JH,H = 
6.0, C=CH), 4.10 (2 H, d, J = 6.0, CH2Cl), 3.99 (2 H, s, CH2OH), 2.16-1.99 (8 H, m, 
CH2CH2), 1.73, 1.66 and 1.60 (3 x 3 H, 3 x s, 3 x CH3). 
13C NMR (75 MHz, CDCl3): d 142.7, 135.3, 134.7, 126.0, 123.7, 120.3, 69.02, 41.21, 
39.41, 39.26, 26.18, 26.06, 16.14, 16.05, 13.72. 
HRMS (ES+): calculated for (C15H25O35Cl + [Na])+: 279.1483, found: 279.1492.
7.2.10 Preparation of 8-hydroxy farnesyl diphosphate (8-Hydroxy FDP, 169)
(6E, 10E)-12-Chloro-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-5-ol (178)
Selenium dioxide (33 mg, 0.30 mmol), salicylic acid (41 mg, 0.30 mmol) and 90 % t-
butyl hydroperoxide (0.48 mL, 5.0 mmol) were dissolved in DCM (10 mL) and left to stir 
for 30 min at room temperature. The reaction mixture was cooled to 0 ºC after which 
farnesyl chloride (0.22 g, 1.0 mmol) in DCM (5 mL) was added and left to stir for 24 h at 
0 °C. The reaction was quenched with saturated aqueous sodium bicarbonate solution 
(20 mL). Hexane (20 mL) was added and DCM was removed under reduced pressure. 
t-Butyl hydroperoxide was removed by co-evaporation with toluene (2 x 20 mL) under 
reduced pressure. The crude oil was dissolved in diethyl ether (20 mL). The biphasic 
layers were separated and the aqueous layer was washed with additional diethyl ether 
(3 x 20 mL). The organic extracts were combined, washed with brine (10 mL) and dried 
over anhydrous sodium sulfate. The solvent was removed under reduced pressure. 
The crude oil was purified by flash chromatography on silica gel (9.5:0.5, hexane: ethyl 
acetate) to give the title compound as a yellow oil (42 mg, 21%).
1H NMR (300 MHz, CDCl3): d (ppm) 5.44 (1 H, t, JH,H = 8.0, CHCH2Cl), 5.36 (1 H, t, JH,H
= 7.0, CHCH2CH2), 5.08 (1 H, t, JH,H = 8.0, CHCH2CHOH), 4.10 (2 H, d, JH,H = 8.0, 
CH2Cl), 3.98 (1 H, t, JH,H = 8.0, CCHCH2CHOH), 2.33-2.05 (6 H, m, CH2CHOH and 
CH2CH2), 1.73 (6 H, s, 2 x CH3), 1.64 and 1.62 (2 x 3 H,2 x s,2 x CH3). 
13C NMR (75 MHz, CDCl3): d 142.5, 138.2 and 137.4 (3 x CH3CCH), 125.2, 120.5 and
120.2 (3 x CH3CCH), 52.80 (CHOH), 45.94 (CH2Cl), 39.05 (CH3CCH2), 34.20
(OHCHCH2), 25.99 (CH3CCH2CH2), 25.64, 25.03, 8.76 and 8.14 (4 x CH3). 
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(2E, 6E)-8-Hydroxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate (169)
(Bu4N)3+
To a stirred solution of 178 (40 mg, 0.20 mmol) in anhydrous acetonitrile (5 mL) was 
added 121 (0.28 g, 0.30 mmol). The reaction was left for 48 h to stir under nitrogen. 
The solvent was removed under reduced pressure and the resulting crude oil was 
purified by flash chromatography on silica gel (6:2.5:0.5, isopropanol: water: 
ammonium hydroxide). Fractions that contained the diphosphate as judged by 
comparison with an authentic FDP standard by TLC (6:3:1, isopropanol: water: 
ammonium hydroxide) were collected. The isopropanol was removed under reduced 
pressure and the remaining solution was lyophilized to give the title compound as 
colourless oil (100 mg, 57%).
1H NMR (500 MHz, CDCl3): d 5.37 (1 H, t, JH,H = 6.0, CHCH2O), 5.30 (1 H, t, JH,H = 7.0, 
CHCH2CH2), 5.06 (1 H, t, JH,H = 7.0, CHCH2CHOH), 4.45 (2 H, m, CHCH2O), 3.93 (1 H, 
t, JH,H = 6.5, CHCH2CHOH), 3.30-3.26 (24 H, m, 12 x NCH2CH2CH2CH3), 2.25 -1.98 (6
H, m, CH2CH and CH2CH2), 1.67-1.56 (36 H, m, 12 x NCH2CH2CH2CH3and 4 x CCH3), 
1.45-1.40 (24 H, m, 12 x NCH2CH2CH2CH3), 0.96 (36 H, t, JH,H = 7.0, 12 x 
NCH2CH2CH2CH3).
31P NMR (121 MHz, D2O): d -7.53 (m), -7.93 (d, JP,P = 16.5).
LRMS (ES-) m/z: 397.12 (100%, [M - H]-), 379.10 (3, M-H2O).
HRMS (ES-): calculated for (C15H28O8P2 - [H])-: 397.1181, found: 397.1190.
7.2.11 Preparation of 8-acetoxy farnesyl diphosphate (8-Acetoxy FDP, 167)
(2E, 6E)-8-Acetoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate (167)
(Bu4N)3+
To a stirred solution of 169 (50 mg, 0.045 mmol) in deuterated chloroform (2 mL), was 
added acetic anhydride (0.017 mL, 0.18 mmol) and pyridine (0.014 mL, 0.18 mmol). 
The reaction was left to stir at room temperature over 48 h and was quenched with 
saturated aqueous sodium bicarbonate solution (10 mL). The biphasic layers were 
separated and the chloroform layer was washed with brine (5 x 5 mL) to remove the 
pyridine. The resulting organic layer was washed dried over anhydrous magnesium 
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sulfate before being filtered under gravity. The solvent was removed under reduced 
pressure to give the title compound as a colourless oil (35 mg, 67%).
1H NMR (500 MHz, D2O): d 5.38-5.33 (2 H, m, 2 x CCH), 5.05 (1 H, t, JH,H = 7.0, CCH), 
4.95 (1 H, t, JH,H = 7.0, CH2CHOH), 4.50 (2 H, t, JH,H = 6.0, CHCH2O), 3.25-3.21 (24 H, 
m, 12 x NCH2CH2CH2CH3), 2.36-2.14 (6 H, m, CH2CHOH and 2 x CHCH2CH2), 2.20 (3
H, s, OCCH3), 1.64-1.57 (36 H, m, 12 x NCH2CH2CH2CH3 and 4 x CHCCH3), 1.42-1.36 
(24 H, m, 12 x NCH2CH2CH2CH3), 0.95 (36 H, t, JH,H = 7.0, 12 x NCH2CH2CH2CH3).
31P NMR (121 MHz, D2O): d -10.06 (m), -10.69 (m).
LRMS (AP+) m/z: 439.13 (100%, [M - H]-), 359.16 (37).
HRMS (ES-): calculated for C17H30O9P2 - [H]-: 439.1287, found: 439.1287.
7.2.12 Preparation of 8-methoxy farnesyl diphosphate (8-Methoxy FDP, 170)
(6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6, 10-
trien-5-ol (179)
Selenium dioxide (0.11 g, 1.0 mmol), salicylic acid (0.14 g, 1.0 mmol), and t-butyl 
hydroperoxide (1.6 mL, 16.3 mmol) were stirred in DCM (20 mL) for 30 min at room 
temperature. The temperature was reduced to 0 °C before the addition of 131 (1.0 g, 
3.3 mmol). The reaction was left to stir for 24 h whilst remaining between 0 – 4 °C. 
DCM was removed using reduced pressure. t-Butyl hydroperoxide was removed by co-
evaporation with toluene (2 x 20 mL) under reduced pressure. The crude residue was 
dissolved in diethyl ether (20 mL) and washed with saturated aqueous sodium 
bicarbonate solution (50 mL). The layers were separated and the aqueous layer was 
extracted with diethyl ether (5 x 20 mL). The combined organic layers were washed 
with brine (20 mL) and dried over anhydrous magnesium sulfate before being filtered
under gravity. The solvent was removed under reduced pressure and the crude oil was 
purified by flash chromatography on silica gel (9:1, hexane: ethyl acetate) to give the 
title compound as a colourless oil (116 mg, 11%).[173,174]
1H NMR (300 MHz, CDCl3): d 5.39-5.34 (2 H, m, 2 x CCHCH2), 5.08 (1 H, t, JH,H = 7.0, 
CCHCH2), 4.63 (1 H, m, OCHO), 4.25 (1 H, dd, JH,H = 12.0 and 6.5, CCHCHAO), 4.05-
3.95 (2 H, m, CCHCHBO and CHOH), 3.98 (1 H, t, JH,H = 7.5, CHOH), 3.92-3.48 (2 H, 
m, OCH2CH2), 2.34-2.04 (6 H, m, CHCH2CH and CHCH2CH2), 1.88-1.50 (6 H, m, 
CHCH2CH2CH2), 1.72, 1.68, 1.63 and 1.61 (4 x 3 H, 4 x s, 4 x CH3). 
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13C NMR (125 MHz, CDCl3): d 140.0, 137.3 and 134.8 (3 x CH3CCH), 125.9, 121.1 and
120.4 (3 x CH3CCH), 98.12 (OCHO), 63.90 (CHOH), 63.85 and 62.46 (2 x CH2O), 
39.39 (CH3CCH2), 34.34 (CH2CHOH), 30.86 (CH2OCHCH2), 26.10 (OCH2CH2CH2), 
25.67 (OCH2CH2CH2), 19.77, 18.19, 16.57 and 11.85 (CH3)
LRMS (ES+) m/z: 345.24 (100%, [M + Na]+).
HRMS (ES+): calculated for (C20H34O3 + [Na])+: 345.2406, found: 345.2418.
2-(((2E, 6E)-8-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl) oxy)
tetrahydro-2H-pyran (180)
To a stirred suspension of sodium hydride (0.40 g, 60% in mineral oil, 9.3 mmol) in 
anhydrous THF (30 mL), was added a solution of 179 (0.50 g, 1.6 mmol) in anhydrous 
THF (20 mL) followed by the addition of methyl iodide (1.5 mL, 23 mmol) 15 min later. 
The reaction was left to stir under argon for 24 h whereupon TLC analysis (8:2, 
hexane: ethyl acetate) showed full consumption of starting material. The reaction was 
quenched with 10% hydrochloric acid (50 mL) and the layers were separated. The 
aqueous layer was washed with diethyl ether (4 x 20 mL) and the pooled extracts were 
washed with 5% sodium hydroxide (3 x 10 mL) and dried over anhydrous magnesium 
sulfate. The solvent was removed under reduced pressure. The crude oil was purified 
by flash chromatography on silica gel (4:1, hexane: ethyl acetate) to give the title
compound as a colourless oil (0.2 g, 38%).
1H NMR (300 MHz, CDCl3): d 5.37 (1 H, t, JH,H = 6.5, CCHCH2), 5.30 (1 H, t, JH,H = 6.5, 
CCHCH2), 5.03 (1 H, t, JH,H = 7.0, CCHCH2), 4.62 (2 H, t, JH,H = 4.0, OCHO), 4.27-3.98 
(2 H, m, CCHCH2O), 3.92-3.48 (2 H, m, OCH2CH2), 3.41 (1 H, t, JH,H = 7.0, CHOCH3), 
3.16 (3 H, s, OCH3), 2.34-2.04 (6 H, m, CCHCH2CH and CCHCH2CH2), 1.75-1.52 (6 H, 
m, OCH2CH2CH2), 1.68, 1.59, and 1.52 (2 x 3 H and 1 x 6 H, 3 x s, 4 x CHCCH3).
13C NMR (125 MHz, CDCl3): d 139.9, 134.5 and 132.9 (3 x CH3CCH), 128.5, 121.2 and
120.9 (3 x CH3CCH), 98.11 (OCHO), 87.64 (CHOCH3), 63.87 and 62.46 (OCH2), 55.90
(OCH3), 39.52 (CH3CCH2), 32.74 (CCHCH2CH), 30.92 (CH2OCHCH2CH2), 26.05
(CH3CCH2CH2), 25.94 (CHCCH3), 25.71 (OCH2CH2CH2), 19.80 (OCH2CH2CH2), 18.12, 
16.55 and 10.69 (3 x CHCCH3). 
LRMS (ES+) m/z: 359.26 (100%, [M + Na]+).
HRMS (ES+): calculated for (C21H36O3 + [Na])+: 359.2562, found: 359.2554.
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(2E, 6E)-8-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-ol (182)
To a solution of 180 (0.20 g, 1.6 mmol) in anhydrous THF (10 mL) was added a 
solution of 10% hydrochloric acid (7 mL) and was left to stir for 4 h. The reaction was 
quenched with saturated sodium bicarbonate solution (10 mL) and the biphasic layers 
were separated. The aqueous layer was washed with diethyl ether (4 x 10 mL) and the 
pooled extracts were washed with brine (10 mL) before being dried over anhydrous 
magnesium sulfate, filtered under gravity and concentrated under reduced pressure. 
The crude oil was purified by flash chromatography on silica gel (4:1, hexane: ethyl 
acetate) to give the title compound as colourless oil (130 mg, 87%).
1H NMR (300 MHz, CDCl3): d 5.42 (1 H, t, JH,H = 7.0, CCHCH2), 5.30 (1 H, t, JH,H = 7.0, 
CCHCH2), 5.02 (1 H, t, JH,H = 7.0, CCHCH2), 4.15 (2 H, d, JH,H = 7.0, CH2OH), 3.41 (1
H, t, JH,H = 7.0, CHOCH3), 3.16 (3 H, s, OCH3), 2.34-2.04 (6 H, m, CHCH2CHO and 
CHCH2CH2), 1.68 (6 H, s, 2 x CCH3), 1.59 and 1.52 (2 x 3 H,2 x s, 2 x CCH3).
13C NMR (125 MHz, CDCl3): d 139.6, 134.5 and 133.0 (3 x CCHCH2), 128.4, 123.8 and
120.8 (3 x CCHCH2), 87.57 (CHOCH3), 59.57 (CH2OH), 55.92 (OCH3), 39.42
(CH3CCH2), 32.65 (CCHCH2CH), 26.01 (CH3CCH2CH2), 25.97, 18.14, 16.41 and 10.70
(4 x CHCCH3). 
LRMS (ES+) m/z: 275.20 (100%, [M + Na]+), 262.22 (20), 221.19 (32), 203.18 (56), 
109.10 (25).
HRMS (ES+): calculated for (C16H28O2 + [Na])+: 275.1987, found: 275.1978.
(2E, 6E)-8-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate (170)
(Bu4N)3+
To a cold, stirred suspension (0 °C) of 182 (0.13 g, 0.50 mmol), lithium chloride (87 mg, 
2.0 mmol) and s-collidine (0.40 mL, 3.0 mmol) in anhydrous DMF (10 mL) was added 
methanesulfonyl chloride (0.026 mL, 0.34 mmol), under nitrogen. The solution was 
stirred for 3 h. The solution was poured into cold water (30 mL) and extracted with 
diethyl ether (4 x 10 mL). Combined organic extracts were washed with saturated 
aqueous copper sulfate solution (3 x 20 mL), water (2 x 20 mL) and saturated aqueous 
ammonium bicarbonate solution (2 x 20 mL). The resulting solution was dried over 
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anhydrous magnesium sulfate, filtered under gravity and concentrated under reduced 
pressure to give the crude chloride intermediate. To a stirred solution of 121 (0.9 g, 1.0
mmol) in anhydrous acetonitrile (5 mL) under N2 was added the solution of the crude 
chloride in acetonitrile (3 mL). This was left to stir for 48 h at room temperature. The 
solvent was removed under reduced pressure and the resulting crude oil was purified 
by flash chromatography on silica gel (6:2.5:0.5, isopropanol: water: ammonium 
hydroxide). Fractions that contained the diphosphate as judged by comparison with an 
authentic FDP standard by TLC (6:3:1, isopropanol: water: ammonium hydroxide) were 
collected. The isopropanol was removed under reduced pressure and the remaining 
solution was lyophilized to give the title compound as colourless oil (306 mg, 52%).
1H NMR (300 MHz, CDCl3): d 5.40 (2 H, m, 2 x CCHCH2), 5.05 (1 H, t, JH,H = 7.5, 
CCHCH2), 4.46 (2 H, m, CH2O), 3.61 (1 H, t, JH,H = 7.0, CHOCH3), 3.19-3.14 (27 H, m, 
12 x NCH2CH2CH2CH3 and CHOCH3), 2.35-2.06 (6 H, m, CHCH2CH and CHCH2CH2), 
1.69-1.51 (36 H, m, 12 x NCH2CH2CH2CH3 and 4 x CH3), 1.36-1.29 (24 H, m, 12 x 
NCH2CH2CH2CH3), 0.92 (36 H, t, JH,H = 7.5, 12 x NCH2CH2CH2CH3).
31P NMR (121 MHz, D2O): d -10.69 (m).
LRMS (ES-) m/z: 411.13 (100%, [M - H]-), 395.14 (19), 331.17 (20).
HRMS (ES-): calculated for (C16H30O8P2 - [H])-: 411.1338, found: 411.1342.
7.2.13 Preparation of 12-methoxy farnesyl diphosphate (12-Methoxy FDP, 171)
2-(((2E, 6E, 10E)-12-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl) oxy)
tetrahydro-2H-pyran (181)
To a stirred suspension of sodium hydride (0.14 g, 60% in mineral oil, 3.7 mmol) in 
anhydrous THF (5 mL), was added a solution of 175 (0.2 g, 0.6 mmol) in anhydrous 
THF (5 mL) followed by the addition of methyl iodide (1.5 mL, 23 mmol) after 15 min. 
The reaction was left to stir under argon for 24 h whereupon TLC analysis (8:2, 
hexane: ethyl acetate) showed full consumption of starting material. The reaction was 
quenched with 10% hydrochloric acid (10 mL) and the layers were separated. The 
aqueous layer was washed with diethyl ether (4 x 10 mL) and the pooled extracts were 
washed with 5% sodium hydroxide (3 x 10 mL) and dried over anhydrous magnesium 
sulfate. The solvent was removed under reduced pressure and the crude oil was 
purified by flash chromatography on silica gel (4:1, hexane: ethyl acetate) to give the 
title compound as a colourless oil (158 mg, 76%).
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1H NMR (300 MHz, CDCl3): d 5.40-5.33 (2 H, m, 2 x CCHCH2), 5.11 (1 H, t, JH,H = 7.0, 
CCHCH2), 4.62 (2 H, t, JH,H = 4.0, OCHO), 4.24 (1 H, dd, JH,H = 12.0 and 6.5, 
CCHCHAO), 4.02 (1 H, dd, JH,H = 12.0 and 7.5, CCHCHBO), 3.93-3.47 (2 H, m, 
OCH2CH2), 3.77 (2 H, s, CH2OCH3), 3.26 (3 H, s, OCH3), 2.15-1.99 (8 H, m, 2 x 
CHCH2CH2), 1.71-1.54 (6 H, m, OCH2CH2CH2), 1.68, 1.63, and 1.60 (3 x 3 H, 3 x s, 3 x 
CCH3).
13C NMR (125 MHz, CDCl3): d 140.4, 135.1 and 132.1 (3 x CCHCH2), 128.4, 124.3 and
120.8 (3 x CCHCH2), 98.01 (OCHO), 78.90 (CH2OCH3), 63.84 and 62.49 (2 x 
CHOCH2), 51.69 (CH2OCH3), 39.79 and 39.47 (2 x CH3CCH2), 30.90 (OCHCH2), 
26.47 and 26.42 (2 x CCHCH2CH2), 25.68 (OCH2CH2CH2), 19.82 (OCH2CH2CH2), 
16.62, 16.16 and 13.97 (3 x CCH3). 
LRMS (AP+) m/z: 359.26 (100%, [M + Na]+).
HRMS (AP+): calculated for (C21H36O3 + [Na])+: 359.2549, found: 359.2562.
(2E, 6E, 10E)-12-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-ol (183)
To a stirred solution of 181 (0.15 g, 0.45 mmol) in methanol (5 mL) was added p-
toluenesulfonic acid (9.0 mg, 45 µmol) and stirred at room temperature for 1 h until 
TLC analysis (8:2, hexane: ethyl acetate) confirmed complete consumption of starting 
material. The solvent was removed under reduced pressure and the residual oil was 
dissolved with diethyl ether (10 mL) and washed with saturated aqueous sodium 
bicarbonate solution (3 x 10 mL) and brine (10 mL). The resulting solution was dried 
over anhydrous magnesium sulfate, filtered under gravity and concentrated under 
reduced pressure to give the title compound as a colourless oil (91 mg, 80%). The 
product was judged by 1H NMR spectroscopy to be sufficiently pure to carry forward 
without further purification.
1H NMR (400 MHz, CDCl3): d 5.43-5.36 (2 H, m, 2 x CCHCH2), 5.11 (1 H, t, JH,H = 7.0, 
CCHCH2), 4.15 (2 H, d, JH,H = 7.0, CH2OH), 3.78 (2 H, s, CH2OCH3), 3.27 (3 H, s, 
CH2OCH3), 2.14-2.00 (8 H, m, 2 x CHCH2CH2), 1.68, 1.63, and 1.60 (3 x 3 H, 3 x s, 3 x 
CCH3).
13C NMR (125 MHz, CDCl3): d 139.8, 135.2 and 132.1 (3 x CCHCH2), 128.2, 124.2 and
123.6 (3 x CCHCH2), 78.85 (CH2OCH3), 59.59 (CH2OH), 57.52 (CH2OCH3), 39.67 and
39.43 (2 x CH3CCH2), 26.42 and 26.40 (CCHCH2CH2), 16.47, 16.16 and 13.99 (CCH3). 
LRMS (ES+) m/z: 275.20 (100%, [M + Na]+), 251.20 (6, [M]+), 235.21 (16), 203.18 (45).
HRMS (ES+): calculated for (C16H28O2 + [Na])+: 275.1987, found: 275.1982.
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(2E, 6E, 10E)-12-Bromo-1-methoxy-2, 6, 10-trimethyl dodeca-2, 6, 10-triene (284)
To a stirred solution of 183 (0.66 g, 2.6 mmol) in anhydrous THF (10 mL) at -10 °C, 
was added phosphorous tribromide (0.12 mL, 1.3 mmol), and this was left to stir for 1 
h. When TLC analysis (8:2, hexane: ethyl acetate) confirmed complete consumption of 
starting material, the phosphorous tribromide and THF were removed under reduced 
pressure. The residual product was diluted with diethyl ether (10 mL) and washed with 
saturated aqueous ammonium bicarbonate solution (3 x 20 mL) and brine (10 mL). The 
resulting solution was dried over anhydrous magnesium sulfate, filtered under gravity
and concentrated under reduced pressure to give the title compound as a colourless oil 
(820 mg, 100%). The product was judged by 1H NMR spectroscopy to be sufficiently 
pure to carry forward without further purification.[168]
1H NMR (300 MHz, CDCl3): d 5.53 (1 H, t, JH,H = 8.5, CHCH2Br), 5.38 (1 H, t, JH,H = 7.0, 
CCHCH2), 5.09 (1 H, m, CCHCH2), 4.02 (2 H, d, JH,H = 8.5, CH2Br), 3.78 (2 H, s, 
CH2OCH3), 3.27 (3 H, s, CH2OCH3), 2.18-2.00 (8 H, m, 2 x CHCH2CH2), 1.73, 1.64, 
and 1.60 (3 x 3 H, 3 x s, 3 x CCH3).
(2E, 6E, 10E)-12-Methoxy-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate 
(171)
(Bu4N)3+
To a stirred solution of 284 (0.82 g, 2.6 mmol) in anhydrous acetonitrile (10 mL) was 
was added 121 (4.7 g, 5.2 mmol). The reaction was left for 48 h to stir under nitrogen. 
The solvent was removed under reduced pressure and the resulting crude oil was 
purified by flash chromatography on silica gel (6:2.5:0.5, isopropanol: water: 
ammonium hydroxide). Fractions that contained the diphosphate as judged by 
comparison with an authentic FDP standard by TLC (6:3:1, isopropanol: water: 
ammonium hydroxide) were collected. The isopropanol was removed under reduced 
pressure and the remaining solution was lyophilized to give the title compound as 
colourless oil (900 mg, 32%).
1H NMR (500 MHz, CDCl3): d 5.36-5.32 (2 H, m, 2 x CCHCH2), 5.07 (1 H, t, JH,H = 6.5, 
CCHCH2), 4.45 (2 H, t, JH,H = 5.5, CHCH2O), 3.74 (2 H, s, CH2OCH3), 3.31-3.28 (24 H, 
m, 12 x NCH2CH2CH2CH3), 3.21 (3 H, s, CH2OCH3), 2.10-1.90 (8 H, m, 2 x 
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CHCH2CH2), 1.61-1.54 (33 H, m, 12 x NCH2CH2CH2CH3 and 3 x CCH3), 1.45-1.38 (24
H, m, 12 x NCH2CH2CH2CH3), 0.94 (36 H, t, JH,H = 7.5, 12 x NCH2CH2CH2CH3).
31P NMR (121 MHz, CDCl3): d -7.40 (d, JP,P = 17), -7.73(d, JP,P = 17).
LRMS (ES-) m/z: 411.13 (87%, [M - H]-), 397.13 (19), 379.12 (8), 347.18 (5), 331.17 
(100).
HRMS (ES-): calculated for (C16H30O8P2 - [H]) -: 411.1338, found: 411.1336.
7.2.14 Preparation of 12-acetamido farnesyl diphosphate (12-Acetamido FDP, 
184)
2-((2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6,
10-trien-1-yl) isoindoline-1, 3-dione (186)
To a stirred solution of pthalimide (0.28 g, 1.9 mmol), triphenylphosphine (0.49 g, 1.9 
mmol), and 175 (0.55 g, 1.7 mmol) in anhydrous THF was added diisopropyl 
azodicarboxylate (0.37 mL, 1.9 mmol) and the reaction was left to stir for 24 h. The
THF was removed under reduced pressure and the crude residual oil was dissolved in 
ether (2 ml) and purified by flash chromatography on silica gel (6:1, hexane: ethyl 
acetate) to give the title compound as a colourless oil (575 mg, 75%).
1H NMR (500 MHz, CDCl3): d 7.85 (2 H, dd, JH,H = 5.5 and 3.0, 2 x NCCCHCH), 7.71 (2
H, dd, JH,H = 5.5 and 3.0, 2 x NCCCHCH), 5.33 (2 H, t, JH,H = 7.0, 2 x CCHCH2), 5.06 (1
H, t, JH,H = 6.5, CCHCH2), 4.62 (1 H, t, JH,H = 4.0, OCHO), 4.26-4.18 (3 H, m, CCH2N
and CCHCHAO), 4.01 (1 H, dd, JH,H = 12.0 and 7.5, CCHCHBO), 3.93-3.46 (2 H, m, 
OCH2CH2), 2.17-1.94 (8 H, m, 2 x CHCH2CH2), 1.71-1.46 (6 H, m, OCH2CH2CH2), 
1.65, 1.63 and 1.56 (3 x 3 H, 3 x s, 3 x CH3).
13C NMR (125 MHz, CDCl3): d 168.4 (2 x NCO), 140.4 and 134.9 (2 x CH3CCH), 134.1 
(2 x NCCCHCH), 132.3 (CH3CCH), 129.3 (2 x NCCCHCH), 127.6 and 124.4 (2 x 
CH3CCH), 123.4 (2 x NCCCHCH), 120.7 (CH3CCH), 97.96 (OCHO), 63.82 and 62.46
(2 x OCH2), 45.12 (CH2N), 39.75 and 39.31 (CHCH2CH2), 30.89 (OCHCH2), 26.59 and
26.45 (CHCH2CH2), 25.67 (OCH2CH2CH2), 19.81 (OCH2CH2CH2), 16.60, 16.16 and
14.82 (CH3). 
LRMS (AP+) m/z: 474.26 (100%, [M + Na]+).
HRMS (AP+): calculated for (C28H37O3N + [Na])+: 474.2620, found: 474.2610.
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(2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2, 6,
10-trien-1-amine (187)
To a stirred solution of 186 (0.12 g, 0.30 mmol) in anhydrous ethanol (10 mL) was 
added hydrazine monohydrate (56 µL, 1.2 mmol). The reaction was left to stir for 24 h
under argon. The ethanol was removed under reduced pressure and the residual oil 
was dissolved in ether (2 mL) and purified by flash chromatography on silica gel (99:1, 
ethyl acetate: triethylamine) to give the title compound as a colourless oil (60 mg, 
71%).
1H NMR (500 MHz, CDCl3): d 5.36 (1 H, t, JH,H = 6.5, CCHCH2), 5.27 (1 H, t, JH,H = 7.0, 
CCHCH2), 5.11 (1 H, t, JH,H = 6.5, CCHCH2), 4.62 (1 H, t, JH,H = 4.0, OCHO), 4.24 (1 H, 
dd, JH,H = 12.0 and 6.5, CCHCHAO), 4.03 (1 H, dd, JH,H = 12.0 and 7.5, CCHCHBO), 
3.93-3.46 (2 H, m, OCH2CH2), 3.17 (2 H, s, CH2NH2), 2.17-1.96 (8 H, m, 2 x 
CHCH2CH2), 1.72-1.49 (6 H, m, OCH2CH2CH2), 1.68, 1.64 and 1.60 (3 x 3 H, 3 x s, 3 x 
CH3).
13C NMR (125 MHz, CDCl3): d 140.3, 135.2 and 135.1 (3 x CCHCH2), 125.7, 124.4 and 
120.9 (3 x CCHCH2), 98.03 (OCHO), 63.87 and 62.49 (2 x OCH2), 49.46 (CH2NH2), 
39.80 and 39.55 (CHCH2CH2), 30.94 (OCHCH2), 26.61 and 26.51 (CHCH2CH2), 25.72
(OCH2CH2CH2), 19.84 (OCH2CH2CH2), 16.62, 16.20 and 14.74 (3 x CCH3). 
LRMS (AP+) m/z: 322.27 (100%, [M + H]+), 242.28 (5), 177.11 (12), 118.13 (17).
HRMS (AP+): calculated for (C20H35O2N + [H])+: 322.2746, found: 322.2732.
N-((2E, 6E, 10E)-2, 6, 10-Trimethyl-12-((tetrahydro-2H-pyran-2-yl) oxy) dodeca-2,
6, 10-trien-1-yl) acetamide (191)
A stirred solution of 187 (0.14 g, 0.40 mmol) dissolved in isopropenyl acetate (0.22 mL, 
2.2 mmol) was heated to 60 °C and left to stir for 3 h. The excess isopropenyl acetate 
and side product, acetone, was removed under reduced pressure to give the title 
compound as a colourless oil (156 mg, 99%). The product was judged by 1H NMR 
spectroscopy to be sufficiently pure to carry forward without further purification.
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1H NMR (500 MHz, CDCl3): d 5.49 (1 H, m, NH), 5.35 (1 H, t, JH,H = 6.0, CCHCH2), 5.26 
(1 H, t, JH,H = 7.0, CCHCH2), 5.11 (1 H, t, JH,H = 6.0, CCHCH2), 4.62 (1 H, t, JH,H = 4.0, 
CH), 4.22 (1 H, dd, JH,H = 12.0 and 6.5, CCHCHAO), 4.02 (1 H, dd, JH,H = 12.0 and 7.5,
CCHCHBO), 3.92-3.48 (2 H, m, OCH2CH2), 3.76 (2 H, d, JH,H = 6.0, NHCH2), 2.17-1.94 
(11 H, m, 2 x CCHCH2CH2 and NHCCH3), 1.72-1.52 (6 H, m, OCH2CH2CH2), 1.67, 1.60 
and 1.59 (3 x 3 H, 3 x s, 3 x CH2CCH3).
13C NMR (125 MHz, CDCl3): d 170.1 (NHCO), 140.2, 135.0 and 131.9 (3 x CH3CCH), 
126.9, 124.5 and 121.0 (3 x CH3CCH), 98.02 (OCHO), 63.85 and 62.52 (2 x OCH2), 
47.25 (NHCH2), 39.79 and 39.45 (CCHCH2CH2), 30.93 (OCHCH2), 26.53 and 26.46
(CCHCH2CH2), 25.71 (OCH2CH2CH2), 23.49 (NHCCH3), 19.85 (OCH2CH2CH2), 16.61, 
16.18 and 14.67 (3 x CH2CCH3). 
LRMS (AP+) m/z: 386.27 (100%, [M + Na]+), 364.29 (2, [M + H]+), 177.11 (11).
HRMS (AP+): calculated for (C22H37O3N + [Na])+: 386.2671, found: 386.2670.
N-((2E, 6E, 10E)-12-Hydroxy-2, 6, 10-trimethyl dodeca-2, 6, 10-trien-1-yl)
acetamide (192)
To a stirred solution of 191 (0.13 g, 0.40 mmol) in methanol (5 mL) was added p-
toluenesulfonic acid (9 mg, 0.04 mmol) and stirred at room temperature for 1 h. The 
solvent was removed under reduced pressure and the residual oil was dissolved with 
diethyl ether (10 mL) and washed with saturated aqueous sodium bicarbonate solution 
(3 x 10 mL) and brine (10 mL). The resulting solution was dried over anhydrous 
magnesium sulfate, filtered under gravity and concentrated under reduced pressure to 
give the title compound as a colourless oil (90 mg, 87%). The product was judged by 
1H NMR spectroscopy to be sufficiently pure to carry forward without further 
purification.
1H NMR (500 MHz, CDCl3): d 5.40 (1 H, t, JH,H = 7.0, CCHCH2), 5.27 (1 H, t, JH,H = 7.0, 
CCHCH2), 5.10 (1 H, t, JH,H = 7.0, CCHCH2), 4.14 (2 H, d, JH,H = 7.0, CH2OH), 3.75 (2
H, d, JH,H = 6.0, NHCH2), 2.15-1.97 (8 H, m, 2 x CCHCH2CH2), 1.99 (3 H, s, NCCH3), 
1.67, 1.60 and 1.59 (3 x 3 H, 3 x s, 3 x CH2CCH3).
13C NMR (125 MHz, CDCl3): d 170.1 (NHCO), 139.5, 135.0 and 131.8 (3 x CH3CCH), 
126.8, 124.3 and 123.8 (3 x CH3CCH), 59.56 (CH2OH), 47.20 (NHCH2), 39.63 and
39.38 (2 x CCHCH2CH2), 26.39 and 26.33 (2 x CCHCH2CH2), 23.48 (NHCCH3), 16.44, 
16.16 and 14.68 (3 x CH2CCH3).
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LRMS (AP+) m/z: 302.21 (100%, [M + Na]+), 262. 21 (4, [M - H2O]+), 242.28 (9), 177.11 
(20).
HRMS (AP+): calculated for (C17H29O2N + [Na])+: 302.2096, found: 302.2096.
N-((2E, 6E, 10E)-12-Bromo-2, 6, 10-trimethyldodeca-2, 6, 10-trien-1-yl) acetamide 
(193)
To a stirred solution of 192 (90 mg, 0.30 mmol) in anhydrous THF (5 mL) at -10 °C, 
was added phosphorous tribromide (15 µL, 0.20 mmol), and this was left to stir for 1 h. 
The phosphorous tribromide and THF were removed under reduced pressure. The 
residual product was diluted in diethyl ether (10 mL) and washed with saturated 
aqueous ammonium bicarbonate solution (3 x 20 mL) and brine (10 mL). The resulting 
solution was dried over anhydrous magnesium sulfate, filtered under gravity and 
concentrated under reduced pressure to give the title compound as a colourless oil 
(100 mg, 90%). The product was judged by 1H NMR spectroscopy to be sufficiently 
pure to carry forward without further purification.
1H NMR (500 MHz, CDCl3): d 5.51 (1 H, t, JH,H = 8.5, CCHCH2Br), 5.26 (1 H, t, JH,H = 
7.0, CCHCH2), 5.12-5.04 (1 H, m, CCHCH2), 4.01 (2 H, d, JH,H = 8.5, CH2Br), 3.75 (2 H, 
d, JH,H = 5.5, NHCH2), 2.25-1.97 (8 H, m, 2 x CCHCH2CH2), 2.00 (3 H, s, NHCCH3), 
1.71, 1.60 and 1.58 (3 x 3 H, 3 x s, 3 x CH2CCH3).
(2E, 6E, 10E)-12-Acetamido-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl 
diphosphate (184)
(Bu4N)3+
To a stirred solution of 193 (0.10 g, 0.30 mmol) in anhydrous acetonitrile (5 mL) was 
added 121 (0.50 g, 0.60 mmol). The reaction was left for 48 h to stir under nitrogen. 
The solvent was removed under reduced pressure and the resulting crude oil was 
purified by flash chromatography on silica gel (6:2.5:0.5, isopropanol: water: 
ammonium hydroxide). Fractions that contained the diphosphate as judged by 
comparison with an authentic FDP standard by TLC (6:3:1, isopropanol: water: 
ammonium hydroxide) were collected. The isopropanol was removed under reduced 
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pressure and the remaining solution was lyophilized to give the title compound as 
colourless oil (30 mg, 9%).
1H NMR (500 MHz, D2O): d 5.41 (1 H, m, CCHCH2), 5.24 (1 H, m, CCHCH2), 5.15 (1 H, 
m, CCHCH2), 4.42 (2 H, m, CH2O), 3.62 (2 H, s, NHCH2), 2.11-1.94 (8 H, m, 2 x 
CHCH2CH2), 1.96 (3 H, s, NCCH3), 1.68 (3 H, s, CH2CCH3), 1.57 (3 H, s, CH2CCH3), 
1.55 (3 H, s, CH2CCH3). 
31P NMR (243 MHz, D2O): d -8.5 (m), -10.69 (d, JP,P = 22).
LRMS (ES-) m/z: 438.14 (100%, [M – H]-), 411.13 (62), 339.22 (43).
HRMS (ES-): calculated for (C17H30O8NP2 - [H]) -: 438.1447, found: 438.1453.
7.2.15 Preparation of 12-amino farnesyl diphosphate (12-Amino FDP, 185)
(9H-Fluoren-9-yl) methyl ((2E, 6E, 10E)-2, 6, 10-trimethyl-12-((tetrahydro-2H-
pyran-2-yl) oxy) dodeca-2, 6, 10-trien-1-yl) carbamate (196)
To a stirred solution of 187 (0.12 g, 0.40 mmol) in dioxane (10 mL), was added Fmoc
chloride (120 mg, 0.6 mmol) and sodium bicarbonate (50 mg, 0.60 mmol). The reaction 
mixture was left to stir at room temperature for 24 h. The dioxane was removed under 
reduced pressure and the residual oil was dissolved in ether (2 mL). The crude oil was
purified by flash chromatography on silica gel (95:5, hexane: ethyl acetate) to give the 
title compound as a colourless oil (870 mg, 74%).
1H NMR (500 MHz, CDCl3): d 7.77 (2 H, d, JH,H = 7.5, 2 x CCHCH), 7.60 (2 H, d, JH,H = 
7.5, 2 x CCHCH), 7.40 (2 H, t, JH,H = 7.5, 2 x CCHCH), 7.31 (2 H, t, JH,H = 7.5, 2 x 
CCHCH), 5.36 (1 H, t, JH,H = 6.0, CCHCH2CH2), 5.28 (1 H, t, JH,H = 7.0, CCHCH2CH2), 
5.11 (1 H, t, JH,H = 6.5, CCHCH2CH2), 4.62 (1 H, t, JH,H = 4.0, OCHCH2CH2), 4.43 (2 H, 
d, JH,H = 7.0, NCOCH2), 4.25-4.21 (2 H, m, CHCH2OCN and CCHCHAO), 3.91-3.49 (1
H, dd, JH,H = 12.0 and 7.5, CCHCHBO), 3.72 (2 H, d, JH,H = 5.5, NHCH2), 2.13-1.98 (8 H, 
m, 2 x CCHCH2CH2), 1.74-1.50 (6 H, m, OCH2CH2CH2), 1.67, 1.60 and 1.59 (3 x 3 H, 3 
x s, 3 x CH3).
13C NMR (125 MHz, CDCl3): d 156.5 (2 x NCO), 144.0 and 141.4 (4 x CCHCH), 140.0, 
134.8 and 134.0 (3 x CH3CCH), 127.6 and 127.0 (4 x CCHCH), 126.5 (CCHCH2CH2), 
125.2 (2 x CCHCH), 124.3 (CCHCH2CH2), 120.8 (CCHCH2CH2), 112.0 (2 x CCHCH), 
97.78 (OCHCH2), 66.57 (NCOCH2), 63.64 and 62.27 (CH2OCHCH2), 48.85 (NHCH2), 
47.37 (CHCH2OCN), 39.58 and 39.48 (2 x CCHCH2CH2), 30.73 (OCHCH2), 26.36 and
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26.27 (2 x CCHCH2CH2), 25.52 (OCH2CH2CH2), 19.62 (OCH2CH2CH2), 16.41, 16.00 
and 14.31 (3 x CCH3). 
LRMS (AP+) m/z: 566.32 (100%, M + Na+).
HRMS (AP+): calculated for (C35H45O4N+[Na]) +: 566.3246, found: 566.3230.
(9H-Fluoren-9-yl) methyl ((2E, 6E, 10E)-12-hydroxy-2, 6, 10-trimethyl dodeca-2, 6,
10-trien-1-yl) carbamate (197)
To a stirred solution of 196 (0.87 g, 1.6 mmol) in methanol (10 mL) was added p-
toluenesulfonic acid (30 mg, 0.16 mmol) and stirred at room temperature for 1 h. The 
solvent was removed under reduced pressure and the residual oil was dissolved with 
diethyl ether (10 mL) and washed with saturated aqueous sodium bicarbonate solution 
(3 x 10 mL) and brine (10 mL). The resulting solution was dried over anhydrous 
magnesium sulfate, filtered under gravity and concentrated under reduced pressure to 
give the title compound as a colourless oil (630 mg, 86%). The product was judged by 
1H NMR spectroscopy to be sufficiently pure to carry forward without further 
purification.
1H NMR (500 MHz, CDCl3): d 7.76 (2 H, d, JH,H = 7.5, 2 x CCHCH), 7.59 (2 H, d, JH,H = 
7.5, 2 x CCHCH), 7.40 (2 H, t, JH,H = 7.5, 2 x CCHCH), 7.31 (2 H, t, JH,H = 7.5, 2 x 
CCHCH), 5.39 (1 H, t, JH,H = 7.0, CCHCH2CH2), 5.27 (1 H, t, JH,H = 6.5, CCHCH2CH2), 
5.10 (1 H, m, CCHCH2CH2), 4.42 (2 H, d, JH,H = 7.0, NCOCH2), 4.22 (1 H, m, 
CHCH2OCN), 4.12 (2 H, m, CH2OH), 3.71 (2 H, d, JH,H = 5.5, NHCH2), 2.17-1.99 (8 H, 
m, 2 x CCHCH2CH2), 1.66, 1.61 and 1.60 (3 x 3 H, 3 x s, 3 x CH3).
13C NMR (125 MHz, CDCl3): d 156.7 (2 x NCO), 144.2 and 141.5 (4 x CCHCH), 139.7, 
135.1 and 132.3 (3 x CH3CCH), 127.8 and 127.2 (4 x CCHCH), 126.6 (CCHCH2CH2), 
125.2 (2 x CCHCH), 124.3 (CCHCH2CH2), 123.7 (CCHCH2CH2), 120.2 (2 x CCHCH), 
66.72 (NCOCH2), 60.56 (CH2OH), 47.56 (CHCH2OCN), 39.64 and 39.40 (2 x 
CCHCH2CH2), 26.43 and 26.38 (2 x CCHCH2CH2), 16.44, 16.19, 14.53 (3 x CH3). 
LRMS (AP+) m/z: 482.27 (100%, M + Na+), 442.27 (11, M+).
HRMS (AP+): calculated for (C30H37O3N + [Na])+: 482.2671, found: 482.2679.
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(9H-Fluoren-9-yl) methyl ((2E, 6E, 10E)-12-bromo-2, 6, 10-trimethyl dodeca-2, 6,
10-trien-1-yl) carbamate (198)
To a stirred solution of 197 (0.62 g, 1.3 mmol) in anhydrous THF (10 mL) at -10 °C, 
was added phosphorous tribromide (0.64 mL, 0.70 mmol), and this was left to stir for 1 
h. The phosphorous tribromide and THF were removed under reduced pressure. The 
residual product was diluted in diethyl ether (10 mL) and washed with saturated 
aqueous ammonium bicarbonate solution (3 x 20 mL) and brine (10 mL). The resulting 
solution was dried over anhydrous magnesium sulfate, filtered under gravity and 
concentrated under reduced pressure to give the title compound as a colourless oil 
(630 mg, 89%). The product was judged by 1H NMR spectroscopy to be sufficiently 
pure to carry forward without further purification.
1H NMR (500 MHz, CDCl3): d 7.77 (2 H, d, JH,H = 7.5, 2 x CCHCH), 7.60 (2 H, d, JH,H = 
7.5, 2 x CCHCH), 7.41 (2 H, t, JH,H = 7.5, 2 x CCHCH), 7.31 (2 H, t, JH,H = 7.5, 2 x 
CCHCH), 5.52 (1 H, t, JH,H = 8.5, CCHCH2Br), 5.28 (1 H, t, JH,H = 7.0, CCHCH2CH2), 
5.09 (1 H, m, CCHCH2CH2), 4.42 (2 H, d, JH,H = 7.0, NCOCH2), 4.23 (1 H, t, JH,H = 6.5, 
CHCH2OCN), 4.02 (2 H, d, JH,H = 8.5, CH2Br), 3.73 (2 H, m, NHCH2), 2.19-1.97 (8 H, 
m, 2 x CCHCH2CH2), 1.72, 1.62 and 1.60 (3 x 3 H, 3 x s, 3 x CH3).
(2E, 6E, 10E)-12-Amino-3, 7, 11-trimethyl dodeca-2, 6, 10-trien-1-yl diphosphate
(185)
(Bu4N)3+
To a stirred solution of 198 (0.63 g, 1.2 mmol) in anhydrous acetonitrile (5 mL) was 
added 121 (2.2 g, 2.4 mmol). The reaction was left for 48 h to stir under nitrogen. The 
solvent was removed and the resulting crude oil was purified by flash chromatography 
on silica gel (6:2.5:0.5, isopropanol: water: ammonium hydroxide). Fractions that 
contained the diphosphate as judged by comparison with an authentic FDP standard 
by TLC (6:3:1, isopropanol: water: ammonium hydroxide), were collected. The 
isopropanol was removed under reduced pressure and the remaining solution was 
lyophilized to give the title compound as colourless oil (120 mg, 22%).
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1H NMR (500 MHz, CDCl3): d 5.38-5.26 (2 H, m, 2 x CCHCH2), 5.08 (1 H, m, 
CCHCH2), 4.48 (2 H, m, CHCH2O), 3.66 (2 H, s, NH2CH2), 3.38-3.35 (36 H, m, 18 x 
NCH2CH2CH2CH3), 2.09-1.95 (8 H, m, 2 x CCHCH2CH2), 1.65 (45 H, m, 18 x 
NCH2CH2CH2CH3 and 3 x CCH3), 1.44-1.43 (36 H, m, 18 x NCH2CH2CH2CH3), 0.97-
0.95 (54 H, m, 18 x NCH2CH2CH2CH3)
31P NMR (243 MHz, CDCl3): d -7.71 (m).
LRMS (ES-) m/z: 396.13 (55%, M – H-), 375.22 (56), 339.27 (100), 312.23 (30).
HRMS (ES-): calculated for (C15H29O7NP2 - [H]) -: 396.1341, found: 396.1331.
7.2.16 Preparation of ethyl 2-(bis (2, 2, 2 trifluoroethoxy) phosphoryl) propanoate
(141)
Method 1:
Ethyl 2-(diethoxyphosphoryl) propanoate (144)
Ethyl 2-bromopropionate (14 mL, 0.10 mol) was preheated to 140 °C before triethyl 
phosphite (21 mL, 0.12 mol) was added drop-wise. The temperature was raised to 180 
°C and the reaction was left to reflux for 24 h. The resulting oil was cooled down and 
fractionally distilled under reduced pressure. After confirmation by NMR analysis and 
GC-MS, it was determined that the fraction that distilled above 170 °C gave the title 
compound (18.3 g, 65%) as a yellow oil.
1H NMR (300 MHz, CDCl3): d 4.24-4.11 (6 H, m, 3 x OCH2CH3), 3.01 (1 H, dq, JP,H = 
23.5 and JH,H = 7.5, PCH), 1.44 (3 H, dd, JP,H = 18 and JH,H = 7.5, PCHCH3), 1.33, 1.32 
and 1.27 (9 H, 3 x t, JH,H = 7.0, 3 x CH2CH3).
13C NMR (125 MHz, CDCl3): d 169.9 (OCO), 62.87 and 62.82 (2 x CH2OP), 61.57 
(CH2OC), 40.16 (CHP), 16.60 and 16.57 (2 x CH3CH2OP), 14.29 (CH3CH2OC), 11.93 
(CHCH3).
31P NMR (121 MHz, CDCl3): d 23.9.
LRMS (EI+) m/z: 238.10 (22%, [M]+), 211.07 (25, [M-C2H3]+), 193.06 (79), 165.05 (100), 
109.01 (46).
HRMS (EI+): calculated for C9H19O5P+: 238.0970, found: 238.0969.
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Ethyl 2-(dichlorophosphoryl) propanoate (145)
Phosphorous pentachloride (51.1 g, 250 mmol) was added in small portions to an ice 
cooled 144 (23.0 g, 100 mmol). After stirring for 1 h at room temperature, the solution
was heated to 80 °C for 24 h. Once the reaction mixture was cooled and concentrated
under reduced pressure, the residue was fractionally distilled. The fraction above 140 
°C gave the title compound (13.3 g, 61%) as a yellow oil.
1H NMR (300 MHz, CDCl3): d 4.34-4.24 (2 H, m, OCH2CH3), 3.66 (1 H, dq, JP,H = 18.5 
and JP,H = 7.0, PCH), 1.68 (3 H, dd, JP,H = 27.5 and JH,H = 7.0, PCHCH3), 1.32 (3 H, t, 
JH,H = 7.0, OCH2CH3).
31P NMR (121 MHz, CDCl3): d 44.28 (s).
HRMS (EI+): calculated for C5H9O3PCl2+: 217.9666, found: 217.9673.
Ethyl 2-(bis (2,2,2-trifluoroethoxy) phosphoryl) propanoate (141)
To a stirred solution of 145 (13 g, 60 mmol) in toluene (100 mL) at 0 °C was added a 
solution of trifluoroethanol (12.6 g, 130 mmol) and diisopropylethylamine (16.2 g, 130 
mmol) in toluene (100 mL) that had been cooled to 0 °C prior to addition. The reaction 
mixture was then left to stir at room temperature for 6 h. After concentrating under 
reduced pressure, the resulting oil was fractionally distilled under reduced pressure.
The fraction boiling at 150-160 °C gave the title compound (4.6 g, 22%) as a colourless 
oil.
1H NMR (300 MHz, CDCl3): d 4.49-4.38 (4 H, m, 2 x CH2CF3), 4.23 (2 H, q, JH,H = 7.0, 
CH2CH3), 3.20 (1 H, dq, JP,H = 22.5 and JH,H = 7.5, PCH), 1.52 (3 H, dd, JP,H = 19.5 and 
JH,H 7.5, PCHCH3), 1.29 (3 H, t, JH,H = 7.0, CH2CH3).
13C NMR (125 MHz, CDCl3): d 168.7 (OCO), 122.6 (2 x CF3), 62.77 (2 x CF3CH2), 
62.41 (CH2OC), 40.29 (CHP), 14.13 (CH3CH2OC), 11.80 (CHCH3).
31P NMR (121 MHz, CDCl3): d 27.3.
HRMS (EI+): calculated for C9H13O5PF6+: 346.0405, found: 346.0406.
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Method 2:
Ethyl 2-(bis ((trimethylsilyl) oxy) phosphoryl) propanoate (146)
Triethyl 2-phosphonopropionate (6.60 mL, 27.7 mmol) and trimethylsilyl chloride (19.2 
mL, 177 mmol) were combined in 3 pressure tubes, initially flushed with argon. The 
solutions were heated to 100 °C and left to stir for 7 days. The solutions were 
combined and concentrated under reduced pressure to give the title compound (9.9 g) 
as a yellow oil. 
1H NMR (500 MHz, CDCl3): d 4.20-4.16 (2 H, m, OCH2), 2.99-2.86 (1 H, m, PCH), 1.40 
(3 H, dd, JP,H = 19 and JH,H 7.5, PCHCH3), 1.28 (3 H, t, JH,H = 7, CH2CH3), 0.30 (18 H, s, 
6 x SiCH3). 
31P NMR (121 MHz, D2O): d 4.75.
LRMS (ES+) m/z: 327.12 (100%, M + H+), 283.12 (17), 255.08 (92), 241.07 (26).
HRMS (ES+): calculated for (C11H27O5PSi2 + [H])+: 327.1213, found: 327.1199.
Ethyl 2-(dichlorophosphoryl) propanoate (145)
To a stirred solution of 146 (10.5 g, 32.2 mmol) in DCM (100 mL) was added DMF (1 
mL). Oxalyl chloride (6.8 mL, 80 mmol) was added gradually over a period of 10 
minutes and the reaction was left to stir for 1 h. The solvent was removed under 
reduced pressure to give the crude title compound (6.8 g). 
1H NMR (300 MHz, CDCl3): d 4.34-4.24 (2 H, m, CH2CH3), 3.66 (1 H, dq, JP,H = 18.5 
and JH,H = 7, PCH), 1.68 (3 H, dd, JP,H = 27.5 and JH,H 7.0, PCHCH3), 1.32 (3 H, t, JH,H = 
7.0, CH2CH3).
31P NMR (121 MHz, CDCl3): d 44.28.
HRMS (EI+): calculated for C5H9O3P35Cl2+: 217.9666, found: 217.9673.
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Ethyl 2-(bis (2,2,2-trifluoroethoxy) phosphoryl) propanoate (141)
To stirred solution of 145 (6.80 g, 31.2 mmol) in DCM (50 mL) at 0 °C was added a 
solution of triethylamine (22.7 mL, 163 mmol) and 2,2,2-trifluoroethanol (7.90 mL, 109 
mmol) in DCM (50 mL), drop-wise. 4-N,N-Dimethylaminopyridine (66 mg, 0.50 mmol) 
was then added and the resulting solution was left to stir for 24 h. The reaction was 
diluted with DCM (50 mL), washed with brine (3 x 50 mL), dried over anhydrous 
magnesium sulfate, filtered under gravity and concentrated under reduced pressure. 
The crude oil was purified by flash chromatography on silica gel (2:1, hexane: ethyl 
acetate) to give the title compound as a colourless oil (9.1 g, 84%).
1H NMR (300 MHz, CDCl3): d 4.49-4.38 (4 H, m, 2 x CH2CF3), 4.23 (2 H, q, JH,H = 7.0, 
CH2CH3), 3.20 (1 H, dq, JP,H = 22.5 and JH,H = 7.5, PCH), 1.52 (3 H, dd, JP,H = 19.5 and 
JH,H = 7.5, PCHCH3), 1.29 (3 H, t, JH,H= 7, CH2CH3).
13C NMR (125 MHz, CDCl3): d 168.7 (OCO), 122.6 (2 x CF3), 62.77 (2 x CF3CH2), 
62.41 (CH2OC), 40.29 (CHP), 14.13 (CH3CH2OC), 11.80 (CHCH3).
31P NMR (121 MHz, CDCl3): d 27.3.
19F NMR (470 MHz, CDCl3): d -75.38.
LRMS (EI+) m/z: 346.04 (22%, M+), 319.02 (20), 301.00 (100), 274.02 (72), 245.99 
(67).
HRMS (EI+): calculated for C9H13O5PF6+: 346.0405, found: 346.0406.
7.2.17 Preparation of (2E, 6E)-3, 7, 11-trimethyldodeca-2, 6, 10-trienal (279)
To a stirred solution of (2E, 6E)-Farnesol (50.0 mg, 227 µmol) in hexane (5 mL) was 
added manganese dioxide (500 mg, 5.75 mmol). This solution was left to stir for 48 h. 
After TLC analysis (8:2, hexane: ethyl acetate) showed complete consumption of the 
starting material, the solution was diluted with hexane (20 mL) and passed through a 
celite plug. The celite was washed with ethyl acetate (2 x 10 mL) and the combined 
organic extracts were concentrated under reduced pressure to give the title compound
as a colourless oil (35 mg, 70%).
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1H NMR (500 MHz, CDCl3): d 9.96 (1 H, d, JH,H = 8.0, CHCHO), 5.86 (1 H, d, JH,H = 8.0, 
CHCHO), 5.08-5.01 (2 H, m, 2 x C=CH), 2.24-1.92 (8 H, m, 2 x CH2CH2), 2.14, 1.64, 
1.57 and 1.56 (4 x 3 H, 4 x s, 4 x CH3).
13C NMR (125 MHz, CDCl3): d 191.5 (CHO), 164.2 (CCHCHO), 136.7 and 131.7 (2 x 
CCHCH2), 127.6 (CCHCHO), 124.3 and 122.6 (2 x CCHCH2), 40.78 and 39.79 (2 x 
CHCH2CH2), 26.77 and 25.87 (2 x CHCH2CH2), 25.83, 17.86, 17.78 and 16.23 (4 x 
CH3). 
LRMS (EI+) m/z: 220.18 (10%, M+), 202.17 (37), 187.15 (39), 173.13 (13), 159.12 (40), 
145.10 (36), 119.08 (54), 93.06 (100), 67.05 (90).
HRMS (EI+): calculated for C15H24O+: 220.1827, found: 220.1827.
7.2.18 Preparation of methyl (R)-2-((1R, 4R, 4aS, 8aS)-4, 7-dimethyl-1, 2, 3, 4, 4a, 
5, 6, 8a-octahydronaphthalen-1-yl) propanoate (11R-88)
To a stirred solution of (11R)-50 (25 mg, 0.10 mmol) in toluene (2 mL) was added N,N-
dimethylformamide (10 µL, 0.69 µmol). The reaction was stirred at 0 °C while oxalyl 
chloride (9.4 mL, 0.11 mmol) was added drop-wise. The solution was left to stir for 30 
min before a mixture of triethylamine (100 µL) and methanol (900 µL) was added drop-
wise over 10 min. The mixture was stirred for 1 h and then the excess methanol was 
removed under reduced pressure. The toluene suspension was washed with water (2 x 
5 mL), dried over anhydrous sodium sulfate, filtered under gravity and concentrated 
under reduced pressure. The crude oil was purified by flash chromatography on silica 
gel (9:1, hexane: ethyl acetate) to give the title compound as a colourless oil (14 mg, 
78%).
1H NMR (500 MHz, CDCl3): d 5.12 (1 H, bs, CH3C=CH), 3.67 (3 H, s, CH3OC), 2.50 (2 
H, m, OCCHCHCH), 1.97-1.78 (3 H, m, CH3CCH2CHb), 1.63 (3 H, s, CH=CCH3), 1.63-
1.55 (3 H, m, CH3CCH2CHa and OCCHCH and CH3CHCHb), 1.41 (1 H, m, 
CH3CHCH2), 1.26 (2 H, m, OCCHCHCHa and CH=CCH2CH2CH), 1.13 (3 H, d, J = 7.0, 
CHCH3), 1.09-0.92 (2 H, m, CH3CHCHaCHb), 0.86 (3 H, d, J = 6.5, CHCH3).
13C NMR (125 MHz, CDCl3): d 178.2 (OCO), 136.1 (CH=CCH3), 119.7 (CH=CCH3), 
51.62 (COCH3), 44.19 (CHCHCO), 43.27 (CHCHCO), 41.94 (CHCH2CH2C=CH), 36.63 
(CH=CCH3), 35.48 (CH3CHCH2CH2), 27.89 (CH3CHCH2CH2), 27.68 (CH3CHCH2CH2), 
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26.84 (CH2CH2C=CH), 25.99 (CH2CH2C=CH), 24.05 (CH3CHCH2), 19.92 (CH=CCH3), 
15.34 (CH3CHCO).
LRMS (EI+) m/z: 250.19 (1.4%, M+), 219.17 (2.8), 201.16 (3.4), 162.13 (100), 147.11 
(35.2), 121.10 (11.7), 91.05 (19.3), 79.05 (16.5).
HRMS (EI+): calculated for C16H26O2+: 250.1933, found: 250.1930.
7.2.19 Preparation of (R)-2-((1R, 4R, 4aS, 8aS)-4, 7-dimethyl-1, 2, 3, 4, 4a, 5, 6, 8a-
octahydronaphthalen-1-yl) propanal (11R-49)
To a stirred solution of 88 (11 mg, 44 µmol) in anhydrous THF (1 mL) at -78 °C was 
added DIBAL-H (1 M in toluene, 44 µL, 44 µmol), drop-wise, and the reaction was left 
to stir for 30 min. The reaction was quenched by addition of saturated aqueous sodium 
bicarbonate solution (5 mL) and left to stir for 1 h. The layers were separated and the
aqueous layer was extracted with diethyl ether (3 x 5 mL). The pooled organic extracts 
were washed with brine (10 mL) and dried over anhydrous sodium sulfate before being 
filtered under gravity and concentrated under reduced pressure. The crude oil was
purified by flash chromatography on silica gel (19:1, hexane: ethyl acetate) to give the 
title compound as a colourless oil (3 mg, 31%). 
1H NMR (500 MHz, CDCl3): d 9.57 (1 H, d, J = 3.5, CHO), 5.12 (1 H, bs, CH3C=CH), 2.48 (1 
H, m, C=CHCH), 2.37 (1 H, m, OCHCH), 1.98-1.79 (3 H, m, CH3CCH2CHb), 1.64 (3 H, s, 
CCH3), 1.63-1.56 (3 H, m, CH3CCH2CHa and OCHCHCH and CH3CHCHb), 1.41 (2 H, 
m, CH3CHCH2 and OCHCHCHCHa), 1.29 (1 H, m, CH=CCH2CH2CH), 1.13 (1 H, dd, J
= 13.0 and 3.0, OCHCHCHCHb), 1.07 (3 H, d, J = 7.0, OCHCHCH3), 0.96 (1 H, ddd, J 
= 24.5, 13.0 and 3.0, CH3CHCH2), 0.88 (3 H, d, J = 6.5, CHCH3).
13C NMR (125 MHz, CDCl3): d 206.3 (CHO), 136.3 (CH=CCH3), 119.8 (CH=CCH3), 
48.65 (OCHCH), 42.06 (CH3CCH2CH2CH), 41.69 (OCHCHCH), 36.80 (C=CHCH), 
35.47 (CH3CHCH2CH2), 27.92 (CH3CHCH2CH2), 27.55 (CH3CHCH2CH2), 26.79
(CH2CH2C=CH), 25.96 (CH2CH2C=CH), 24.04 (CH3C=CH), 19.91 (CH2CHCH3), 11.96
(CH3CHCHO).
LRMS (EI+) m/z: 220.18 (29.3%, M+), 202.17 (40.9), 187.15 (77.2), 162.14 (100), 
147.12 (46.8), 131.10 (25.5), 91.06 (46.5), 79.06 (38.1).
HRMS (EI+): calculated for C15H24O+: 220.1827, found: 220.1830.
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7.2.20 General procedures for incubations of ADS with FDP or FDP analogues
Analytical incubations
FDP (or FDP analogue, 0.4 mM) was combined with ADS (1 µM) in an incubation 
buffer (250 µL) (Buffer composition is given in Section 7.1.4). The incubation was 
overlaid with pentane (1 mL) and left to gently shake overnight at room temperature. 
The next day, the organic layer was extracted and analysed by GC-MS. 
Preparative scale incubations 
To minimize losses of volatile sesquiterpenoid products during incubation and workup, 
reactions were performed in sealed Schott bottles containing incubation buffer with 
FDP (or FDP analogue, 0.2 - 0.4 mM) and enzyme (1 µM). The incubation was overlaid 
with pentane (10-20% of incubation volume). Each incubation solution was gently 
agitated (24 h, RT) after which the pentane layer was separated using a separating 
funnel. The aqueous layer was extracted with additional pentane (3 x 10 mL). Each 
extraction was separated by first, freezing the emulsion formed by mixing both layers in 
liquid nitrogen. Upon thawing, the pentane trapped in the emulsion was freed and 
collected. The pooled pentane extracts were concentrated under reduced pressure to 
yield the product as a yellow oil.
Amorphadiene (45)
1H NMR (500 MHz, CDCl3): d (ppm) 5.05 (1 H, bs, CH=CCH3), 4.87 (1 H, bs, C=CHA), 
4.64 (1 H, bs, C=CHB), 2.55 (1 H, m, CH2CCHCH), 1.96-0.89 (11 H, m, 
(CH2)2CHCH(CH2)2CH), 1.74 (3 H, s, CH2=CCH3), 1.60 (3 H, s, CH=CCH3), 0.88 (3 H, 
d, J = 6.5, CH2CHCH3).
13C NMR (125 MHz, CDCl3): d 148.2 (CH3C=CH2), 134.8 (CH3C=CH), 121.1 
(CH3C=CH), 110.0 (CH3C=CH2), 47.85 (CH2=CCH), 42.02 (CH3CCH2CH2CH), 37.84 
(C=CHCH), 35.61 (CH3CHCH2), 26.68 (CH3CCH2), 26.01 (CH3CHCH2CH2), 23.83 
(CH3C=CH), 22.77 (CH3C=CH2), 20.03 (CH3CHCH2). 
LRMS (EI+) m/z: 204.19 (63.5%, M+), 189.16 (88.6), 175.15 (16.8), 162.14 (41.3), 
147.12 (33.5), 133.10 (28.8), 119.08 (100), 105.07 (47.0), 93.07 (69.9), 79.05 (45.5), 
67.05 (12.3).
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14-Methyl amorphadiene (211)
1H NMR (500 MHz, CDCl3): d (ppm) 5.06 (1 H, bs, CH=CCH3), 4.87 (1 H, bs, 
CH3C=CHA), 4.64 (1 H, bs, CH3C=CHB), 2.57 (1 H, m, CH2=CCHCH), 1.74 (3 H, s, 
CH2=CCH3), 1.60 (3 H, s, CH=CCH3), 0.88 (3 H, d, J = 6.5, CH2CHCH3).
LRMS (EI+) m/z: 218.20 (53.6%, M+), 203.18 (45.3), 189.16 (100), 175.15 (17.2), 
162.14 (22.3), 147.12 (25.4), 133.10 (59.9), 119.09 (20.1), 105.07 (60.7), 93.07 (43.8), 
79.05 (33.7).
Dihydroartemisinic aldehyde (mixture of 11-R and 11-S epimers) (11R-49 and 
11S- 49)
1H NMR (500 MHz, CDCl3): d (ppm) 9.62 (1 H, d, J = 3.5, CHO, (11S)), 9.57 (1 H, d, J
= 3.5, CHO, (11R)), 5.26 (1 H, bs, CH3C=CH, (11S)), 5.12 (1 H, bs, CH3C=CH, (11R)), 
2.48 (2 H, m, 2 x C=CHCH, (11R) and (11S)), 2.39 (2 H, m, 2 x OCHCH, (11S) and 
(11R)), 1.91-1.25 (20 H, m, 2 x (CH2)2CHCH(CH2)2, (11R) and (11S)), 1.63 (6 H, s, 2 x 
CCH3), 1.08 (3 H, d, J = 7.0, OCHCHCH3, (11R)), 1.06 (3 H, d, J = 7.0, OCHCHCH3, 
(11S)), 0.87 (6 H, d, J = 6.5, 2 x CHCH3, (11R) and (11S)).
13C NMR (125MHz, CDCl3): d 206.3 (CHO), 136.3 (CH=CCH3), 119.8 (CH=CCH3), 
48.65 (OCHCH), 42.06 (CH3CCH2CH2CH), 41.69 (OCHCHCH), 36.80 (C=CHCH), 
35.47 (CH3CHCH2CH2), 27.92 (CH3CHCH2CH2), 27.55 (CH3CHCH2CH2), 26.79 
(CH2CH2C=CH), 25.96 (CH2CH2C=CH), 24.04 (CH3C=CH), 19.91 (CH2CHCH3), 11.96 
(CH3CHCHO).
LRMS (EI+) m/z: 220.18 (21.6%, [11R-49]+), 202.17 (39.9), 187.15 (68.6), 162.14 
(100), 147.12 (43.3), 131.09 (18.24), 105.07 (20.4), 91.05 (21.2), 79.05 (16.8).
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LRMS (EI+) m/z: 220.18 (20.9%, [11S-49]+), 202.17 (58.4), 187.15 (100), 162.14 (81.4), 
145.10 (52.2), 131.09 (28.1), 105.07 (25.7), 91.06 (25.4), 79.05 (15.6).
11S-Dihydroartemisinic aldehyde
1H NMR (500 MHz, CDCl3): d (ppm) 9.62 (1 H, d, J = 3.5, CHO), CHO, 5.26 (1 H, bs, 
CH3C=CH), 2.48 (1 H, m, C=CHCH), 2.39 (1 H, m, OCHCH), 1.91-1.25 (10 H, m, 
(CH2)2CHCH(CH2)2), 1.63 (6 H, s, 2 x CCH3), 1.06 (3 H, d, J = 7.0, OCHCHCH3), 0.87 
(3 H, d, J = 6.5, CHCH3).
8-Methoxy-g-humulene (262)
1H NMR (500 MHz, CDCl3): d (ppm) 5.88 (1 H, d, J = 6.0, CH=CH), 5.52 (1 H, t, J = 8.0, 
CH3C=CHCH2), 5.48 (1 H, d, J = 6.0, CH=CH), 4.89 (1 H, d, J = 2.0, CHA=C), 4.81 (1 H, 
d, J = 2.0, CHB=C), 3.30 (1 H, dd, J = 2.5 and 9.0, OCH), 3.10 (3 H, s, OCH3), 1.71-
1.25 (8 H, m, 2 x CH2CH2), 1.37 (3 H, s, OCHCCH3) 0.97 and 0.96 (2 x 3 H, 2 x s, 2 x 
CH3CCH3).
13C NMR (125 MHz, CDCl3): d 148.8 (C=CH2), 143.0 (CH3C=CH), 135.9 (CH3C=CH), 
129.4 and 125.5 (CH=CH), 113.5 (C=CH2), 90.28 (CHO), 55.65 (OCH3), 41.36 
(CCH3)2), 36.41 and 32.78 (2 x CCH2), 31.33 and 30.29 (CH3CCH3), 28.33 (CH2CH=C), 
18.15 (OCH3), 10.75 (OCHCH2).
LRMS (EI+) m/z: 234.20 (6.4%, M+), 219.18 (4.2), 202.17 (86.3), 187.15 (100), 173.13 
(33.2), 159.12 (83.1), 145.10 (51.5), 131.09 (88.5), 119.09 (45.8), 105.07 (76.5), 91.05 
(96.7), 79.05 (52.6), 67.05 (14.5).
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